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new agents for scintigraphic imaging of infection and 
inflammation. 
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ABSTRACT 
 
Several radiopharmaceuticals are currently used for diagnosis of inflammatory and 
infectious diseases in patients. Most inflammatory and infectious processes can be 
visualized with radiolabeled autologous leukocytes, currently considered to be the most 
appropriate radiopharmaceutical for this purpose. Radiolabeled leukocytes can accurately 
delineate most inflammatory and infectious foci. The preparation of radiolabeled 
leucocytes however, is time-consuming and elaborate and requires the handling of 
potentially contaminated blood. Therefore, there is a great interest in the development of 
new radiopharmaceuticals comprising the same imaging qualities but without these 
disadvantages. Besides radiolabeled leukocytes several other radiopharmaceuticals, such 
as 67Ga-citrate and radiolabeled anti-granulocyte antibodies are used to image infection 
and inflammation. However, these latter agents accumulate in infectious and inflammatory 
lesions in a non-specific manner or have suboptimal diagnostic characteristics. Nowadays 
there is a great interest in the development of radiolabeled chemotactic and chemokinetic 
cytokines that accumulate and are retained in infectious and inflammatory foci by means 
of specific interaction with infiltrating inflammatory cells. Here we describe the specific 
characteristics of the chemotactic and chemokinetic compounds that are currently studied 
as potential radiopharmaceuticals to visualize infectious and inflammatory foci. The 
characteristics of a series of cytokines (IL-1, IL-2), chemokines (IL-8, PF-4, MCP-1, NAP-
2), complement factors (C5a, C5adR), chemotactic peptides (fMLF) and other chemotactic 
factors (LTB4) are described. The potential of these compounds to serve as imaging 
agent are discussed. 
 
INTRODUCTION 
 
The role of nuclear medicine in the management of patients suspected of infectious or 
inflammatory disorders is eminent. Diagnosis of infectious and inflammatory disorders by 
means of scintigraphic imaging generally allows adequate and rapid delineation of 
infectious and inflammatory foci. Visualization of the localization and the extent of an 
inflammatory process allows guided verification procedures, therapeutic decisions and 
initiation of appropriate treatment in most cases. In most institutions scintigraphic imaging 
to detect inflammatory and infectious foci is performed with radiolabeled leukocytes1. 
However, due to several insuperable disadvantages of this agent, there is a great interest 
in the development of new radiopharmaceuticals for this application2,3. A new 
radiopharmaceutical should accumulate efficiently and rapidly in the infected or inflamed 
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tissue. Furthermore it should clear rapidly from the blood and other non-target tissues. A 
promising class of compounds in this field of research are chemotactic and chemokinetic 
mediators and their analogs4. The use of radiolabeled chemotactic compounds (fMLF, 
chemokines) is based on the high affinity interaction of these compounds with their 
receptors expressed on specific leukocyte sub-populations5. In addition, due to their low 
molecular weight, they can penetrate rapidly into the inflamed tissue and clear rapidly from 
the non-target tissue and from the circulation6,7. In addition, antagonists of these 
chemotactic mediators may provide good alternative agents, especially when biological 
effects of the agonistic peptides limit clinical application. Since the knowledge of the 
human inflammatory response has expanded and the number of identified chemokines 
and chemokine receptors has increased, it is now possible to investigate in detail those 
chemokines for their potential as radiopharmaceutical for visualization of inflammatory 
processes.  
 
Chemokines and chemokine receptors 
During an inflammatory response a complex variety of mediators is released in order to 
control this process8. Tissue injury and the release of mediators (e.g. histamine, TNFα) 
trigger the inflammatory response. The subsequent increased blood supply, increased 
vascular permeability and influx of leukocytes aim at efficient elimination of invading 
micro-organisms and repair of injured tissue9. Following initiation, the response is 
continued and finally terminated as described in Table 1. Usually the cause of the 
infection/inflammation is eliminated during the subsequent stages of the inflammatory 
response. The release of the mediators that control the process occurs following two 
major pathways. The first pathway (I) is the release of mediators present in the granules of 
macrophages and granulocytes, the second pathway (II) involves release of arachidonic 
acid by mast cells triggering the lipoxygenase and the cyclo-oxygenase pathway as 
indicated in Table 28,10-28. Each mediator has its specific function and induces its biological 
effects by interaction with specific receptors on blood cells, endothelial cells or smooth 
muscle cells that align the blood vessels. The majority of mediators that is released are 
chemokines that target chemokine receptors that belong to the large family of G-protein-
coupled receptors (GPCRs).  
Membrane proteins of the GPCR superfamily, consist of seven hydrophobic 
transmembrane domains, always involved in signaling processes from the extracellular 
side of the cell towards the intracellular environment29. Binding of receptor specific ligands 
to GPCRs induces various intracellular pathways affecting the cell metabolism, gene 
expression and cell division. The GPCRs are classified into five families; class A through 
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E (Table 3). Members of the GPCR class A (receptors related to the Rhodopsin and 
adrenergic receptors) become activated after interaction with chemotactic compounds and 
cytokines30. In nuclear medicine radiolabeled chemotactic mediators, cytokines or their 
antagonists are considered promising vehicles for scintigraphic imaging of infection and 
inflammation9. It was hypothesized that the high affinity interaction of radiolabeled 
mediators with their receptors expressed on white blood cells (granulocytes, monocytes, 
macrophages) might facilitate the specific localization of the radiolabeled receptor binding 
ligand in the inflammatory foci31. 
 
Table I. Course of an inflammatory process and the adaptive immune response 
Induction of inflammatory response 
1. 
Inflammatory response is triggered by tissue injury or by establishment of microorganisms at 
the site of infection. Establishment of microorganisms involves adherence to the epithelial 
surface (skin or internal mucosal surfaces of the respiratory, gastro-intestinal and urogenital 
tract). 
Initiation of inflammatory response; increased blood supply 
2. The inflammation is initiated by release of histamine by mast cells and basophils and of 
serotinin by platelets, which induces increased blood supply. Activation of resident 
macrophages leads to release of cytokines and chemokines (TNF-α, IL-1).  
Elongation of the inflammatory process; Increased vascular permeability and  
emigration into the infected tissue 
3. Release of chemokines and cytokines leads to upregulation of selectin and recruitment of neutrophils and macrophages. Activation of the complement cascade (especially factor C5a) 
and leukotriene B4 enable these cells to cross the endothelium and enter the infected tissue. 
Besides IL-1 other chemokines like IL-8, NAP-2 and PF-4 are involved in chemotaxis of 
PMNs. 
Termination of inflammation 
4. 
Complement regulatory proteins and a number of anti-inflammatory cytokines (e.g. IL-10, IL-
1ra, TGFβ) downregulate the inflammatory process. Once the inflammatory response leads to 
effective clearance of inflammatory agent and affected tissue, the tissue will return to its 
normal healthy situation. 
 
Furthermore, due to the low molecular weight of these compounds these molecules are 
cleared rapidly from the blood. Due to tremendous progress in the field of Immunology 
and Molecular Biology, the knowledge of these mediators and their receptors has 
expanded. Characterization of genes encoding for such mediators, allowed synthesis 
(chemically and by recombinant DNA techniques) of several ligands. Chemotactic 
molecules and receptor antagonists became available as well as information on their 
structure and biological characteristics. Nowadays more than 45 chemokines and nearly 
20 chemokine receptors have been identified, characterized and described32. For nuclear 
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medicine applications only a small fraction of these chemokines or receptor antagonists 
have been studied so far. 
 
fLMF analogs 
N-formyl peptides, such as N-formyl-methionyl-leucyl-phenylalanine (fMLF), were among 
the first identified potent chemoattractants for phagocytic leukocytes. N-formyl peptides 
are cleavage products of mitochondrial and bacterial proteins. These peptides activate at 
least two of the GPCRs found on granulocytes and monocytes via high affinity interaction 
(Kd = 10-30 nM)33. The GPCRs activated after binding of fMLF belong to the Class A 
GPCRs and the receptor shows partial sequence homology with the CXC receptor34. First 
studies performed with fMLF as a radiopharmaceutical for imaging of infection and 
inflammation were carried out in the 1980s35,36. These studies showed localization in the 
infection within one hour after injection, however, even a dose as low as 10 ng/kg induced 
leukopenia. Several antagonists were developed to circumvent the effect on the number of 
granulocytes in the circulation. Unfortunately, these antagonists showed lower uptake in 
the infection, most likely due to reduced affinity for the receptors37. Babich et al. compared 
the high affinity 99mTc-labeled N-fMLFK antagonist with a low (N-acetyl-MLFK) and a 
moderate affinity antagonist (N-isobutyloxycarbonyl-MLFK) in an E. coli infection model in 
rabbits38. The activity concentration at the site of infection of the three analogs correlated 
with the affinity of each compound for the receptor. Another study with 99mTc-HYNIC-
fMLFK in rabbits with intramuscular infection showed that this compound visualized the 
infected foci at 2 h p.i. with a moderate abscess-to-normal-tissue ratio of 7.5 at 4 h p.i.. 
White blood cell (WBC) counts of the animals were determined and a transient drop to 
65% of the initial counts was observed during the first 30 minutes after injection of the 
radiolabeled peptide39.  A recent study was performed with radiolabeled f-Met-Leu-Phe-
Lys (fMLFK). 99mTc-EC-f-MLFK showed high affinity binding to human granulocytes40. 
Despite this in vitro interaction, the authors concluded that after intravenous injection in 
normal mice the high abdominal activity (at 1 h p.i. 25% ID in the liver, 50% ID in the 
intestines) would limit the applicability of this compound. Unfortunately due to relative low 
accumulation in infected foci and biological effects on WBC counts, chemotactic fMLF 
analogs have limited perspective as an imaging agent. 
 
IL-1 
Interleukin-1 (IL-1) is a 17 kDa proinflammatory cytokine, mainly produced by monocytes, 
activated macrophages and neutrophilic granulocytes9. Two almost identical forms of IL-1 
(IL-1-α and IL-1-β) have been identified, which both bind to the same IL-1 receptors. Two 
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types of IL-1 receptors have been described: IL-1R (type 1) and IL-1R (type 2). The type-1 
receptor is expressed predominantly on T-cells and cells of mesenchymal origin and binds 
both IL-1α and IL-1β with equal affinity. The type-2 receptor is expressed on B-cells, 
granulocytes and macrophages and has a higher affinity for IL-1α41. IL-1 receptor 
expression increases following the stimulation of cells by IL-1. The main biological activity 
of IL-1 is T-cell proliferation and promotion of IL-2 synthesis11. The central role of IL-1 and 
the IL-1 receptor in the inflammatory response explains the presence of IL-1 receptor 
positive leukocytes at the site of an infection or an inflammation. Radiolabeled IL-1 
receptor-binding agents were studied in vivo for the applicability as infection imaging 
agent9. Although radiolabeled IL-1 showed reasonable imaging characteristics in several 
animal models, clinical application was limited due to biological effects of this cytokine  
(i.e., hypotension, headache and fever) even at very low doses (10 ng/kg). In a 
comparative study the imaging abilities of IL-1α, IL-1β and IL-1 receptor antagonist (ra) 
were assessed in a rabbit model of acute infection42. All three agents visualized the 
abscess and highest uptake in this rabbit model was obtained after injection of 123I-IL-1β. 
However, due to the strong biological effects of IL-1α and IL-1β, only IL-1ra could be 
studied in humans. In a clinical study in patients with reumatoid arthritis 123I-IL-1ra 
visualized the inflamed joints with moderate target-to-background ratios (ca. 2-to-1), which 
were in the same range as the ratios obtained with the control agent 123I-labeled human 
serum albumin (HSA). In addition, the major part of the agent cleared via the hepatobiliary 
route, impeding visualization of infectious foci in the abdomen43. Therefore, IL-1 receptor-
binding agents were not further developed for infection imaging agent. 
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Table II. Release of the mediators following two major pathways. 
Pathway Mediator Source Receptor Target Mediator effect Ref 
Histamine Mast cells, basophils H1, h2, h3 CNS, smooth 
muscle, heart 
Vasodilatation 
Increased vascular 
permeability 
16 
Bradykinin Body fluid B1, B2 Endothelial cells, 
Mast cells, sensory 
neurons 
Vasodilatation 
Increased vascular 
permeability 
17 
18 
Vasoactive 
intestinal 
peptide  
(VIP) 
nerve endings, 
immune cells and 
some neoplastic cells 
VPAC1R 
VPAC2R 
Blood cells, 
Tissue T-cells 
Vasodilatation 19 
20 
Complement 
factor 5a  
(C5a) 
Plasma precursor C5a receptor Endothelial cells, 
Mast cells, 
Phagocytes 
Increased vascular 
permeability 
upregulation of 
adhesion molecules 
10 
Platelet 
activating 
factor  
(PAF) 
neutrophils, basophils, 
platelets, and 
endothelial cells 
PAF receptor Various cells like 
neuthrophils, 
monocytes and lung 
cells 
Increased vascular 
permeability 
Upregulation of 
adhesion molecules 
21 
22 
Tumor 
necrosis 
factor alpha 
(TNF-alpha) 
macrophages, 
monocytes, 
neutrophils, T-cells, 
NK-cells 
TNFRSF1a 
TNFRSF1b 
Epithelial cells 
Myeloid cells 
Upregulation adhesion 
molecules 
Neutrophil 
mobilization 
23 
24 
Interleukin 1 
(IL-1) 
monocytes, activated 
macrophages or 
peripheral neutrophil 
granulocytes 
CD121a           
(Type 1) 
CD121b           
(Type 2) 
 
T-cells 
 
B-cells, 
granulocytes, 
macrophages 
Upregulation adhesion 
molecules 
Neutrophil 
mobilization 
11 
Interleukin 2 
(IL-2) 
T-cells expressing CD4 ILR2-alpha   
(TAC-
antigen,p55) 
ILR2-beta    
(p75, CD122)
IL2R-gamma 
Activated T-cells Proliferation of T-
lymphocytes 
8 
12 
 
I 
Granule 
release 
Interleukin 8 
(IL-8) 
monocytes, 
macrophages, T-
lymphocytes, 
fibroblasts, endothelial 
cells, and keratinocytes
CXCR1 
CXCR2 
Neutrophils Chemotaxis of PMN 
Activation of integrins 
13 
25 
15 
Leukotrienes 
B4 
(LTB4) 
neutrophil 
polymorphonuclear 
leukocytes 
BLT1 
BLT2 
Leukocytes, 
thymus and Spleen 
Activation of immune 
cells 
Chemotaxis 
Enhanced adhesion of 
leukocytes 
Enhanced vascular 
permeability 
14 
Leukotrienes 
C4 
macrophages and mast 
cells 
CysLT1 
 
CysLT2 
Spleen, leukocytes 
lung macrophages 
Heart, adrenal 
medulla, leukocytes 
Brochoconstriction 
Vasodilatation 
Increased vascular 
permeability 
26 
Prostaglan-
dines 
probably all cells EP1, EP2, 
EP3, EP4 
Widely distributed Platelet agregation 
vasodilation 
27 
28 
II 
Lipoxy-
genase 
pathway 
Thrombox-
anes 
probably all cells TXA2 Thymus, spleen, 
lung, kidney, heart 
Platelet agregation 
vasodilation 
28 
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Table III.Chemotactic molecules target G-protein coupled receptors. 
 GPCR class A through E 
  Class A rhodopsin like GPCR 
  Amine receptors 
   - Histamine 
   - Serotonin 
  Peptide receptors 
   - Bradykinin 
   - IL-8 
   - Chemokines 
    • C-C (e.g. MCP-1: CCR2) 
    • C-X-C (e.g. IL-8: CXCR1, CXCR2, NAP-2: CXCR2) 
   - fMLP 
  Rhodopsin receptors 
  Nucleotide receptors 
  Platelet activating factor 
  Leukotriene B4 
  Class B secretine like 
  Secretine 
  Vasoactive intestinal peptide (VIP) 
  Class C metabotropic glutamate/pheromone 
  Class D fungal pheromone 
  Class E cAMP receptors (Dictostelium) 
 
IL-2 
Interleukin-2 (IL-2) is a 133 amino acid cytokine with a molecular weight of 15.4 kDa that 
stimulates proliferation of T-lymphocytes12. In addition, in the presence of other factors like 
IL-4, IL-2 promotes proliferation of activated B-cells as well. The biological activities of IL-2 
are mediated by a membrane receptor that is expressed on activated (not on resting) T-
cells. Resting granulocytes and activated B-cells express this receptor just 
sporadically12,44. Radiolabeled IL-2 receptor targeting agents could therefore be of interest 
mainly in chronic inflammatory processes (i.e. autoimmune disorders), characterized by 
minor hemodynamic changes and infiltration of T-lymphocytes5,45. The imaging 
characteristics of both radioiodinated and 99mTc-labeled IL-2 has been studied in a several 
animal models as well as in patients. Signore et al. showed that 123I-Interleukin-2 
accumulated in pancreatic region of diabetic non-obese diabetic (NOD) mice but not in the 
pancreatic region of healthy BALB/c mice46.  
These findings were confirmed by measurement of dissected organs of the mice at 
several time points after injection of 125I-IL-247. Imaging studies in patients with 123I-IL-2 
showed focally enhanced intestinal uptake in patients with active Crohn’s Disease and 
Coeliac disease. Autoradiography (with 125I-IL-2) of biopsy material revealed that this 
accumulation could be attributed to specific binding to IL2R-positive cells48,49. IL-2 has 
been labeled with 99mTc via a two-step reaction using a N3S bifunctional chelator50. The 
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99mTc-IL-2 fully preserved affinity for the receptor and the in vivo stability of the compound 
was superior as compared to the 125I-IL-2 stability. In a clinical study 29 patients with ileal 
and/or colonic Crohn’s Disease underwent both 99mTc-IL-2 scintigraphy and 99mTc-
HMPAO-granulocyte scintigraphy51. In more than 40% of the scans both the 99mTc-IL-2 
and 99mTc-granulocytes scintigraphs were concordantly positive. Although both agents 
showed positive scans in 18 out of the 29 patients (62%), the accumulation of IL-2 and the 
granulocytes usually localized in different colonic segments. The difference in 
accumulation between the two agents indicated that depending on the stage of 
inflammation regions with different types infiltrated immune cells can be present. Another 
clinical study has been reported recently82. In this study, the accumulation of 99mTc-IL-2 
was correlated to the degree of T-lymphocytes infiltration in patients with atypical 
pigmentary cutaneous lesions. Although scintigraphic images revealed low tumor to 
background ratios in patients with positive IL-2 scans (1.26±0.19, n=15), positive scans 
revealed IL-2 accumulation that correlated with the percentage of IL-2 receptor positive 
lymphocytes, determined by histology. Due to the findings of this study, the authors want 
to investigate the correlation between 99mTc-IL-2 scintigraphy and the outcomes of IL-2 
immunotherapy. 
 
IL-8 
IL-8 is a member of the CXC chemokines. Classification of chemokines is based on the 
number and sequential relationship of the first two of four conserved cysteine residues of 
the aminoacid sequence. IL-8 is a non-glycosylated chemotactic cytokine (i.e. chemokine) 
of 8 kDa13. This cytokine is produced by a number of cell types such as stimulated 
monocytes, macrophages and endothelial cells52. The role of IL-8 in infection and 
inflammation is significant; IL-8 has chemotactic activities for all known types of migratory 
immune cells and inhibits the adhesion of leukocytes to activated endothelial cells. 
Consequently, IL-8 exhibits anti-inflammatory activity and is a cytokine found in both acute 
and subacute inflammatory processes53,54. The interleukin-8 (IL-8) receptor is a dimeric 
glycoprotein consisting of a 59 kDa and a 67 kDa subunit. There are at least two major IL-
8 receptor types; CXCR1 en CXCR2. The receptors are mainly expressed on neutrophils 
and bind IL-8 with different affinity (Kd of IL-8 for CXCR1 is 0.8-4.0 nM, and for CXCR2 is 
0.3-2.0 nM). Both receptors belong to the Class A GPCRs (Rhodopsin-like) peptides 
receptors. 
Radiolabeled IL-8 has been studied extensively as infection imaging agent. The potential 
of radiolabeled IL-8 to image inflammation was reported for the first time by Hay et al.. 
This group showed that radioiodinated IL-8 accumulated in inflammatory lesions in a rat 
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model55. The uptake of IL-8, radioiodinated via the chloramine-T method, in carrageenan-
induced sterile inflammations in rats, peaked at 1-3 hours after injection and declined 
thereafter. In addition, this group performed an imaging study with 131I-labeled human 
recombinant IL-8 (rhIL-8) in patients. In this study 131I-rhIL-8 succesfully delineated 
infections in 8 of the 8 patients with active foot infection and osteomyelitis. 131I-rhIL-8 did 
not accumulate in degenerative joint disease or succesfully treated infections56. This study 
showed that radiolabeled rhIL-8 is a feasible infection imaging agent. Van der Laken et al. 
showed specific interaction of radioiodinated IL-8 with its receptor on human granulocytes. 
Imaging experiments in rabbits demonstrated that radiolabeled IL-8 visualized acute 
infection and inflammation already in a few hours after injection. Due to rapid blood 
clearance high target-to-background ratios were obtained42. More importantly, they 
demonstrated that the labeling method had a major effect on the in vivo biodistribution of 
radioiodinated IL-8. The scintigraphic imaging characteristics of IL-8 labeled via the 
Bolton-Hunter method were clearly superior to IL-8 labeled via the iodogen method59. The 
specific activity of the IL-8 preparations used in these studies in rabbits were relatively 
low; the imaging dose of 123I-IL-8 (25 µg/kg) caused a transient drop of peripheral 
leukocyte counts to 45%, followed by a leukocytosis (170 % of preinjection level) during 
several hours. Rennen et al. developed a 99mTc-labeled IL-8 preparation using HYNIC as a 
chelator and performed in vitro as well as in vivo experiments with 99mTc-HYNIC-IL-857,58. 
These studies demonstrated that 99mTc-IL-8 comprised excellent imaging characteristics 
with even higher uptake in the abscess and very high abscess-to-background ratios (>100 
at 8 h p.i.) as compared to radioiodinated IL-8. The agent rapidly accumulated in infectious 
and inflammatory foci and low activity concentrations were found in blood already one 
hour after injection. Due to HYNIC conjugation and labeling with 99mTc, a 25-fold reduction 
of the peptide dose was achieved as compared to radioiodinated IL-8. Due to further 
improvements of the labeling procedure, imaging doses of 99mTc-IL-8 did not induce any 
changes in WBC counts in the circulation58,59.  
In a recent study, 99mTc-IL-8 was tested for its potential to visualize pulmonary infection. 
Radiolabeled IL-8 was evaluated in three different rabbit models of respectively fungal 
infection, pneumococcal and E. coli induced pneumonia81. Despite the fact, that previous 
results demonstrated physiologic uptake of the compound in the lungs, images showed 
that 99mTc-IL-8 clearly visualized pulmonary infection in all three models rapidly after 
injection. The currently achieved radiochemical characteristics of 99mTc-IL-8 warranted 
progression to clinical studies. Clinical studies with 99mTc-IL-8 started in 2004. 
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Platelet factor-4 
Platelet factor-4 (PF-4) is a CXC chemokine synthesized in megakaryocytes and platelets 
that activate neutrophils and monocytes21. In solution PF-4 monomers may form dimers 
and tetramers. PF4 is structurally related to IL-8, but the native PF4 peptide does not have 
affinity for CXCR1 or CXCR2 receptor as is the case with IL-8. As yet no cell surface 
receptor for PF4 has been identified, it has been shown however that slight modifications 
at the N-terminus of PF-4 leads to binding to the CXCR2 receptor60. PF-4 also shows 
affinity for heparin. Moyer et al. tested a PF4 analogue (P483) consisting of the heparin-
binding region of PF-4 and a lysine-rich sequence to facilitate rapid renal clearance. 
Preclinical evaluation of this PF-4 analog indicated that P483 had enhanced affinity for 
leukocytes when complexed with heparin. Likewise, the infection imaging properties of 
99mTc-P483 could be improved after P483 complexation with heparin. They tested the 
radiolabeled PF4-heparin analog P483H in a rabbit model61. Intravenous injection of 
99mTc-P483H visualized intramuscular E. coli abscesses in rabbits already a few hours 
after injection and revealed higher abscess-to-contralateral and abscess-to-blood ratios as 
compared to the radiolabeled WBCs. 99mTc-labeled P483H was evaluated clinically62. 
Thirty patients were injected with various doses of radiolabeled peptide (29 µg, 145 µg 
and 290 µg). Twenty patients also underwent 111In-labeled autologous leukocyte 
scintigraphy for comparison. In most patients 99mTc-P438H rapidly and accurately detected 
the focal infection. The radiolabeled compound showed retention in kidneys, lung, thyroid 
liver and spleen. In this preliminary clinical evaluation P438H revealed a relatively low 
specificity of 81% and sensitivity of 86%. Additionally, the relatively high pulmonary uptake 
of P438H will limit the application of the agent to visualize infections and inflammations in 
the chest.  
 
C5a 
The complement anaphylatoxin C5a is a chemotactic peptide involved in several stages 
during the inflammatory process. This peptide induces smooth muscle contraction, 
increases vascular permeability and induces expression of adhesion molecules on the 
endothelial cells10. C5a also acts directly on neutrophils and monocytes by increasing their 
adherence to endothelial cells and their migration toward the site of infection. C5a, like 
other chemotactic peptides, signals via transmembrane receptors of the Class A GPCRs. 
A comparative study with 99mTc-HYNIC-C5a and its natural metabolite C5a-des-Arg (74) 
(C5adR) was recently performed in rabbits with intramuscular infection63. The affinity of 
C5a for the C5a receptor expressed on monocytes and neutrophils is approximately 
twenty-five times higher than that of C5adR. Consequently, C5a is biologically much more 
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potent than C5adR64. In a rabbit model both agents visualized the infection from one hour 
postinjection. However, this comparative study showed that the uptake of C5a in the 
abscess was five times higher than that of C5adR. Due to the lower affinity of C5adR for 
the C5a receptor there was insufficient accumulation of C5adR in tissues infiltrated with 
receptor-positive cells. Due to the low uptake and abscess-to-muscle ratios obtained with 
C5adR, the authors considered this less bioactive peptide inadequate for imaging of 
infectious or inflammatory foci, while C5a cannot be applied clinically due to its 
pronounced biological effects. 
  
Leukotriene B4 
Leukotriene B4 (LTB4) is a chemotactic dihydroxy fatty acid that is able to activate 
neutrophils. Binding of LTB4 to its specific receptors (BLT1 and BLT2) stimulates 
leukocyte functions such as trans-endothelial migration and chemotaxis65,66 comparable 
with those of classic chemotactic peptides such as fMLP and IL-867. Two receptors for 
LTB4 have been described belonging to class A of GCPRs68,69. The first identified 
receptor; BLT1 is a high affinity receptor for LTB4 and is mainly expressed on neutrophils. 
The second receptor, BLT2, has lower LTB4 affinity and is expressed more ubiquitously, 
with highest expression in spleen, leukocytes, ovary and liver15. Based on its receptor 
expression, it was hypothesized that radiolabeled BLT1 receptor binding agents could be 
used to visualize inflammatory processes. Several radiolabeled LTB4 antagonists have 
been synthesized and studied for the potential to visualize inflammatory and infectious 
lesions70,71. Early studies with a 99mTc-labeled LTB4 antagonist RP517 demonstrated that 
this agent accumulated rapidly and efficiently in acute intramuscular infection72.  
However, due to hepatobiliary clearance of this rather lipophilic compound (the receptor 
binding moiety of the agent contains three aromatic rings), clinical applicability was limited. 
Recently, modified LTB4 antagonists were synthesized in order to reduce physiologic 
uptake in abdominal organs. 
 
MCP-1 
Monocyte chemoattractant peptide-1 (MCP-1) is a cytokine that is produced mainly by 
monocytes and endothelial cells. MCP-1 is an activator of basophils, inducing 
degranulation and the release of histamines73. MCP-1 is a chemotactic factor for 
monocytes but not for neutrophils74. Two MCP-1 specific receptors are described that 
exhibit high affinity for MCP-1 (CCR1, CCR2)75. MCP-1 has a high affinity for the CCR2B 
receptor (Kd = 0.3 nM)76. Based on its selective receptor expression on monocytes, it was 
hypothesized that radiolabeled MCP-1 may be applicable to visualize subacute and 
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chronic inflammatory processes, because these processes are characterized by an influx 
of macrophages and monocytes. Blankenberg et al. studied whether 99mTc-labeled 
recombinant human MCP-1 could visualize the presence of monocyte and macrophage 
infiltration in subacute and chronic soft tissue inflammation in Sprague-Dawly rats77. This 
study showed that MCP-1 was able to visualize the inflammatory lesions, however, 
accumulation in the abscess was relatively low.  
 
NAP-2 
Recently, a study with radiolabeled neutrophil-activating-peptide-2 (NAP-2) has been 
described. NAP-2 is -like IL8- a CXC-subfamily chemokine consisting of 70 amino acids 
and selectively binds the CXCR2 receptor (Kd = 2-4 nM) and does not have affinity for the 
CXCR1 receptor15,78. In this study, both 125I-NAP-2 and 125I-IL-8 localized in subcutaneous 
carrageenan-induced abscesses in rats79. In this model IL-8 gave the highest activity 
concentration in the inflamed tissue, while at later time points the lesion-to-control 
hindlimb ratios of NAP-2 were higher. Additionally, a comparative study has been 
performed where CXCR2 receptor-affinity of three NAP-2 analogs was compared with 
abscess uptake of the 99mTc-labeled NAP-2 compounds80. The results indicated that there 
was a relationship between affinity of the compounds and its uptake at the site of infection. 
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CONCLUSIONS 
 
Nuclear Medicine infection and inflammation imaging techniques aim at visualization of 
infectious and inflammatory processes. Knowledge and understanding of biological, 
physiological pathways and molecular interactions of the human inflammatory response 
encourage the development of new imaging agents. Theoretically, these new agents could 
accumulate rapidly and specifically at the site of inflammation due to their interaction with 
the receptor expressed on activated or infiltrated immune cells. From the studies on 
chemokines and chemotactic receptor binding agents so far, it appears that not all 
chemotactic agents are suitable to serve as a vehicle for infection/inflammation imaging: 
1. Some of these agents induce biological effects even at very low doses, impeding 
clinical application (e.g. fMLP, IL-1, C5a). 
2. The uptake of various agents in the target is too low. This could be either due to the 
low affinity for the receptor, to unfavorable pharmacokinetics or to the low receptor 
density on involved immune cells (e.g. fMLP, NAP-2, C5adR). 
3. The physiologic uptake in the lung or bowel may hamper visualization of foci in 
thorax or abdomen, respectively (e.g. 123I-IL-1, 99mTc-P483H). 
Fortunately, various chemotactic compounds indeed have shown rapid and high 
accumulation in infectious foci and fast background clearance in animal models. 
Additionally, improved labeling procedures result in high specific activities and by this 
means reduce biologic effects. Because of the diverse characteristics of the various 
chemotactic compounds studied so far in several animal models, it is difficult to predict 
which compound will have the most favorable imaging characteristics. The results with 
99mTc-HYNIC-IL-8 in various rabbit models reveal positive future prospects. IL-2 already 
showed clinical potential to visualize inflammatory disorders in various specific patient 
populations. Because of the large number of mediators and analogs, the search for new 
radiopharmaceuticals will continue in future. Clinical studies are warranted to determine 
the potential of these new agents in specific patient populations with infectious or 
inflammatory disorders.  
Significant research on the characteristics of chemotactic receptor binding ligands and 
clinical studies still have to be performed before an applicable, safe and appropriate 
radiopharmaceutical will become available. The success for the development of such a 
radiopharmaceutical will depend on the prolific cooperation of chemists, physicists, 
biological scientists and nuclear medicine specialists. 
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OUTLINE OF THIS THESIS 
 
Nuclear Medicine infection and inflammation imaging techniques aim to visualize 
infectious and inflammatory processes to determine the localization and extension of the 
inflammatory foci in patients. Over the last decades many compounds were studies for 
this application, since the current standard radiopharmaceutical for this purpose –
radiolabeled leukocytes- requires laborious preparation and is accompanied with 
hazardous risks.   
Nowadays, there is a great interest in the development of radiolabeled chemotactic and 
chemokinetic cytokines that accumulate and are retained in infectious and inflammatory 
foci by specific interaction with infiltrated inflammatory cells. Chapter 1 describes the 
specific characteristics of the chemotactic and chemokinetic compounds that are currently 
studied as potential radiopharmaceutical to visualize infectious and inflammatory foci. The 
characteristics of a series of cytokines (IL-1, IL-2), chemokines (IL-8, PF-4, MCP-1, NAP-
2), complement factors (C5a, C5adR), chemotactic peptides (fMLF) and other chemotactic 
factors are described. The potentials of these compounds to serve as an imaging agent 
are discussed. 
In chapter 2 a basic study to determine the potential of the bivalent 111In-labeled 
leukotriene B4 (LTB4) antagonist, DPC11870, is described. The LTB4 antagonist 
DPC11870 was labeled with 111In and analyzed for the ability to visualize intramuscular E. 
coli infection in rabbits. In addition, it was investigated whether the visualization was due 
to receptor-mediated interaction at the site of the infection. Once specificity of 111In-
DPC11870 accumulation at the site of infection was established and the agent could be 
used to visualize infectious lesions, the applicability of this compound was determined in 
more clinically relevant animal models, in chapter 3 and chapter 4. The radiolabeled LTB4 
antagonist was evaluated in a rabbit model of acute colitis and in a model of pulmonary 
aspergillosis infection. Results of the radiolabeled LTB4 antagonist were compared with 
99mTc-labeled granulocytes and 67Ga-citrate, the commonly used radiopharmaceuticals to 
visualize abdominal infection and pulmonary infection respectively, and with 18F-FDG.  
In the studies mentioned above, the results indicated that accumulation of 111In-DPC11870 
in the abscess continued while radioactivity had cleared from the circulation almost 
completely. As a consequence of this remarkable observation, we investigated the 
pharmacodynamics of 111In-DPC11870 and performed several experiments to determine 
the mechanism of accumulation of the radiolabeled LTB4 antagonist in the abscess 
(chapter 5). The pharmacodynamics was studied by serial imaging and by ex vivo 
counting of dissected tissues. The mechanism of abscess visualization was investigated in 
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rabbits where intramuscular infection was induced 16 h after i.v. administration of 111In-
DPC11870. In addition, heterologous leukocytes and bone marrow cells of a donor rabbit 
were labeled with 111In-DPC11870 in vitro and the biodistribution of these in vitro 
radiolabeled cells was compared with the biodistribution of 111In-DPC11870. 
Since 99mTc is a radionuclide with better imaging characteristics than 111In (physical half-
life, gamma-energy, availability), we developed two LTB4 antagonists that were 
structurally related to DPC11870 and could be labeled with 99mTc. In chapter 6 we 
describe the chemical synthesis of the bivalent DTPA conjugated LTB4 antagonist 
DPC11870, the bivalent HYNIC-conjugated analog MB81 and the monovalent HYNIC-
conjugated LTB4 antagonist MB88. We investigated the labeling efficiency and in vivo 
characteristics of 99mTc-MB81 in a rabbit model of intramuscular E. coli infection after 
radiolabeling with three different coligand systems (Tricine, TPPTS or Isonicotinic acid). In 
chapter 7 the imaging characteristics and kinetics of both HYNIC-conjugated LTB4 
antagonists, MB81 and MB88 were evaluated and compared with the characteristics of 
111In-DPC11870. 
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ABSTRACT 
 
Several radiolabeled chemotactic peptides have been tested for their suitability to 
visualize infection and inflammation. Leukotriene B4 (LTB4) receptor binding ligands could 
be useful agents to visualize neutrophilic infiltrations since the LTB4 receptor is 
abundantly expressed on neutrophils after an inflammatory stimulus. In this study we 
investigated the in vivo and in vitro characteristics of a new hydrophilic 111In-labeled LTB4 
antagonist. 
Methods:  The LTB4 antagonist DPC11870 was labeled with 111In and i.v. injected in New 
Zealand White rabbits with E. coli infection in the left thigh muscle. The pharmacokinetics 
and biodistribution were studied by serial scintigraphic imaging (0-24 h p.i.) and by ex vivo 
counting of dissected tissues (6, 24 h p.i.). The receptor-mediated in vivo localization of 
the compound was investigated in three rabbits that received an excess of non-radioactive 
In-labeled agent, two minutes prior to the administration of the 111In-labeled LTB4 
antagonist. 
Results: In rabbits with intramuscular E. coli infection the abscess was visualized as early 
as 2 h after injection. Accumulation in the abscess increased with time resulting in 
excellent images at 6 h p.i.. Blood clearance was rapid in the first hours after injection 
(t½α =30±6 min, 85%, t½β =25.7±0.8 h, 15%). Abscess-to-background ratios, as derived 
from the ROI analysis, increased up to 34±7 at 24 h p.i. The images of both groups 
showed moderate uptake in liver, spleen, kidneys and bone marrow. No activity was seen 
in the bladder, indicating almost complete retention in the kidneys. The uptake in the 
abscess could be blocked completely by injection of an excess of non-radioactive agent, 
indicating specific receptor-ligand interaction of the radiolabeled agent in the infected 
tissue. Biodistribution data showed that after saturation of the LTB4 receptor the abscess 
uptake was significantly reduced (0.08±0.01 %ID/g vs. 0.24±0.06 %ID/g, p =0.008).  
Conclusion: The modified LTB4 antagonist, DPC11870, visualized infectious foci rapidly 
after injection due to specific receptor-ligand interaction. Because of the high abscess-to-
background ratios that were obtained and the fact that no accumulation of radioactivity 
was observed in the gastro-intestinal tract, this compound has good characteristics to 
visualize infectious and inflammatory foci. 
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INTRODUCTION 
 
For the scintigraphic imaging of infection and inflammation, the use of radiolabeled 
autologous leukocytes is considered the gold standard. Since the preparation of 
radiolabeled white blood cells is laborious and requires handling of potentially 
contaminated blood, there is an ongoing search for an agent that is capable to visualize 
infectious and inflammatory foci, and that can be prepared instantaneously1. Ideally, such 
a radiopharmaceutical preferably would be synthesized chemically instead of using 
material with a biologic origin. Furthermore, these compounds should be easily and rapidly 
radiolabeled and would not provoke immunological responses2. A number of compounds 
have been tested for this application e.g., radiolabeled antibodies, liposomes, and 
receptor binding peptides3,4. 
The use of radiolabeled chemotactic peptides as an infection-imaging agent is based on 
the enhanced expression of high affinity receptors on infiltrating granulocytes activated 
after an inflammatory response. Several of these peptides (chemokines, platelet factor 4, 
fMLP and other chemotactic compounds) have been studied for the detection of infection 
and/or inflammation5. 
In this study, we examined the characteristics of an 111In-labeled leukotriene B4 (LTB4) 
antagonist for its potential to visualize infectious foci scintigraphically. LTB4 is a very 
potent chemoattractant that activates granulocytes and macrophages as a reaction to an 
inflammatory response6,7. At the site of the inflammation, enhanced LTB4 synthesis 
occurs mainly by leukocytes from arachidonic acid via the 5-lipoxygenase pathway8. LTB4 
responses are receptor mediated, and two classes of stereospecific binding sites for LTB4 
have been identified. The first type of receptor, BLT1 is a high affinity receptor (Kd for 
LTB4 is 1 nM) mainly expressed on human neutrophils9. The second receptor type, BLT2 
is a low affinity receptor (Kd for LTB4 is 23 nM) that is more ubiquitously expressed6,10. 
Binding of LTB4 to BLT1 and BLT2 receptors promotes chemotaxis and chemokinesis. 
Therefore, LTB4 is considered to be an important mediator in both acute and chronic 
inflammatory diseases9,11. 
In a previous study we showed the potential of a 99mTc-labeled LTB4 antagonist, RP517, 
for its ability to visualize experimental infection12-14. The disadvantage of RP517, however, 
was its hepatobiliary clearance, causing high uptake in the organs of the digestive tract, 
relatively early after injection. This gastrointestinal uptake of RP517 limits its applicability 
as an infection imaging agent12. 
Since the radiolabeled LTB4 antagonist showed rapid and high accumulation in the 
infected tissue, we produced a hydrophilic bivalent LTB4 antagonist conjugated with a 
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diethylenetriaminepentaacetic acid (DTPA) moiety to allow radiolabeling with 111In. In the 
present study, the leukocyte binding characteristics of this modified bivalent LTB4 
antagonist was studied both in vitro and in vivo.  
  
MATERIALS AND METHODS 
 
DPC11870 synthesis 
DPC11870 (Fig.1) is a bivalent LTB4 antagonist consisting of two identical LTB4 receptor-
binding moieties each modified with four cysteic acid as pharmacokinetic modifiers. The 
LTB4-binding moieties are joined via the carboxyl groups of glutamic acid and conjugated 
with DTPA.  
A complete description of the synthesis of DPC11870 will be described elsewhere. Briefly, 
the tetra-cysteic acid derivative of SG385 prepared as reported previously15 was 
dimerized by reaction with the bis-TFP ester of Boc-glutamic acid.  Removal of the Boc 
group and conjugation with DTPA anhydride gave crude DPC11870. The product was 
further purified by RP-HPLC. RP-HPLC analysis on a C18 column eluted with a 0.5%/min 
acetonitril gradient of the purified and lyophilized product gave a single peak.  The purified 
DPC11870 was characterized further by NMR and Mass Spectrometry. 
 
Figure 1. 
Structural formula of  
DPC11870. 
 
 
 
 
 
 
 
 
 
 
Radiolabeling of DPC11870 
Labeling of DPC11870 with 111In was performed in metal-free 0.25 M ammonium acetate 
buffer, pH 5.5 for 30 min at room temperature. Labeling experiments were performed in 
order to determine the maximum specific activity of the radiolabeled agent. Radiochemical 
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purity was checked by ITLC on silica gel strips (Gelman Sciences, Inc., Ann Arbor, MI) in 
0.1 M Na-citrate buffer, pH 6.0. Strips were analyzed in a well-type gamma counter 
(Wizard, Pharmacia-LKB, Uppsala, Sweden). In addition, RP-HPLC was performed on a 
C18 column (Zorbax Rx-C18 4.6 mm x 25 cm) on a Agilent 1100 system equipped with an 
in-line radiodetector (Canberra Packard, Brussels, Belgium). During analysis, a gradient 
was used from 100 % solvent NH4Ac, pH 7.0 to 100 % acetonitrile in 50 minutes, at a flow 
rate of 1 mL/min. 
Labeling with non-radioactive InCl3 (Aldrich, Milwaukee, WI) was performed under the 
same conditions as described above. A three-fold molar excess of InCl3 was added to 
DPC11870 in ammonium acetate buffer, pH 5.5. 
 
Receptor Binding Assay  
In vitro binding studies were performed on purified human granulocytes. The granulocytes 
were purified as described previously16. To 1 x 108 cells increasing amounts of non-
radioactive In-DPC11870 (0-10 µM) were added in the presence of 10,000 cpm 111In-
DPC11870 (0.4 nM) in 0.25 M Tris/HCl, pH 7.2. After incubation during 1 h at 37°C, cells 
were washed twice (5 min, 5000 x g), supernatant was discarded and the radioactivity in 
the pellet (total bound activity) was measured in a shielded well-type gamma counter 
(Wizard, Pharmacia-LKB, Uppsala, Sweden). 
The specifically bound fraction versus the non-radioactive LTB4 antagonist concentration 
was plotted. The IC50 (50% inhibitory concentration) was determined as being the 
concentration of non-radioactive In-DPC11870 that caused 50% inhibition of the maximum 
binding of the 111In-DPC11870.  
 
Infection Model 
Thirteen female New Zealand White rabbits weighing 2.3-2.8 kg were kept in cages (one 
rabbit per cage) and fed standard laboratory chow and water ad libitum. An E. coli 
infection was induced in the left thigh muscle by intramuscular injection of 4 x 109 colony-
forming units (CFU) of E. coli. During this procedure the rabbits were anaesthetized by 
subcutaneous injection of 0.7 mL of a mixture of 0.315 mg/mL fentanyl and 10 mg/mL 
fluanison (Hypnorm®, Janssen Pharmaceutica, Buckinghamshire, UK). All animal 
experiments were approved by the local animal welfare committee in accordance with the 
Dutch legislation and carried out in accordance with their guidelines. 
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Imaging and Biodistribution 
Twenty-four hours after the induction of the infection, when swelling of the infected muscle 
was apparent, thirteen rabbits were intravenously injected with 11 MBq 111In-DPC11870 (3 
µg) in the lateral ear vein. Three rabbits received 2 mg non-radioactive In-DPC11870 two 
minutes prior to the injection of the radiolabeled compound. The excess of non-radioactive 
agent was injected to induce saturation of the LTB4 receptors in vivo. This experiment 
was performed in order to determine receptor-specific accumulation of 111In-DPC11870 in 
the abscess. 
For scintigraphic imaging, the rabbits were immobilized in a mold and placed prone on a 
gamma camera (Orbiter, Siemens, Hoffman Estates, IL) using a medium-energy parallel 
hole collimator. Images (300,000 cts/image) were obtained up to 24 h post injection (p.i.) 
and stored digitally in a 256x256 matrix. All images were windowed identically, allowing a 
fair comparison among the various experiments. The scintigraphic results were analyzed 
by drawing regions of interest (ROI) over the abscess and the contralateral muscle 
(background). Abscess-to-contralateral muscle ratios were calculated. 
The three rabbits that received an excess of non-radioactive agent and five rabbits, only 
injected with radiolabeled antagonist were euthanized at 6 h p.i. with a lethal dose of 
sodium phenobarbital to determine the biodistribution of the agent. At 24 h p.i. the other 
five rabbits were euthanized. A blood sample was taken by cardiac puncture. Tissues 
were dissected and weighed. The activity in tissues was measured in a shielded well-type 
gamma counter together with the injection standards and was expressed as the 
percentage of the injected dose per gram (%ID/g). 
 
Pharmacokinetics 
The pharmacokinetics of the 111In-labeled agent were studied in detail in two rabbits that 
were injected with the 111In-DPC11870 and two rabbits that received an excess of non-
radioactive DPC11870, prior to the 111In-DPC11870. Blood samples were drawn at  –1, 3, 
15, 30, 90, 120, 240, 360 and 1440 min p.i. The activity in the samples was determined in 
a gamma counter and expressed as a percentage of injected dose assuming that the total 
blood weight accounted for 6% of total body weight17. The t½α and t½β were calculated 
assuming a two-phase linear model for the blood clearance. In addition, blood samples 
were divided into two portions; one tube was used for white blood cell analysis, the 
second tube was centrifuged (5 min, 1500 x g) and activity in the pellet and plasma were 
determined. 111In-DPC11870 and the plasma samples were analyzed by Fast Protein 
Liquid Chromatography (FPLC) on a Biosep 3000 gelfiltration column (Phenomenex), 
using Phosphate Buffered Saline, pH 7.2 (PBS) as eluens, 1 mL/min. 
Scintigraphic imaging of infection  
Statistical Analysis  
All mean values are presented as mean ± standard deviation. Statistical analysis was 
performed using the two-sided Student t-test. The level of significance was set at 0.05. 
 
RESULTS 
 
Figure 2. 
HPLC radiogram of 
111In-DPC11870 using 
a C18 RP-HPLC 
column eluted with a 
5%/min acetonitrile 
gradient. 
 
 
 
 
 
 
 
 
Radiolabeling and Receptor Binding Studies 
The RP-HPLC radioactivity elution profile showed that the unbound 111In eluted with the 
void volume with a retention time (Rt) of 2.5 min, whereas the labeled compound eluted 
with a Rt of 30.1 min (51% acetonitrile) (Fig. 2). 
RP-HPLC analysis showed that the maximum specific activity achieved with a labeling 
efficiency exceeding 95% was 3.7 MBq/µg DPC11870 (12 MBq/nmol). 
The IC50 of DPC11870 was 10 nM. Nonspecific binding was determined as the binding of 
111In-DPC11870 to granulocytes in presence of 10 µM non-radioactive In-DPC11870. The 
nonspecific binding of 111In-DPC11870 to the granulocytes was relatively high (40%). The 
competitive binding assay was also carried out using human lymphocytes and 
erythrocytes. 111In-DPC11870 did not bind specifically to these cell types. The amount of 
111In-DPC11870 bound to these cells (incubated in presence and absence of non-
radioactive In-DPC11870) did not exceed 5%. 
 
 
 
 
Activity
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Figure 3. 
3a. Scintigraphic images of a rabbit E. coli thigh muscle infections. The rabbits received 3 µg, 11 
MBq 111In-DPC11870 intravenously. Anterior images were acquired immediately, 2, 6 and 24 h after 
injection of 111In-DPC11870. 3b. Scintigraphic image of a rabbit that received 2 mg non-radioactive 
In-DPC11870 before the injection of the 111In-labeled LTB4 antagonist. This anterior image was 
acquired 6 h after injection of the radiolabel. 
 
 
Figure 4. 
Biodistribution data obtained 6 
hours postinjection of 111In-
DPC11870. Each bar 
represents the mean values ± 
SD. Values were analyzed 
using a unpaired T-test; * = P 
< 0.05, ** = P < 0.01. P-values 
refer to differences in uptake 
of radiolabel between rabbits 
also injected with 2 mg non-
radioactive LTB4 antagonist, 
compared with rabbits only 
injected with the radiolabeled 
compound (3 µg). 
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aging and Biodistribution 
ction of 111In-DPC11870 are shown in Fig. 3. 
us foci were visualized. Visualization of the 
Im
The scintigraphic images after the inje
Immediately after injection of the radiolabeled LTB4 antagonist, accumulation of 
radioactivity was observed in lung, liver and kidneys. Subsequently, accumulation of 
activity was seen in spleen and bone marrow.  
As early as two hours after injection the infectio
abscess improved with time. At 24 h p.i. the abscess and kidneys were the tissues with 
the highest activity concentration. No activity was seen in the bladder at any time point. In 
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ues as summarized 
on-radioactive In-DPC11870, the uptake of 
Figure 5. 
 of 111In-DPC11870 in 
 
harmacokinetics 
activity concentrations in the blood after injection of 111In-DPC11870 
addition, there was no visualization of the digestive tract, indicating that the compound 
was not cleared via the hepatobiliary route (Fig. 3a). Abscess-to-contralateral muscle 
ratios as derived from ROI analysis of the images increased significantly between 6 h p.i. 
(18±4) and 24 h p.i. (34±7) (p=0.022). In the rabbits pre-injected with an excess of non-
radioactive In-DPC11870 the infected thigh muscle was not visualized, indicating that 
abscess uptake of 111In-DPC11870 was receptor-mediated (Fig. 3b).  
The biodistribution data derived from ex vivo counting of dissected tiss
in Fig. 4, were consistent with the scintigraphic images. Uptake of 111In-DPC11870 in the 
abscess, at 6 h p.i. was 0.24±0.06 %ID/g and remained constant until 24 h p.i. (0.25±0.02 
%ID/g). The radioactivity concentrations in the blood at 6 and 24 h p.i were 0.09±0.03 
%ID/g and 0.03±0.01 %ID/g, respectively. Uptake in bone marrow and spleen was 
relatively high; (0.59±0.04 %ID/g and 0.69±0.08 %ID/g, respectively at 6 h p.i.), while 
uptake in the other tissues was relatively low.  
In the rabbits pre-injected with an excess of n
radiolabel in the abscess was significantly lower (0.03±0.02 %ID/g versus 0.24±0.06 
%ID/g, p< 0.004). Uptake in the spleen and the bone marrow was also significantly lower 
in these animals (0.09±0.01 %ID/g versus 0.69±0.08 %ID/g, p< 0.0003, and 0.12±0.04 
%ID/g versus 0.59±0.04 %ID/g, p<0.002 respectively). The blood levels in these animals 
were significantly higher (0.18±0.02 %ID/g versus 0.09±0.03 %ID/g, p < 0,004). 
 
Blood clearance
NZW rabbits. The average amount 
and SD of activity of two rabbits are 
expressed as %ID/g present in the 
blood and plasma. Plasma 
concentration was corrected using the 
hematocrit of the animals. 
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In Fig. 5a the radio
are depicted. In the first hours after injection of the radiolabeled compound the clearance 
was fast (t½α 30±6 min, 85%), at later time points the compound cleared from the blood 
much more slowly (t½β 25.7±0.8 h, 15%). Considering the molecular weight of the agent, 
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Figure 6. 
d cell counts after injection 
 
ISCUSSION 
he present studies demonstrated that DPC11870 can be labeled with 111In easily and 
the t½β is remarkably high, suggesting association to blood cells or serum proteins. 
Measurement of plasma samples demonstrated that more than 98% of the radioactivity 
was found in the plasma (Fig. 5). FPLC analysis of plasma samples on a gel filtration 
column showed one radioactive peak at 11 min, co-eluting with proteins with a molecular 
weight 50-100 kDa. Incubation of the 111In-labeled compound in PBS with 0.5% bovine 
serum albumin (BSA) and analysis with FPLC on a gel filtration column, resulted in elution 
patterns with one activity peak with a retention time corresponding with BSA (11 min). 
Neither the rabbits injected with 111In-DPC11870 nor animals injected with 111In-DPC11870 
and excess of non-radioactive compound showed significant changes in white blood cell 
counts. As shown in figure 6, the white blood cell concentration before injection of the 
111In-DPC11870, was 7.6±3.3x109/L and at all time points postinjection, the cell 
concentration was within the normal range (3.2-13.2x109/L). This indicated that this LTB4 
antagonist did not induce changes in peripheral leukocyte counts.  
 
White bloo
111of the In-DPC11870. The initial 
amount of white blood cells is 
represented as 100 %. The number of 
cells determined after injection is 
calculated as percentage of this initial 
value. 
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efficiently, resulting in a high specific activity and high radiochemical purity. The IC50, 
determined at 10 nM, indicated that 111In-DPC11870 binds to its receptor with high affinity. 
The in vitro receptor binding results suggest that 111In-DPC11870 accumulates in infected 
tissue by binding to LTB4 receptor-positive cells. The in vivo imaging experiments showed 
that the 111In-labeled LTB4 antagonist was able to visualize E. coli infection in rabbits 
already a few hours after the injection. Due to rapid blood clearance in the first hours after 
the injection low background activity was seen which, in combination with the rapid 
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ound indicated that the 
 to the images obtained with the more lipophilic agent RP517, there was no 
 that the compound cleared from the blood rapidly in the 
ability to 
accumulation at the site of infection, resulted in excellent visualization of the infectious foci 
at 6 h p.i. The activity concentration in the infectious foci did not increase from 6 to 24 h. 
Improvement of contrast in the images at 24 h p.i. was due to the ongoing activity 
clearance from the background. The relatively high uptake of radiolabel in the bone 
marrow is remarkable. Apparently, the compound easily enters the bone marrow 
compartment, where it may bind to LTB4 receptor-positive cells. 
Administration of excess of non-radioactive In-labeled comp
targeting of infectious foci was a result of specific receptor-ligand interaction. The in vivo 
receptor blocking experiments also indicated that the targeting of cells in the bone marrow 
and spleen was dependent on interaction with receptor-positive cells. These findings are 
in accordance with those of Yokomizo et al.18 who showed that highest expression of 
human BLT1 mRNA was observed in leukocytes, followed by cells in the spleen and 
thymus.  
Compared
accumulation in the gastro-intestinal tract12. Abscess uptake for 111In-DPC11870 was 
higher at all time points as compared to that of 99mTc-RP517 (0.035±0.007 %ID/g at 4 h 
p.i., 0.12±0.02%ID/g at 20 h p.i.). On the other hand, blood levels of 99mTc-RP517 were 
lower (0.024±0.004 %ID/g at 4 h p.i, 0.004±0.0004 %ID/g at 20 h p.i.), resulting in lower 
background activity. In this animal model abscess-to-contralateral muscle ratios were in 
the same range for both agents. 
Pharmacokinetic analysis showed
first hours after administration. The distribution half-life (t½α) was in accordance with the 
low molecular weight of the compound. A fraction of the radiolabeled agent (15%), 
however, seemed to clear more slowly from the blood (t½β = 25.7 h) which is unusual for 
a low molecular weight compound (molecular weight: 3,127 Da). This slow clearance may 
be due to interaction of the radiolabeled agent with serum proteins19. The FPLC analysis 
of plasma samples indeed showed that 111In-DPC11870 interacted with albumin. 
Radiolabeled chemotactic peptides have been intensively studied for their applic
image infectious and inflammatory foci. Their theoretically high affinity for blood cell 
receptors, good penetrating ability and rapid background clearance suggest that they are 
ideal candidates for this application. A main disadvantage of some chemotactic and 
chemoattractive compounds is the induction of transient leukopenia after i.v. injection4.  
The data in this study show that In-DPC11870 does not provoke any of these changes in 
rabbits, even at very high doses (2 mg). Therefore, it seems unlikely that the LTB4 
antagonist used in this study will provoke side effects after i.v. administration in patients. 
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ONCLUSION 
he present study demonstrates that the radiolabeled bivalent LTB4 antagonist, 
dings, further in vitro and in vivo studies are warranted, preferably 
1. oerman OC, Dams ET, Oyen WJ, Corstens FH, Storm G. Radiopharmaceuticals for scintigraphic 
2. rmaceuticals for the study of 
3. and inflammation. Lancet. 
4. r ML. Radiolabeled peptides in diagnosis and therapy. Semin Nucl Med. 
5. akur ML. Imaging infection/inflammations. Pathophysiologic basis and 
6.  n. Crit Rev Immunol. 1990;10:1-12. 
stem. Int J 
8. gical inhibition of leukotriene actions. Pharm World Sci. 
9. scott SM. The scent of a phagocyte: Advances on leukotriene B4 receptors. J Exp 
10. . Leukotriene B4 and inflammatory disease. Agents Actions. 1988;24:114-119. 
12. lled leukotriene B4 receptor antagonist 
13. ng 99m-Tc-
14. d 
LTB4 receptor antagonist useful for iImaging infection and inflammation. Bioconjug Chem. 
2002;13:881-886. 
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T
DPC11870 meets the most important requirements of a radiopharmaceutical to visualize 
infection and inflammation. The agent visualizes infectious foci within a few hours after 
injection. The compound can be labeled easily and efficiently, does not provoke 
hematological changes in the peripheral blood and can be produced relatively easy via 
chemical synthesis. 
Because of these fin
with an analog that can be labeled with 99mTc. Attempts to replace the DTPA moiety with a 
99mTc-chelating moiety will be undertaken.  
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ABSTRACT 
 
The use of radiolabeled leukocytes is considered the gold standard for scintigraphic 
imaging of inflammatory bowel disease (IBD). The disadvantages of 99mTc-HMPAO-
leukocytes however, encourage the search for new imaging agents with at least similar 
diagnostic accuracy, but without the laborious preparation and subsequent risk of 
contamination. In this study, we investigated the imaging characteristics of a new imaging 
agent that specifically binds to the leukotriene B4 (LTB4) receptors expressed on 
neutrophils. Imaging characteristics of the 111In-labeled LTB4 antagonist (DPC11870) 
were compared with those of 18F-fluorodeoxyglucose (FDG) and 99mTc-HMPAO-
granulocytes in a rabbit model of experimental colitis.  
Methods: Acute colitis was induced in New Zealand White (NZW) rabbits by infusion of 
trinitrobenzene sulfonic acid (TNBS) in the descending colon. Forty-eight hours after 
induction of colitis all animals were injected intravenously with 99mTc-granulocytes, FDG or 
111In-DPC11870. The pharmacokinetics and biodistribution were studied by serial 
scintigraphic imaging and by ex vivo counting of dissected tissues.  
Results: All three radiopharmaceuticals visualized the inflamed colon as early as 1 h 
postinjection. However, as compared to 99mTc-granulocytes both 111In-DPC1170 and FDG 
were superior in visualizing the inflamed lesions. The biodistribution data showed that the 
uptake in the inflamed colon of 111In-DPC11870 was highest (0.72±0.18 %ID/g) followed 
by 99mTc-granulocytes (0.40±0.11 %ID/g) and FDG (0.16±0.04 %ID/g). Due to low activity 
concentrations in the non-inflamed colon the radiolabeled LTB4 antagonist also revealed 
the highest affected-to-non-affected-colon ratio (11.6 for 111In-DPC11870, 5.5 for 99mTc-
granulocytes and 4.1 for FDG).  
Conclusion: The radiolabeled LTB4 antagonist DPC11870 clearly delineated acute colitis 
lesions in NZW rabbits within one hour postinjection. Due to high uptake in the inflamed 
lesions and low activity concentration in the non-inflamed colon, images acquired with 
111In-DPC11870 were superior as compared with 99mTc-granulocytes or FDG. 
 
INTRODUCTION 
 
Several nuclear medicine imaging techniques are currently used as a tool for diagnosis of 
inflammatory and infectious diseases in patients. In general, scintigraphic imaging of 
inflammatory and infectious foci is performed using radiolabeled leukocytes. Especially in 
cases of inflammatory bowel disease (IBD) radiolabeled leukocytes are considered the 
best of the currently available scintigraphic imaging agents. 99mTc-HMPAO-leukocytes are 
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a useful radiopharmaceutical in management of patients with Crohn’s disease. Uptake of 
radioactivity correlated with endoscopy and histology1. Despite the fact that 111In- or 99mTc-
labeled leukocytes are considered adequate imaging agents, their laborious preparation 
and the handling of potentially contaminated blood, has stimulated the search for an 
alternative radiopharmaceutical comprising the same imaging qualities. Recent reports 
suggest that FDG may be such an alternative2,3. FDG positron emission tomography 
(PET) is a distinguished imaging tool in clinical oncology based on its ability to image the 
increased glucose uptake of tumor cells. Several studies have shown that increased 
glucose metabolism is not restricted to malignant cells4. Increased FDG accumulation also 
occurs in inflammatory cells5,6. Besides FDG, chemokine receptor binding agents may be 
used for imaging of infection and inflammation7,8. The use of radiolabeled chemotactic 
peptides (e.g. fMLP, chemokines) is based on the high affinity interaction with their 
receptors specifically expressed on (activated) white blood cells. Since many of these 
leukocytes infiltrate at the site of inflammation, interaction with these receptors in vivo may 
lead to accumulation of the radiolabeled agent in the infectious or inflammatory foci. As 
compared with the radiopharmaceuticals currently used to image infectious and 
inflammatory lesions, the small molecular weight, leading to rapid penetration in the focus 
and fast clearance from the blood, and the absence of potential hazard associated with 
handling blood products are additional advantages and warrant further investigation of 
these agents9. LTB4 is one of the chemotactic molecules that potentially could be studied 
for this purpose. LTB4 activates granulocytes and macrophages as a reaction to an 
inflammatory response10,11. Two types of LTB4 receptors have been identified12,13. The 
first receptor type, BLT1 is a high affinity receptor mainly expressed on human 
neutrophils. The second receptor type, BLT2 is a low affinity receptor that is expressed 
more ubiquitously with high expression in spleen, leukocytes, ovary and liver10,14. It has 
been reported recently that 99mTc-labeled LTB4 antagonist RP517 binds to the neutrophil 
LTB4 receptor, and is also capable of imaging myocardial inflammation caused by 
coronary artery occlusion and reperfusion in a dog model15.  We found that RP517 is 
capable of rapidly visualizing intramuscular E. coli abscesses in rabbits16. The high 
lipophilicity of RP517 results in predominantly hepatobiliary excretion, making imaging of 
infectious and inflammatory foci in the abdomen difficult. The LTB4-antagonist used in this 
study was DPC11870. DPC11870 is structurally related to RP517, but is made less 
lipophilic by the addition of pharmacokinetic modifying groups. We found that DPC11870 
binds to human granulocytes with high affinity in vitro. Therefore, it was hypothesized that 
in vivo interaction with granulocytes at the site of inflammation, combined with reduced 
uptake in the GI tract, could lead to visualization of the inflamed colon. In this study we 
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investigated the imaging characteristics of the 111In-labeled Leukotriene B4 antagonist 
DPC11870, 18F-fluorodeoxyglucose (FDG) and 99mTc-leukocytes in a rabbit model of 
acute, chemically induced colitis. 
  
MATERIALS AND METHODS 
 
DPC11870 
DPC11870 is a bivalent LTB4 antagonist consisting of two identical LTB4 receptor-binding 
moieties, conjugated with DTPA in order to allow radiolabeling with 111In. The labeling of 
20 µg DPC11870 and 75 MBq  111In was performed in metal-free 0.25 M ammonium 
acetate buffer, pH 5.5 during 30 minutes at room temperature17. Radiochemical purity was 
checked by ITLC on silica gel strips (Gelman Sciences, Inc., Ann Arbor, MI) in 0.1 M Na-
citrate buffer pH 6.0 and by reversed phase HPLC on a C18 column (Zorbax Rx-C18, 4.6 
mm x 25 cm) on an Agilent 1100 HPLC system, using a linear gradient from 100% NH4Ac 
buffer, pH 7.0 to 100% acetonitrile in 50 minutes, at a flow rate of 1 mL/min. Specific 
activity of the 111In-DPC11870 was 3.7 MBq/µg (12 MBq/nmol) and the chemical purity 
exceeded 95%. 
 
Radiolabeling of Granulocytes 
Since radiolabeled leukocytes obtained from infected donors showed better imaging 
characteristics as compared to leukocytes obtained from healthy donors18, blood was 
obtained from a donor rabbit in which acute colitis was induced 48 h before as described 
below. The collection of 50 mL blood and the purification and labeling of granulocytes with 
185 MBq 99mTc-HMPAO was performed as described previously19. Labeling efficiency 
exceeded 80%.’ 
 
18FDG 
18FDG was commercially obtained from Tyco Healthcare (DRN 9957, Petten, The 
Netherlands). Activity concentration was 1.22 GBq/11.3 ml at calibration time. 
 
Animal Model 
Fifteen female NZW rabbits weighing 2.3-2.8 kg were kept in cages (one rabbit per cage) 
and fed standard laboratory chow and water ad libitum. Thirty minutes prior to the 
induction of colitis and during the imaging experiment all animals were sedated with a 
subcutaneous injection of 0.7 ml Hypnorm (Fentanyl 0.315 mg/mL + Fluanisone 10 
mg/mL) (Janssen Pharmaceutical, Buckinghamshire, UK). Induction of colitis was 
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performed as described previously, with minor modifications20,21. A flexible silicone tube 
(diameter 2.6 mm, 40 cm length) was inserted into the colon, the tip placed at 20 cm from 
the anal sphincter. Via the tube 1 mL 50% ethanol, followed by 1 mL ethanol containing 25 
mg trinitrobenzene sulfonic acid (TNBS, Sigma Chemicals, St.Louis, MO) and 3 mL 
ethanol were injected into the colon. After the induction, animals had free access to the 
normal amount of food and water. All animal experiments were approved by the local 
Animal Welfare Committee in accordance with the Dutch legislation and carried out in 
accordance with their guidelines. 
 
Imaging and Biodistribution 
Forty-eight hours after the induction of colitis animals received an intravenous injection 
with 11 MBq 111In-DPC11870, 18.5 MBq 99mTc-HMPAO-granulocytes or 30 MBq FDG. To 
compare the uptake of 111In-labeled LTB4 antagonist in the abdominal region of a healthy 
animal, one extra healthy rabbit was also injected with 11 MBq 111In-DPC11870. For 
scintigraphic imaging of 111In-DPC11870 and 99mTc-granulocytes, the rabbits were 
immobilized in a mold and placed prone on a gamma camera (Orbiter, Siemens, Hoffman 
Estates, IL) using a low-energy (99mTc-granulocytes) or a medium-energy parallel hole 
collimator (111In-DPC11870). Images (300,000 cts/image) were obtained at various time 
points after injection and stored in a 256x256 matrix. All images were windowed 
identically, allowing a fair comparison among the various experiments. For PET imaging, 
animals were imaged at one hour postinjection using a rotated half-ring dedicated PET 
scanner (Siemens Ecat ART/CTI, Knoxville, TN, USA), scan distance 28.35 cm for 16 
minutes (38% transmission). Animals were euthanized after acquirement of the last 
image. A blood sample was drawn by cardiac puncture. Tissues were dissected and 
weighed. The amount of radioactivity in the tissues was measured in a shielded well-type 
gamma counter (Wizard, Canberra Packard Brussels, Belgium) together with the injection 
standards and was expressed as the percentage of the injected dose per gram (% ID/g). 
Affected-to-non-affected colon ratios were calculated for each inflamed colon segment, 
using uptake of the compound in an unaffected segment at the proximal end as reference 
value. The mean and standard deviation of the individual ratios were calculated for each 
radiolabeled compound. The different time points at which biodistribution was performed 
was considered the optimal time point for each radiolabeled compound. Imaging after 
injection of FDG at time points beyond 1 h p.i. is hardly feasible due to its short biological 
and physical half life. In case of 99mTc-HMPAO-granulocytes, leakage of 99mTc-HMPAO 
and subsequent excretion to the gall bladder and intestine restricts the maximum imaging 
and evaluation time19,22. 
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Statistical Analysis  
All mean values are presented as mean ± standard deviation. Statistical analysis was 
performed using ANOVA. The level of significance was set at 0.05. 
 
Figure 1. 
Scintigraphic images of rabbits with acute 
colitis and a healthy rabbit acquired at 
several time points after iv injection of the 
radiopharmaceutical. Rabbits are placed 
prone one the gamma camera. Anterior 
images were acquired after injection of 
99mTc-granulocytes, 18.5 MBq per rabbit, 
images 0, 1, 2 and 3 h p.i. (A), 111In-
DPC11870, 11 MBq per rabbit, images 
acquired 0, 1, 2, 4 and 6 h p.i (B) or FDG, 
30 MBq per rabbit, 3D representation of an 
image acquired at 1 h p.i.(C) and 111In-
DPC11870, 11 MBq injected in a healthy 
rabbit, images acquired 0, 1, 2, 4 and 6 h p.i 
(D). 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
Two days after the induction of colitis all animals had diarrhea. The rabbits ate less food 
but their water intake and behavior were normal. The scintigraphic images acquired at 
several times postinjection are shown in Fig 1. Each of the three radiopharmaceuticals 
visualized the inflamed colon at 1 h postinjection. The uptake of radiolabeled granulocytes 
at the site of the inflamed colon was moderate, especially as compared to the uptake of 
111In-DPC11870 at the same time points. Both FDG and 111In-DPC11870 clearly 
delineated the colitis and showed low uptake in noninflamed colon, however 111In-
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DPC11870 visualized the inflamed lesions even better as compared to FDG. The images 
acquired after injection of 111In-DPC11870 in a healthy animal, showed no accumulation of 
radioactivity in the abdominal area at neither time points. The general in vivo behavior of 
the three radiotracers was very different. Immediately after injection the 99mTc-
granulocytes showed high uptake in lung and liver. The activity concentration in both 
organs decreased with time. In all images uptake of radioactivity was seen in the bone 
marrow. The pharmacokinetics of 111In-DPC11870 was totally different from that of the 
99mTc-granulocytes. A few minutes after injection, the radiolabeled LTB4 antagonist mainly 
localized in the circulation (heart), liver and kidneys. At later time points the radioactivity in 
the circulation decreased whereas the activity accumulated in the bone marrow and 
inflamed colon. The PET images of rabbits acquired one hour after FDG injection showed 
that radioactivity concentration was high in the kidneys. Before PET scanning, the bladder 
was emptied by means of catheterisation.  
Fig. 2 summarizes the biodistribution data of FDG at 1.5 h p.i, 99mTc-granulocytes at 3 h p.i 
and the 111In-DPC11870 at 6 h p.i. These time points were considered optimal for the 
individual radiopharmaceuticals.  
 
Figure 2. 
Biodistribution data of rabbits (iv) 
injected with 99mTc-granulocytes, 
111In-DPC11870 and FDG. Uptake 
in organs and tissues is 
expressed as %ID/g. Each bar 
represents the mean values ± SD. 
Ex vivo biodistribution was 
performed at 1 h p.i. for FDG, 3 h 
p.i. for 99mTc-granulocytes and 6 h 
p.i. for 111In-DPC11870. 
 
 
 
 
The uptake in the inflamed colon was highest for 111In-DPC11870 followed by 99mTc-
granulocytes (0.72±0.18% ID/g vs 0.40±0.11% ID/g, respectively). The uptake of FDG in 
the inflamed colon was relatively low (0.16±0.04% ID/g). Furthermore, the total % ID in the 
inflamed colon was significantly higher for 111In-DPC11870 as compared with the other 
two radioactive tracers (P<0.004) whereas there was no significant difference in colon 
uptake between 99mTc-granulocytes and FDG (P>0.6). Although the radioactivity 
concentration in the non-affected part of the colon was highest in rabbits injected with 
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111In-DPC11870, the affected-to-non-affected colon ratio was nevertheless highest with 
this radiopharmaceutical (11.6 for 111In-DPC11870, 5.5 for 99mTc-granulocytes and 4.1 for 
FDG, Fig. 3). After dissection of the tissues, the activity in the colon tissue and the content 
of the colon were measured separately. Each of the three radiolabeled compounds 
showed low activity concentrations in the content of the colon, as shown in Fig. 4. There 
were no significant differences in radioactivity concentrations in the content between the 
three agents (p>0.6). For the technetium-99m-labeled granulocytes the radioactivity 
concentration was high in spleen and bone marrow (0.98±0.23% ID/g and 1.06±0.33% 
ID/g, respectively). The 111In-DPC11870 biodistribution data revealed a similar high uptake 
in bone marrow (0.95±0.17% ID/g), whereas the uptake in the spleen was considerably 
lower (0.45±0.10% ID/g). For this agent, a considerable amount of activity was localized in 
the kidneys (0.33±0.04% ID/g). Biodistribution data derived from animals injected with 
FDG indicated that a large fraction of the injected dose was excreted from the body 
already within one hour postinjection. Uptake of FDG in all organs (except inflamed colon) 
was very low. Activity concentration in the bone marrow and spleen were low with this 
agent (0.12±0.02% ID/g and 0.11±0.03% ID/g, respectively). 
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ISCUSSION 
he present study demonstrated that both 111In-DPC11870 and FDG are excellent agents 
ukotrienes and leukotriene antagonists as 
eported the applicability of FDG for imaging of infection 
 
D
 
T
to visualize experimental colitis in NZW rabbits. Both agents are superior as compared to 
99mTc-leukocytes, the standard imaging agent for scintigraphic evaluation of inflammatory 
bowel disease in patients. Images acquired after injection of 111In-DPC11870, visualized 
the inflamed colon as early as one hour postinjection. The activity concentration of the 
radiolabeled DPC11870 in the colon at time 4 h p.i. was high. Visualization of the inflamed 
lesions in the colon was better than with FDG.  
Numerous studies have focused on the role of le
chemotactic compounds, to mediate infection and inflammation10,23. Due to the anti-
inflammatory effect of LTB4 antagonists, the mechanism of interaction and the receptor 
specificity of these compounds have been studied extensively24. Yokomizu et al.12,13 
reported that two different LTB4 receptors can be identified. The high affinity receptor 
BLT1, is mainly expressed on activated polymorphonuclear leukocytes present at the site 
of infection or inflammation. Accumulation of 111In-DPC11870, at the site of the inflamed 
colon most likely occurs due to interaction with the BLT1 receptor expressed on these 
infiltrated cells. In vitro binding studies showed that DPC11870 binds to purified human 
granulocytes with high affinity17. 
Recently, several investigators r
and inflammation. Animal models demonstrated that FDG accumulates in both acute and 
chronic infectious lesions2,25. It is hypothesized that FDG accumulation in infectious and 
inflammatory lesions occurs as a consequence of enhanced uptake of FDG in neutrophils, 
macrophages, causative microorganisms and/or granulation tissue5,26. Uptake of FDG in 
these cells is enhanced because of the increased glycolysis and the intensified stimulation 
of the hexose monophosphate shunt in these cells27. In addition, activated inflammatory 
cells also have an increased expression of glucose transporters and, affinity of glucose 
transporters (for deoxyglucose) is increased by several cytokines and growth factors28,29. 
FDG-PET for visualization of infectious and inflammatory foci is nowadays a frequent 
subject of investigation in patient studies. Hannah et al.27 were among the first 
investigators who described a patient with increased FDG bowel uptake, probably due to 
inflammation in the bowel wall. In a separate study in five patients diagnosed with colitis, 
Kresnik et al.30 showed that FDG-PET was able to detect colitis at an early clinical stage. 
The results of the present study, in rabbits with acute colitis, confirmed this increased FDG
uptake in the inflamed lesions in the colon. With FDG-PET the visualization was rapid and, 
due to the rapid and complete clearance of activity from the remainder of the body, there 
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lonic content indicated that each of the 
NCLUSION 
mTc-granulocytes, 111In-labeled LTB4 antagonist DPC11870 and FDG all visualize acute 
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ABSTRACT 
 
Radiolabeled chemotactic peptides are studied for their applicability to visualize infectious 
and inflammatory foci. Since a radiolabeled Leukotriene B4 (LTB4) antagonist could 
visualize intramuscular E. coli abscesses in rabbits within a few hours after injection, here 
we tested the imaging characteristics of this agent in a more clinically relevant model of 
pulmonary aspergillosis.  
Objectives: The pharmacokinetics and imaging characteristics of the 111In-labeled LTB4 
antagonist DPC11870 were studied in New Zealand White (NZW) rabbits with 
experimental pulmonary aspergillosis infection. Imaging characteristics of 111In-DPC11870 
were compared with those of 67Ga-citrate, a radiopharmaceutical commonly used to detect 
pulmonary infections in patients.  
Methods:  Pulmonary aspergillosis was induced in the left lung of rabbits by intratracheal 
inoculation of 1x108 conidia of A.fumigatus. Three days after the inoculation, the rabbits 
received 111In-DPC11870 or 67Ga-citrate intravenously. Images were acquired at several 
time points up to 24 hours postinjection (24 h p.i.).  
Results: Pulmonary aspergillosis was visualized with both agents. Images acquired after 
injection of 111In-DPC11870 showed uptake in the pulmonary lesions from 6 h p.i. Due to 
accumulation at the site of infection and clearance from the background the images 
improved with time. Region of interest analysis at 24 h p.i. revealed an infected-to-normal 
lung ratio of 5.0±1.5 for 111In-DPC11870 as compared to 2.9±0.6 for 67Ga-citrate.  
Conclusion: The radiolabeled LTB4 antagonist DPC11870 clearly delineated 
experimentally induced pulmonary aspergillosis in rabbits. Images acquired at 24 h 
postinjection were superior to those obtained after injection of 67Ga-citrate. 
 
INTRODUCTION 
 
Invasive pulmonary aspergillosis (IPA) is a common fungal infection that may affect 
morbidity and mortality in immunocompromised patients1. It is of great importance to 
detect aspergillosis infection at an early stage because this will improve the therapeutic 
outcome in patients2. For the diagnosis of IPA, high-resolution chest computed 
tomography (CT) scanning is most often performed. Besides CT, other diagnostic 
methods like culturing the fungus and non-culture-based methods such as serodiagnosis 
or polymerase-chain-reaction (PCR) may be applied3. Scintigraphic imaging techniques 
may have an additional value in the diagnosis of IPA. Scintigraphic imaging techniques 
are based on physiological changes in contrast to radiological techniques that are based 
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on morphological alterations. 67Ga-citrate is a commonly used radiopharmaceutical to 
visualize pulmonary and mediastinal infection, especially in immunocompromised patients 
where low white blood cell counts (WBC) hamper the use of radiolabeled leukocytes3. 
Several other radiolabeled agents are studied for the applicability to image infection and 
inflammation. In particular radiolabeled chemotactic peptides are promising imaging 
agents because of their favorable pharmacokinetic characteristics4,5. In this study we 
investigated the ability of the Indium-111-labeled leukotriene B4 (LTB4) antagonist 
DPC11870 to image experimentally induced aspergillosis in NZW rabbits. 
Leukotriene B4 receptors (BLT1 and BLT2) are expressed mainly on leukocytes6. In vitro 
binding of LTB4 to the BLT receptors results in intracellular signal transduction and 
subsequent chemotaxis7. LTB4 expression and receptor targeting plays an important role 
in the response of the immune system against infection and inflammation. Furthermore, 
overproduction of LTB4 contributes to inflammatory diseases and LTB4 antagonists have 
been developed to exploit their anti-inflammatory effect8. LTB4 targets leukotriene B4 
receptors expressed on neutrophilic granulocytes that migrate towards and infiltrate in the 
inflammatory and infectious lesion9. This mechanism of receptor targeting may also be 
applicable to visualize inflammatory and infectious processes by using radiolabeled LTB4 
antagonists. In this study a bivalent LTB4 antagonist was labeled with 111In and its ability 
to visualize pulmonary aspergillosis in NZW rabbits was compared to that of 67Ga-citrate. 
  
MATERIALS AND METHODS 
 
DPC11870 
Synthesis of the compound was based on the PEG-tethered LTB4 antagonist SG385 
described in a previously report10. Boc-cysteic acid and Boc-Glu(OTfp)-OTfp were 
prepared a described11,12. All other reagents were purchased from Aldrich Chemical 
Corporation or Fluka Chemical Corporation. 
The tetra-cysteic acid derivative of SG385 was prepared by the sequential coupling of 
Boc-cysteic acid in Dimethylformamide (DMF) using Benzotriazol-tetramethyluronium-
hexafluorophosphate (HBTU) coupling reagent. Boc removal was achieved by treatment 
with 50:50 trifluoroacetic acid (TFA): methylene-chloride(DCM). Purifications were 
performed after the addition of the 1st cysteic acid (partitioning between CHCl3 and water) 
and after the addition of the 2nd and 4th cysteic acids (HPLC on C18 silica using 0.1% 
TFA-modified acetonitril (ACN)/water mobile phases). Products were recovered from 
HPLC mobile phases by lyophilization. The tetra-cysteic acid derivative 11870 was 
checked with HPLC and high resolution Mass Spectrometry (MS). In addition, the 
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dimerization was achieved by reaction of 11870 with the bis-TFP ester of Boc-glutamic 
acid and (Hydroxy-azabenzotriazole) HOAt in DMF. The crude reaction product was 
treated with TFA/DCM/Et3SiH to remove the Boc protecting group. The product was 
purified with C18 HPLC in a 0.1 M ammonium acetate-modified ACN/water mobile phase. 
Conjugation with diethylene-triamine-penta-acetic acid (DTPA) was accomplished by 
reaction with DTPA anhydride in DMF.  Purification gave DPC11870 in 73% yield from 
intermediate DPC11870. HPLC analysis of the lyophilized product gave a single peak. 
Additional quality control was performed with 1H NMR and performance of high resolution 
MS showed a value of [M+2H]: 1563.5056 for this C123H182N26O53S8 structure. 
 
Radiolabeling of DPC11870 
DPC11870 labeling with 111InCl3 was performed in metal-free 0.25 M ammonium acetate 
buffer, pH 5.5 for 30 minutes at room temperature. Radiochemical purity was checked by 
ITLC (Rf 111In-DPC11870: 0-0.5, Rf unbound 111In: 1.0) and by RP-HPLC on a C18 column 
(Zorbax Rx-C18 4.6 mm x 25 cm) as described previously13. 
 
67Ga-citrate 
67Ga-citrate was commercially obtained from Tyco Healthcare (DRN 3103, Petten, The 
Netherlands). Activity concentration was 37 MBq/mL at calibration time. 
 
Aspergillus Fumigatus 
Aspergillus fumigatus used for the induction of the infection was isolated from an 
immunocompromised patient diagnosed with an aspergillosis fumigatus infection. The 
inoculum was prepared from a frozen isolate that was subcultured two times onto 
Sabouraud dextrose slants, followed by an incubation period of five days at 30°C. Conidia 
were harvested with phosphate buffered saline (PBS) (Gibco, Invitrogen BV, Breda, The 
Netherlands) containing 0.20% Tween 20 (Sigma Chemical Co. St.Louis, MO, USA). 
Conidia were washed three times in Hanks Balanced Salt Solution (HBSS) without Ca and 
Mg (BioWhittaker Europe, Verviers, Belgium) and transferred to a 50 mL conical tube and 
counted in a hemo-cytometer. The concentration was adjusted to give each rabbit a 
predetermined inoculum of 1x108 conidia of A.fumigatus in a volume of 250 µL. 
 
Induction of Pulmonary Aspergillosis 
Fourteen female New Zealand White (NZW) rabbits weighing 2.3-2.8 kg were used during 
the experiments. Animals were housed individually and fed standard laboratory chow and 
water ad libitum. All animal experiments were approved by the local animal welfare 
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committee in accordance with the Dutch legislation and carried out in accordance with 
their guidelines. 
 
Twelve rabbits received cytarabine (cytosine arabinoside) injections to affect the immune 
system. Immunosuppression with cytarabine injections was accomplished by modification 
of a method to induce neutropenia in rabbits14. Cytarabine injections were given at 4 
consecutive days in order to lower the white blood cell counts and allow the Aspergillosis 
infection to establish. The other two animals remained healthy and served as control 
animals (to compare the pharmacokinetics of 111In-DPC11870 in cytarabine treated 
animals)(Table 1). Aspergillosis was induced essentially as described by Groll et al. with a 
few modifications regarding our application14. Cytarabine (Onco-Tain, Faulding 
Pharmaceuticals nv, Brussels, Belgium) was administered intravenously (525 mg/m2) on 
day –4 through –1 prior to the injection of radiolabeled compound. At day –3, after the 
second dose of cytarabine, A.fumigatus conidia were inoculated in ten animals. Two 
animals injected with cytarabine were not inoculated and served as a second control 
group. Before inoculation, animals were sedated with a subcutaneous injection of 0.7 ml 
Hypnorm (Fentanyl 0.315 mg/mL + Fluanisone 10 mg/mL) (Janssen Pharmaceutical, 
TABLE 1                                       Schematic Overview of Animal Experiments 
 Days 
Rabbit 
no. 
-4 -3 -2 -1 0 1 
1–5: 
group A 
Cytarabine 
Blood 
 
Cytarabine + 
Induction 
Aspergillosis 
Cytarabine Cytarabine Blood + 
111In-
DPC11870 
+ 
imaging 
Imaging + 
Biodistribution 
6-10: 
group B 
Cytarabine 
Blood 
Induction 
Aspergillosis 
+ Cytarabine 
Cytarabine Cytarabine Blood + 
67Ga-citrate 
+ 
imaging 
Imaging + 
Biodistribution 
11-12: 
group C 
Cytarabine 
Blood 
Cytarabine Cytarabine Cytarabine Blood + 
111In-
DPC11870 
+ 
imaging 
Imaging + 
Biodistribution 
13-14: 
group D 
Blood    Blood + 
111In-
DPC11870 
+ 
imaging 
Imaging + 
Biodistribution 
 
Blood samples were taken on day _4 and 0 to determine WBC count. Animals were injected with 
cytarabine on days _4 through 0, and aspergillosis was induced on day _3. At day 0, animals were 
injected with 111In-DPC11870 (groups A, C, and D) or 67Ga-citrate. Animals of group C were not 
inoculated with aspergillosis, and animals from group D were not injected with aspergillosis or 
cytarabine. 
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Buckinghamshire, UK). During inoculation the rabbits were anesthetized by inhalation 
anesthesia with a mixture of isoflurane, nitrous oxide and oxygen and placed on the 
operation table. The inoculum of 1x108 conidia (250 µL was given intra-tracheally into the 
left lung, together with 50 µL of 5% Evans blue dye (E2129, Sigma-Aldrich, Zwijndrecht, 
The Netherlands) via a syringe attached to a polyethyleen 0.76x1.22 mm catheter (PE 
tube, Maxxim Medical, Oss, The Netherlands). 
 
Imaging and Biodistribution 
At day zero (three days after inoculation of A.fumigatus) nine rabbits (2 healthy, 2 injected 
with cytarabine only and 5 animals both injected with cytarabine and infected with 
A.fumigatus) received an injection with 11 MBq 111In-DPC11870 (3 µg) via the ear vein. 
The other five animals pretreated with cytarabine and induced with aspergillosis received 
11 MBq 67Ga-citrate intravenously. Images (300,000 cts/image) were acquired 
immediately after injection of the radiolabeled preparations and at 2, 4, 6 and 24 h p.i. For 
scintigraphic imaging, the rabbits were immobilized in a mold and placed prone on the 
medium-energy parallel hole collimator of the gamma camera in the anterior position 
(Orbiter, Siemens, Hoffman Estates, IL). Images were stored digitally in a 256x256 matrix. 
All images were windowed identically, allowing a fair comparison of the images acquired 
during the various experiments. The scintigraphic results were analyzed by drawing 
regions of interest (ROI) over the abscess and the contralateral non-infected lung 
(normal). Infected-to-normal lung ratios were calculated. At 24 h p.i. all rabbits were 
euthanized with a lethal dose of sodium pentobarbital and organs were dissected. A blood 
sample was taken by cardiac puncture and tissues were weighed and measured for the 
amount of radioactivity to determine the biodistribution of both agents. The activity in 
tissues was measured in a shielded well-type gamma counter (Wizard, Pharmacia-LKB, 
Uppsala, Sweden) together with the injection standards. Radioactivity concentration was 
expressed as percentage of the injected dose per gram (%ID/g). 
 
Hematological and Histopathological Studies 
Blood samples were collected from all rabbits, both at day –4 prior to the first cytarabine 
injection and at day 0 (time of injection of the radiolabel), in order to determine the WBC of 
the animals. 
During dissection of the animals samples of the infected (left) and non-infected lung were 
aseptically removed. One part of each lung sample was cultured for A.fumigatus during 24 
h at 37°C on Sabouraud dextrose agar plates. A second specimen of lung tissue was fixed 
in phosphate-buffered formalin. After measurement of radioactivity, these tissues were 
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embedded in parrafin. Tissues sections were stained with hematoxylin-eosin or Grocott 
methenamine and histopathologically examined. 
 
Statistical Analysis  
All values are presented as mean ± standard deviation. Statistical analysis was performed 
using the two-sided Student t-test. The level of significance was set at 0.05. 
 
RESULTS 
 
Radiolabeling of DPC11870 
RP-HPLC analysis and ITLC quality control indicated that the radiochemical purity (RCP) 
exceeded 99%. Specific activity was 3.7 MBq/µg DPC11870 (12 MBq/nmol). 
 
Aspergillus Fumigatus 
Culturing of the conidia solution confirmed that the inoculum consisted of A.fumigatus 
conidia. Animals infected with A.fumigatus showed clinical symptoms from two days after 
conidia inoculation. The respiration frequency of the rabbits was increased and the 
infected animals showed more shallow breathing as compared to the control animals. 
Intake of water and food was normal. 
 
Figure 1 
Histological sections of 
NZW rabbits of healthy 
lung tissue (A and C) and 
lung tissue with invasive 
pulmonary aspergillosis (B 
and D). Hematoxylin-eosin 
stain (A and B) showing 
massive infiltration of 
PMNs in the infected lung 
tissue (B). Grocott 
methenamine silver 
staining (C and D) 
indicated the presence of 
A.fumigatus hyphae and 
germinating conidia in the 
infected lung tissue (D). 
Magnification A-D: 200x. 
Inset in D shows 
magnification of 400x. 
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Hematological and Histopathological Studies 
The mean WBC concentration of the rabbits, at the time of injection of the first cytarabine 
injection (day –4) was 13.5±5.7x109/L. Four days after cytarabine administration WBC 
concentration of these rabbits were significantly reduced (5.2±2.4x109/L, p=0.0036). 
Normal white blood cell counts in NZW rabbits vary between 5.0 and 11.0x109/L15. The 
white blood cell counts after induction of aspergillosis and injection of cytarabine indicated 
that the rabbits were not persistently neutropenic but the numbers were strongly reduced 
as compared to the first day of the experiment (day 0). 
At dissection all animals inoculated with A.fumigatus showed macroscopic infectious 
lesions in the lungs. In all but one rabbit the infected lung area corresponded with the area 
marked with Evans blue. In one rabbit (injected with 111In-DPC11870) the infection had 
affected both lungs. Culture of A.fumigatus was positive in three out of five animals 
injected with 67Ga-citrate. In three out of the five cases, animals injected with 111In-
DPC11870 and inoculated with aspergillus conidia revealed positive cultures (one of these 
animals showed positive cultures in both lungs). One animal was only positive for 
staphylococcus species. Both lungs from the four control rabbits and the remainder lung 
tissues (control lungs not inoculated with A.fumigatus) were negative after culturing.  
Histological examination of tissue sections of the healthy animals showed no signs of 
infection i.e. infiltration of macrophages or granulocytes was absent (Fig.1A). The sections 
of lungs infected with A.fumigatus conidia showed massive infiltration of mainly 
granulocytes (Fig.1B). Staining with methiamine revealed truncated Aspergillus hyphae 
and germinating conidia in all animals that were inoculated with A.fumigatus conidia 
(Fig.1D). Staining for Aspergillosis was negative for the tissue samples obtained from 
healthy lungs (Fig.1C). 
  
Imaging and Biodistribution 
The scintigraphic images acquired immediately, 2, 4, 6 and 24 hours after injection of 
111In-DPC11870 or 67Ga-citrate are shown in Figure 2. Immediately after injection, rabbits 
injected with 111In-DPC11870 showed uptake of radioactivity in heart, lung, liver and 
kidneys (Fig. 2A). At later time points, accumulation of activity was seen in spleen and 
bone marrow. Radioactivity concentration in the heart (circulation) and in the lungs 
decreased with time. Due to the reduction of radioactivity in the normal lung tissue and 
circulation, and accumulation of activity in the infectious foci, the infectious area in the 
lungs was visualized from 6 h p.i.. Images obtained at 24 h after the injection of the 
radiolabeled LTB4 antagonist showed an even more evident clearance of radioactivity 
from non-infected lung areas. This continuous clearance in combination with ongoing 
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accumulation of radioactivity in the infected lung tissue resulted in distinct visualization of 
the lung lesions at 24 h after injection of the radiolabel. The images showed that except 
for the kidneys, activity concentration in the remainder of the body was low. Images 
acquired at several time points after injection of 67Ga-citrate showed distinct 
pharmacokinetics for this compound as compared to 111In-labeled DPC11870 (Fig 2B). 
Immediately after injection 67Ga-citrate distributed to the different organs and high activity 
concentrations were seen in the kidneys and bladder. Gallium-67 visualized pulmonary 
infection from 2 h postinjection. The pulmonary lesion was visible as a small focal spot in 
the left lung. At this moment there was also uptake of 67Ga in the bone. In contrast to the 
111In-LTB4 antagonist, at time points later than 2 hours p.i. all images of animals injected 
with 67Ga-citrate remained similar.  
 
Figure 2. 
Scintigraphic images 
of NZW rabbits with 
pulmonary 
aspergillosis. The 
rabbits received 11 
MBq 111In-DPC11870 
(A) or 67Ga-citrate (B) 
intravenously. Anterior 
images were acquired 
immediately 2, 4, 6 
and 24 h postinjection 
of the radiolabel. 
Arrows indicate focus 
of infection. 
 
 
 
 
 
 
 
Region of interest analysis of the normal and infected lung area showed increased 
infected-to-normal lung ratios in time after injection of 111In-DPC11870 (Fig. 3). The 
infected-to-normal lung ratios show a constant increase throughout the experiment. 
The infected-to-normal ratios calculated for the 67Ga-citrate showed an increase 
during the interval 0-4 h after the injection of the compound, whereas at later time 
points the ratio remained constant. The infected-to-normal lung ratio obtained from 
A
B
0 2 4 6 24 h 
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the ROI analysis of the 67Ga-citrate images at 24 h postinjection was 1.7-fold lower as 
compared to similar ratios obtained from the 111In-DPC11870 images (p=0.020).  
 
Fig. 3 Fig. 4 
 
Figure 3. 
Region of interest analysis from the images acquired at several time points after injection of 111In-
DPC11870 (n=5) or 67Ga-citrate (n=5) in NZW rabbits with pulmonary aspergillosis revealed infected-
to-normal lung ratios. Error bars indicate standard deviation. 
Figure 4. 
Biodistribution data obtained 24 hours after injection of 111In-DPC11870 (n=5) and 67Ga-citrate (n=5) 
in NZW rabbits with pulmonary aspergillosis. Error bars indicate standard deviation. 
 
 
The biodistribution data (24 h p.i.) derived from the ex vivo counting of dissected tissues 
are presented in Figure 4. The uptake of 111In-DPC11870 in the infected lung tissue at the 
time of biodistribution was very high. Uptake of radioactivity in the infected lung tissue was 
16-fold higher as compared to the uptake in normal lung tissue (0.82% ID/g vs. 0.05% 
ID/g respectively, p= 0.008). Relatively high uptake of the compound was also measured 
in bone marrow and spleen. Biodistribution data obtained with 67Ga-citrate were in 
concordance with the images and highest radioactivity concentration of this 
radiopharmaceutical was measured in the infected lung tissue. As noticed on the images, 
radioactivity concentration of 67Ga-citrate was relatively high in the bone and in the 
kidneys. In contrast to the derived ROI ratios, the infected-to-normal lung ratio calculated 
from the biodistribution data was significantly (4.1-fold) higher at 24 h after 67Ga-citrate 
injection than that of 111In-DPC11870 (p=0.0005). 
To determine whether the cytarabine injections in the animals affected the 
pharmacokinetics and biodistribution pattern of the radiolabeled LTB4 antagonist, non-
infected control animals were included in this study. Images acquired immediately after 
injection of 111In-DPC11870 appeared similar in all groups (data not shown). Images 
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acquired from a cytarabine injected and Aspergillus infected animal, a cytarabine treated 
noninfected animal and a healthy rabbit injected with 111In-DPC11870 acquired at 24 h p.i. 
are shown in Figure 5.  
 
Figure 5. 
Anterior images acquired 24 hours 
postinjection 111In-DPC11870 in a 
NZW rabbit with pulmonary 
infection in both lungs (A), a non-
infected animal treated with 
cytarabine (B) and a rabbit neither 
infected with Aspergillosis nor 
treated with cytarabine (C). 
 
 
 
 
 
 
Rabbits not infected with A.fumigatus conidia (either untreated or treated with cytarabine) 
did not show any accumulation or retention of radioactivity in the lungs. Furthermore, the 
biodistribution of 111In-DPC11870 in the main organs of these animals (exept bone marrow 
and spleen) were comparable with the 111In-DPC11870 distribution in cytarabine treated 
infected rabbits. Distinct differences in radioactivity concentrations were observed in 
spleen and bone marrow of healthy animals and animals suffering from aspergillosis. The 
cytarabine treated animals showed reduced uptake of 111In-DPC11870 in these organs. 
The quantitative measurement of dissected organs revealed that, except for the bone 
marrow and spleen, there were no significant differences in radioactivity concentration in 
the dissected organs between the two groups of rabbits that were treated with cytarabine 
(healthy or infected) and the group healthy, untreated animals (Fig. 6). Radioactivity 
concentration measured in the bone marrow of cytarabine-injected animals (both infected 
and non-infected) was lower (0.28±0.15% ID/g and 0.38±0.20% ID/g, respectively) as 
compared to that in healthy animals (0.93±0.13% ID/g). The radioactivity concentration in 
the non-infected lungs of all three groups of animals was similar. Also, the 111In-
DPC11870 concentration in the blood of rabbits from all three groups was similar 
(0.02±0.01% ID/g in rabbits with aspergillosis, 0.01±0.02% ID/g in rabbits healthy but 
treated animals and 0.03±0.01% ID/g in healthy rabbits not treated with cytarabine).  
 
A B C
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Figure 6. 
Biodistribution data obtained 
24 hours postinjection of 111In-
DPC11870 in NZW rabbits with 
pulmonary infection in the lung, 
n=5 (A), cytarabine (CA) 
treated non-infected animals, 
n=2 (B) and healthy rabbits 
neither injected with cytarabine 
nor infected with A.fumigatus, 
n=2 (C) (** P < 0.05, results 
differ significantly with results 
found in healthy rabbits). Error 
bars indicate standard 
deviation 
 
 
  
DISCUSSION 
 
In the present study scintigraphic imaging of pulmonary aspergillosis with a radiolabeled 
LTB4 antagonist was examined in a rabbit model. The imaging potential of the LTB4 
antagonist was compared with that of 67Ga-citrate. Serial scintigraphic images showed 
that 111In-DPC11870 visualized the pulmonary infection from 6 h onwards. The images 
showed that the radiolabeled LTB4 antagonist accumulated in the infectious lesion while 
activity concentration in the blood and normal lung tissue decreased with time. The 
pharmacokinetic properties of the compound in this model were in concordance with 
results found in previous studies13. Injection of the compound in healthy animals showed 
that except for the amount of radioactivity in bone marrow and spleen, the localization of 
111In-DPC11870 was not affected by the administration of cytarabine. This implied that 
despite the lowered white blood cell counts in the circulation, there were sufficient 
activated neutrophils that migrated to the site of infection. No differences were seen in 
radioactivity concentration in the blood and the major organs. The lower amounts of 
radioactivity in the spleen and bone marrow of animals pretreated with cytarabine was 
probably due to the reduced number of premature white blood cells in these organs. 
Cytarabine is a nucleoside analog with cytotoxic activity mainly affecting replicating cells16. 
The results described above may be due to the fact that repeated injection of cytarabine 
will immediately reduce the numbers of proliferating (LTB4 receptor positive) 
promyelocytes in the bone marrow, whereas mature and activated neutrophils will be less 
affected and would require a longer treatment period with this antimetabolite. This is in 
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concordance with the fact that in these rabbits massive infiltration of leukocytes was found 
in the infected lung tissue (histological staining). 
The primary aim of this study was to test whether the radiolabeled LTB4 antagonist 111In-
DPC11870 could visualize pulmonary aspergillosis in NZW rabbits. In addition we 
compared the imaging and biodistribution characteristics of 111In-DPC11870 with those of 
67Ga-citrate, the radiopharmaceutical generally used to visualize pulmonary infections in 
patients17. Besides the relatively high sensitivity for acute and chronic infection and 
inflammation, 67Ga-citrate possesses a few disadvantages such as a relatively long 
biological half-life and physiologic uptake in bone and excretion via the bowel (the latter 
mainly at later time points)18. Images acquired after injection of 67Ga-citrate in rabbits with 
A.fumigatus infection, clearly delineated the infected lesions in the lungs at early time 
points. Physiologic uptake in the bone was seen on the images from 2 h p.i. and this 
amount of radioactivity did not decrease with time. Region of interest analysis indicated 
that the infected-to-normal lung ratios found with 111In-DPC11870 increased with time (in 
contrast to the ratios found after injection of 67Ga-citrate) and resulted in higher ratios for 
111In-DPC11870 as compared to 67Ga-citrate at 24 h after the injection of the radiolabeled 
agents. The increasing infected-to-normal lung ratios after injection of the radiolabeled 
LTB4 antagonist can be explained by the continuous accumulation of radioactivity at the 
site of infection in combination with ongoing clearance from the blood (corresponding with 
background). The 67Ga-citrate showed faster clearance from the circulation as compared 
to DPC11870 and therefore at later time points the ratios remained constant.  Normally, 
regions of interest (ROIs) obtained from the images are evaluated for diagnosis of 
pulmonary infection. The physiological uptake of 67Ga-citrate in the bone (background 
tissue) deteriorated the images and caused reduced infected-to-normal lung ratios derived 
from the ROI analysis. Our data indicate that despite visualization of the pulmonary 
lesions, physiological uptake in the bone may affect visualization of pulmonary lesions. 
This outcome may be more pronounced in patients especially because in general images 
are acquired at 18-72 hours after the injection of 67Ga-citrate19,20. 
In this study we showed that 111In-DPC11870 clearly visualized pulmonary Aspergillosis in 
rabbits. Visualization of the infection occurred due to accumulation of radioactivity. In a 
previous study we determined that this accumulation is specific and receptor mediated13. 
Because of the massive infiltration of granulocytes in the infectious foci and accumulation 
of 111In-DPC11870 in the lesions, this model represents acute pulmonary infection and 
presumably 111In-DPC11870 might visualize acute pulmonary infection in general. Since 
uptake of 111In-DPC11870 in the bone marrow and retention of radioactivity in the kidneys 
could limit clinical applicability of the compound, we now aim to produce a new analogue 
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of the LTB4 antagonist DPC11870 that can be labeled with 99mTc. A 99mTc-labeled 
compound could not only reduce the absorbed dose to these organs but may also reveal 
improved images because of the higher resolution and reduced visualization of bone 
marrow (due to higher attenuation by the bone). Nevertheless, due to the distinct 
visualization of the pulmonary lesions after injection of 111In-DPC11870, the current agent 
could be a valuable tool for the diagnosis of acute pulmonary infections in patients. 
 
CONCLUSION 
 
The present study demonstrates that the radiolabeled LTB4 antagonist DPC11870 
visualized pulmonary infection in rabbits suffering from Aspergillosis. Lesions were 
visualized from 6 h postinjection and improved with time due to retention of radioactivity in 
the infected lung tissue. The results of this study indicate that 111In-DPC11870 could 
contribute to the diagnosis of acute pulmonary infection. 
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ABSTRACT 
 
Radiolabeled Leukotriene B4 (LTB4) antagonist DPC11870 is able to visualize infectious 
and inflammatory foci in distinct animal models.  
Objectives: Since previous studies showed that accumulation of 111In-DPC11870 in the 
abscess continued while the tracer had cleared from the circulation, we now investigated 
the pharmacodynamics of 111In-DPC11870 and determined the mechanism of 
accumulation of the radiolabeled LTB4 antagonist in the abscess. 
Methods:  111In-DPC11870 was intravenously (i.v.) injected in healthy New Zealand White 
(NZW) rabbits and rabbits with intramuscular E. coli infection. The pharmacodynamics 
were studied by serial imaging and by ex vivo counting of dissected tissues. The 
mechanism of visualization of the abscess was investigated in rabbits with intramuscular 
infection that was induced 16 h after i.v. administration of 111In-DPC11870. In addition, 
heterologous leukocytes and bone marrow cells of a donor rabbit were labeled with 111In-
DPC11870 in vitro and the biodistribution of these in vitro radiolabeled cells was 
compared with that of 111In-DPC11870 in rabbits with an infection.  
Results: The LTB4 antagonist 111In-DPC11870 visualized the intramuscular abscess in 
rabbits already a few hours after injection. Quantitative analysis of the images confirmed 
accumulation of 111In-DPC11870 in the abscess while the compound had cleared almost 
completely from the circulation. Radioactivity concentration in the bone marrow decreased 
more rapidly in infected animals than in healthy animals. Therefore we hypothesized that 
111In-DPC11870 associates with receptor positive (bone marrow) cells and accumulated in 
the abscess due to subsequent migration from the bone marrow to the abscess. 
Accumulation of radioactivity, in the abscess induced 16 h after 111In-DPC11870 injection, 
was similar as in animals i.v. injected with the tracer 24 h after induction of the abscess 
(0.37±0.16 %ID/g). Moreover, differences in radioactivity concentration in the bone 
marrow of healthy and infected animals (0.67±0.29 %ID/g and 0.15±0.03 %ID/g at 24 h 
p.i., respectively) supported our hypothesis. Additional studies with peripheral blood 
leukocytes (WBCs) and bone marrow cells (BMCs) that were ex-vivo labeled with 111In-
DPC11870 showed the ability of these cells to migrate to the abscess (0.40 %ID/g and 
0.52 %ID/g for the 111In-DPC11870-BMCs and 111In-DPC11870-WBCs respectively, 24 h 
p.i.). 
Conclusion: The 111In-labeled LTB4 antagonist DPC11870 accumulates in infectious and 
inflammatory foci due to binding to LTB4 receptors expressed on activated hematopoietic 
cells that subsequently migrate to the site of infection, which leads to visualization of the 
infectious lesions. 
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INTRODUCTION 
 
Detection of infectious and inflammatory foci by means of scintigraphic imaging is 
important because it allows accurate therapeutic decisions and rapid initiation of 
appropriate treatment. Radiolabeled leukocytes are currently considered the gold standard 
to detect infectious and inflammatory lesions in patients1. This radiopharmaceutical 
enables rapid visualization of the lesion but preparation is time-consuming and is 
associated with a potential risk for infection2. At the moment there is interest in the 
development of new radiopharmaceuticals to detect infectious and inflammatory foci with 
the same accuracy as radiolabeled leukocytes but without these disadvantages. 
Chemotactic and chemokinetic peptides are promising agents for this application3,4. These 
compounds have the potential to accumulate at the site of infection and are cleared 
rapidly from non-target tissues and from the circulation. Various studies, however, indicate 
that the use of these agonistic compounds is often limited due to biological activity while 
antagonists often exhibit low receptor affinity5. We have developed an LTB4 antagonist, 
DPC11870, that can be labeled with 111In and that visualizes infectious and inflammatory 
lesions rapidly after injection4,6. 
Leukotriene B4 is a potent chemotactic factor for granulocytes that, upon binding to its 
specific cell surface receptors, stimulates leukocyte functions such as chemotaxis, 
vascular adhesion, transendothelial migration and release of lysosomal enzymes7,8. Since 
leukotriene B4 is an important mediator and leukotriene B4 receptors are expressed by 
polymorphonuclear granulocytes, we investigated the imaging potential of a bivalent 
leukotriene B4 antagonist. We have shown that this radiolabeled antagonist could 
visualize infectious and inflammatory foci in various rabbit models6,9,10. Results also 
demonstrated that 111In-DPC11870 cleared rapidly from the circulation. Furthermore, we 
demonstrated that visualization of the lesions occurred within a few hours after injection of 
the radiolabel. An in vivo receptor blocking experiment demonstrated that accumulation 
and retention at the site of infection was receptor-mediated. 
The aim of this study was to elucidate the mechanism of 111In-DPC11870 accumulation in 
the abscess. Initial experiments were performed to determine the pharmacokinetics of 
111In-DPC11870, whereas additional biodistribution experiments were carried out to 
determine the mechanism of accumulation in the abscess. 
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MATERIALS AND METHODS 
 
Radiolabeling of  DPC11870 
DPC11870 was synthesized and characterized as described previously6,10. The LTB4 
antagonist DPC11870 was labeled with 111In with a specific activity of 3.7 MBq/µg 
DPC11870 (12 MBq/nmol). Quality control of the compound was performed with ITLC and 
HPLC as described previously6.  
 
Infection Model 
Nineteen female NZW rabbits weighing 2.3-2.8 kg were kept in cages (one rabbit per 
cage) and fed standard laboratory chow and water ad libitum. An E. coli infection was 
induced in the left thigh muscle of 11 animals by intramuscular injection of 1 x 1011 colony-
forming units (CFU) of E. coli. During this procedure the rabbits were anaesthetized by 
subcutaneous injection of 0.7 mL of a mixture of 0.315 mg/mL fentanyl and 10 mg/mL 
fluanison (Hypnorm®, Janssen Pharmaceutica, Buckinghamshire, UK). All animal 
experiments were approved by the local animal welfare committee in accordance with the 
Dutch legislation and carried out in accordance with their guidelines. 
 
Whole Body Imaging and Pharmacokinetics 
Twenty-four hours after the induction of the infection, when swelling of the infected muscle 
was apparent, five rabbits (two with intramuscular infection and three healthy) were i.v. 
injected with 11 MBq 111In-DPC11870 (3 µg) in the lateral ear vein. For scintigraphic 
imaging, the rabbits were immobilized in a mold and placed prone on a dual-head 
Siemens Multi-Spect II gamma camera equipped with a medium-energy parallel hole 
collimator. The camera was connected to a Scintiview image processor and ICON 
computer system (Siemens). Scanning was performed (11 cm/min over 70 cm) 
immediately and at various time points up to 24 h p.i. and images were stored digitally in a 
256x256 matrix. All images were adjusted to the same background and intensity level, to 
allow a fair comparison among the various experiments. The pharmacodynamics of 111In-
DPC11870 were studied by analyzing the images quantitatively. Regions of interest (ROI) 
were drawn over the total body, heart, abscess, the contralateral muscle (background), 
lungs, liver, spleen, kidneys and the lumbar spine (bone marrow). For each organ, except 
the bone marrow, the arithmetic mean value of the anterior and posterior region was used. 
For the bone marrow only the posterior ROI was used. ROIs were used to calculate the 
111In-DPC11870 concentrations in the organs at the various time points. The %ID in each 
organ was calculated using the total counts in the ROI of the organ and the total body 
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counts. Since it was not possible to draw a region over the total amount of bone marrow, 
here the %ID was calculated by using the amount of radioactivity measured after 
dissection. The correlation between the %ID found in the bone marrow and the average 
counts in the ROI were determined by linear regression analysis. Subsequently the %ID in 
the bone marrow at all imaging time points was calculated by using this correlation data 
(slope and Y-axis intercept). 
After acquisition of the last image (24 h p.i.) the animals were sacrificed with a lethal dose 
of sodium phenobarbital to determine the biodistribution of the agent. A blood sample was 
taken by cardiac puncture. Tissues were dissected and weighed. The activity in tissues 
was measured in a shielded well-type gamma counter along with the injection standards 
and was expressed as the percentage of the injected dose per gram (%ID/g) or 
percentage injected dose per organ (%ID). 
 
Studies to Determine the Mechanism of Accumulation in the Abscess 
To examine the mechanism of accumulation of the tracer in the abscess in more detail, 
ten healthy rabbits were i.v. injected with 11 MBq 111In-DPC11870 (3 µg). Sixteen hours 
after the injection of the radiolabel, all animals were imaged and a blood sample was 
taken. After this procedure, in five of these animals an intramuscular E. coli infection was 
induced in the left thigh muscle as described above. Images of the healthy and infected 
animals were acquired from 1 h post abscess induction up to 24 h in order to determine 
accumulation of radioactivity at the site of the emerging infection, while the concentration 
of 111In-DPC11870 in the circulation was very low. For scintigraphic imaging, the rabbits 
were immobilized in a mold and placed prone on a gamma camera (Orbiter, Siemens, 
Hoffman Estates, IL) using a medium-energy parallel hole collimator. Images (300,000 
cts/image) were acquired up to 24 h after induction of the abscess (i.e. 40 h postinjection 
(p.i.) radiolabel) and stored digitally in a 256x256 matrix. All images were windowed 
identically (collection of 300,000 counts, same background and intensity level), allowing a 
fair comparison among the various experiments. After completion of the imaging 
experiment animals were sacrificed and biodistribution of the radiolabel was determined 
as described above. 
 
111In-DPC11870 Bound to White Blood and Bone Marrow Cells 
For the isolation and purification of the heterologous leukocytes11 and the bone marrow 
cells, a donor rabbit with an intramuscular E. coli infection was used. Twenty-four hours 
after the induction of the abscess 50 mL of heparinized blood was collected and 
granulocytes were isolated as described previously12. The donor rabbit was sacrificed with 
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an overdose of phenobarbital and bone marrow cells were isolated from both femurs. The 
bone marrow cells were harvested and resuspended in 5 mL Phosphate Buffered Saline 
containing 0.5% BSA (w/v) (PBS/BSA). Cells were centrifuged for 10 minutes at 500 xg. 
The lipid layer and supernatant were removed. Peripheral blood leukocytes and bone 
marrow cells were washed twice with 50 mL incubation buffer (1 mM NaH2PO4, 5 mM 
Na2HPO4, 140 mM NaCl, 0.5 mM MgCl2, 0.15 mM CaCl2, 0.5% BSA, pH 7.4) and 
resuspended in 1 mL incubation buffer. Both cell suspensions were incubated with 750 µL 
111In-DPC11870 (30 MBq) in incubation buffer for 15 minutes at room temperature. After 
the incubation, cells were washed twice with 10 mL incubation buffer and resuspended in 
2.5 mL PBS/BSA). The amount of cell-bound radioactivity was determined. 
Three rabbits with intramuscular E. coli infection (induced 24 h before) were i.v. injected 
with either 4 MBq 111In-DPC11870 (1 µg), 4 MBq of 111In-DPC11870-labeled leukocytes or 
4 MBq 111In-DPC11870-labeled bone marrow cells. The in vitro radiolabeled white blood 
cells (WBCs) and bone marrow cells (BMCs) were i.v. injected to determine whether these 
111In-DPC11870-targeted cells would accumulate at the site of infection. Scintigraphic 
imaging and analysis of the images were performed as described above. The rabbits were 
sacrificed 24 h after the injection of the radiolabel and biodistribution was determined as 
described above. 
 
Statistical Analysis  
Regression analysis was performed on the data obtained from the biodistribution and the 
ROI data obtained from the images. The correlation between these two parameters was 
calculated for each organ. The regression analysis was used to calculate the %ID present 
in the organs at the various time points. 
All mean values are presented as mean ± standard deviation. Statistical analysis was 
performed using the two-sided Student t-test. The level of significance was set at 0.05. 
 
RESULTS 
 
Radiolabeling of  DPC11870 
RP-HPLC analysis and ITLC quality control indicated that in all experiments the 
radiochemical purity of 111In-DPC11870 exceeded 99%.  
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Figure 1. 
Whole body images of a 
rabbit with E. coli thigh 
muscle infection (A) and a 
healthy rabbit (B) (anterior 
images are shown). The 
rabbits received 3 µg, 11 MBq 
111In-DPC11870 
intravenously. Images were 
acquired immediately, 1, 2, 4, 
8 and 24 h after injection of 
111In-DPC11870. 
 
 
 
 
 
 
 
 
 
 
Whole Body Imaging and Pharmacokinetics 
The whole body images acquired up to 24 h after injection of 111In-DPC11870 
demonstrated accumulation of the tracer in the abscess from a few hours after the 
injection (Fig. 1). The images also showed that the compound cleared rapidly from the 
circulation. The radiolabeled LTB4 antagonist showed some physiologic uptake in bone 
marrow and spleen and radioactivity was retained in the kidneys. Remarkably, the images 
displayed ongoing accumulation of radiolabeled compound in the abscess even when the 
majority of the compound had cleared from the circulation (> 4 h postinjection). Comparing 
the images acquired from healthy rabbits with those from rabbits with intramuscular 
infection, no major differences in the distribution of 111In-DPC11870 were observed.  
Biodistribution data are summarized in Fig. 2. The biodistribution data confirmed the 
relatively high uptake of the radiolabeled antagonist in the abscess, the bone marrow and 
the spleen. Distinct differences in radioactivity concentration were found in bone marrow 
and spleen of healthy and infected animals (0.67±0.29 %ID/g vs. 0.15±0.03 %ID/g in bone 
marrow (p=0.011) and 1.14±0.17 %ID/g vs. 0.27±0.05 %ID/g in spleen (p=0.007), for 
healthy and infected animals, respectively). For each organ the regression analysis 
A
B
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showed a good correlation between the two data sets (ROI based uptake vs. uptake in 
dissected tissues). Correlation coefficients were high for most tissues (r: 0.97, 0.93, 070, 
0.80, 0.94, 0,71 and 0.99 for kidney, bone marrow, lung, liver, spleen, heart and muscle 
and abscess, respectively).  
 
Figure 2. 
Biodistribution data obtained 
24 hours postinjection of 111In-
DPC11870 in healthy rabbits 
(noninfected) and rabbits with 
intramuscular abscess 
(infected). Each bar 
represents the mean values ± 
SD. Values were analyzed 
using a unpaired T-test; * = P 
< 0.05, P-values refer to 
differences in uptake of 
radiolabel between healthy 
and infected animals. 
 
 
 
The pharmacodynamics of 111In-DPC11870 for each organ is depicted in Fig. 3. The 
curves of a few organs, however, displayed some remarkable features. Almost 
immediately after injection, uptake of 111In-DPC11870 was observed in lungs, liver, 
kidneys, spleen and bone marrow. With time, radioactivity cleared from these organs 
except from the kidneys. Between 8 and 24 hours postinjection, the amount of 111In-
DPC11870 in lung, spleen, liver remained stable, while activity concentrations 
continuously decreased in blood and bone marrow and increased in the E. coli abscess. 
Uptake of 111In-DPC11870 in the abscess was low immediately after injection but 
increased continuously until 24 h postinjection. When the pharmacodynamics of 111In-
DPC11870 in healthy rabbits was compared to those in animals with an intramuscular 
infection, differences in radioactivity concentrations were observed in blood, kidney, 
spleen and bone marrow. Radioactivity concentration in the bone marrow was comparable 
in healthy and infected animals immediately after injection but radioactivity decreased 
more rapidly from the bone marrow of infected rabbits. Since blood levels were low from 4 
h p.i. and accumulation of radioactivity in the abscess occurred throughout the whole 
experiment (0-24 h p.i.), the enhanced clearance of activity from bone marrow of infected 
animals suggested that 111In-DPC11870 transferred from the bone marrow to the site of 
infection.   
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Figure 3.  
The dynamics of in vivo distribution of 111In-DPC11870 in non-infected (healthy) rabbits (dotted line) 
and rabbits with intramuscular abscess (solid line). %ID was calculated based on total body activity 
and is represented for total body, total blood volume, lungs, bone marrow, spleen, liver, kidneys, total 
muscle and the abscess. Results are reflected as mean %ID±SD. 
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Studies to Determine the Mechanism of Accumulation in the Abscess 
From the results of the pharmacodynamic studies and analysis of the %ID calculated from 
the ROI data, we hypothesized that accumulation of radioactivity at the site of infection 
might be due to migration of radioactivity originating from the bone marrow. To validate 
this hypothesis, healthy animals were injected with 111In-DPC11870. At 16 h p.i., when the 
compound had cleared from the circulation almost completely (7.2±0.9 %ID total blood 
pool activity), animals were imaged and subsequently in five animals an intramuscular 
abscess was induced. At the time of dissection, at 40 h after the injection of 111In-
DPC11870, 2.9±0.4 %ID and 2.2±0.4 %ID of the radioactivity remained in the circulation 
of respectively healthy and infected animals (p=0.012).  
Images acquired just before and at several time points after induction of the abscess are 
shown in Fig. 4. The results of the images prior to the abscess induction (16 h p.i. 111In-
DPC11870) confirmed that the radioactivity concentration in the circulation (region over 
the heart) was low, whereas the concentration of the tracer in the bone marrow was 
relatively high. Subsequent images acquired after the inoculation of bacteria (Fig. 4A) 
showed that there was substantial accumulation of radioactivity in the abscess. In these 
animals there was also some degree of visualization of the bladder, indicating that a small 
amount of the injected dose was excreted via the urine. Comparison of these images with 
the images of animals that were not infected with E. coli (Fig. 4B) revealed that the 
radioactivity concentration in the bone marrow decreased more rapidly in infected animals 
and that 111In-DPC11870 remained associated with the bone marrow in the healthy 
animals.  
 
Figure 4. 
Anterior images of 
rabbits induced with 
an intramuscular 
infection 16 h p.i of 
111In-DPC11870 (A) 
and healthy rabbits 
(B). Images were 
acquired prior to the 
induction of the 
abscess (16 h p.i. of 
the radiolabel) up to 
40 h postinjection 
radiolabel (i.e. 24 h 
postinduction of the 
abscess). 
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The results of the biodistribution were in concordance with the images (Table 1). At the 
time of tissue dissection (24 h after induction of the abscess corresponding with 40 h 
postinjection of 111In-DPC11870) the amount of radioactivity in the bone marrow of healthy 
animals was 33.5±4.3 %ID, whereas 9.2±2.3 %ID was found in the bone marrow of the 
infected animals (p<0.0001). The amount of radioactivity in the abscess was high (8.9±2.5 
%ID) and similar to the amount of radioactivity found in the abscess of infected animals 
injected with 111In-DPC11870 24 h after induction of the abscess. The uptake of 
radiolabeled 111In-DPC11870 in all other organs except in the spleen was highly similar. 
The results of this experiment confirmed our hypothesis that accumulation of 111In-
DPC11870 in the abscess was due to migration of the tracer from the bone marrow. In 
addition, the results showed that radioactivity concentration in the bone marrow of healthy 
rabbits was more retained since the radioactivity concentration in the bone marrow of 
healthy animals was higher as compared to the concentration of the animals with the i.m. 
abscess. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. 
Mean %ID/g of 111In-DPC11870 with SD, in specific organs and tissues of healthy rabbits and rabbits 
that were induced with an intramuscular infection 16 h after injection of the radiolabel. Biodistribution 
was performed 40 h after injection of 11 MBq 111In-DPC11870 (i.e. 24 h after induction of the 
abscess). 
 
 
111In-DPC11870 Bound to White Blood and Bone Marrow Cells 
The mechanism of accumulation of radioactivity in the infectious foci was further 
investigated in a third experiment. In this experiment we determined if 111In-DPC11870 
once bound to leukocytes or bone marrow cells, was able to accumulate in the abscess. 
Biodistribution 111In-DPC11870 in rabbits 40 h p.i. 111In-DPC11870 
 Healthy animals 
 
%ID/g 
E.coli infected animals 
24 h after induction abscess 
%ID/g 
Blood 0.02 ± 0.005 0.01 ± 0.003 
Muscle 0.00 ± 0.001 0.00 ± 0.001 
Femur 0.01 ± 0.006 0.01 ± 0.001 
Marrow 0.75 ± 0.096 0.21 ± 0.050 
Abscess  0.37 ± 0.161 
Lung 0.08 ± 0.019 0.07 ± 0.021 
Spleen 2.83 ± 0.413 1.35 ± 0.182 
Kidneys 0.56 ± 0.120 0.66 ± 0.186 
Liver 0.15 ± 0.033 0.15 ± 0.017 
Intestine 0.01 ± 0.002 0.01 ± 0.002 
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White blood cells and bone marrow cells were isolated from a donor rabbit with an 
intramuscular infection. After in vitro incubation of purified cells with 30 MBq 111In-
DPC11870, initially 30% and 25% of the radioactivity was associated with leukocytes and 
bone marrow cells, respectively. After washing more than 95% of the radioactivity was 
cell-associated. Three animals with intramuscular E. coli infection were injected with either 
free 111In-DPC11870, in vitro 111In-DPC11870-labeled WBCs or in vitro 111In-DPC11870-
labeled BMCs. Images were acquired at several time points after injection. As shown in 
Fig. 5, injection of 111In-DPC11870 revealed images as obtained in previous experiments. 
The images obtained after injection of the in vitro labeled WBCs and BMCs also 
demonstrated accumulation of radioactivity in the abscess. The visualization of the E. coli 
infection was similar for each of the three preparations. Furthermore, the early images 
showed transient entrapment of the cell-associated radioactivity in the lungs. The images 
demonstrated that distribution of the different radiolabels was similar.  
The biodistribution data showed that radioactivity concentrations in the various organs 
were similar except for the kidneys (Fig. 6). Kidney uptake of 111In-DPC11870 and 111In-
DPC11870-BMCs was 0.98 %ID/g and 1.13 %ID/g respectively, while the uptake in the 
kidneys after injection of 111In-DPC11870-WBCs was much lower (0.54 %ID/g). Uptake of 
radioactivity in the kidneys represented loss or metabolized radioactivity. In all animals 
radioactivity concentrations in the blood was very low and the abscess uptake was 
comparable (between 0.34-0.52 %ID/g). 
Figure 5. 
Anterior images of rabbits induced with an 
intramuscular infection and injected with 4 MBq 
111In-DPC11870 (A), 111In-DPC11870-BMCs (B) 
or 111In-DPC11870-WBCs (C). Images were 
acquired immediately after injection of the 
radiolabeled compound and at 2, 6 and 24 h p.i. 
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Figure 6.  
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DPC1
Biodistribution data obtained 
24 hours postinjection of 111In-
DPC11870, 111In- 1870-
BMCs or 111In-DPC11870-
WBCs. Results are presented 
as %ID/g found in the 
individual organ or tissue. 
 
 
ISCUSSION 
 previous studies we showed that the radiolabeled LTB4 antagonist DPC11870 
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efficiently visualized infection and inflammation in various rabbit models of infection and 
inflammation6,9,10. In the present study we determined the pharmacokinetics of 111In-
DPC11870 in etail and investigated the mechanism of accumulation in the absc ss. 
Whole body images confirmed previous findings concerning the rapid and distinct 
visualization of the abscess. The results of the pharmacodynamic analysis also showed 
that radioactivity in the bone marrow decreased more rapidly in infected animals than in 
healthy animals where radioactivity remained bound in the bone marrow. Besides the 
bone marrow, the lungs and the liver also showed decreasing radioactivity concentrations. 
However, the clearance rate in these organs was similar in healthy and infected animals 
and could therefore not cause the accumulation of radioactivity at the site of infection. Also 
the differences in radioactivity concentration in the spleen, between healthy and infected 
animals at 24 h p.i., could not explain the uptake in the abscess since the total amount of 
radioactivity in this organ is by far not equivalent with the amount in the abscess. Since no 
other pharmacodynamic differences were found that correlated with the increasing 
abscess uptake, these results suggested that radioactivity from the bone marrow migrated 
to the abscess. We hypothesized that after injection, 111In-DPC11870 targets receptor 
positive cells and due to subsequent migration of the tracer from the bone marrow, 
radioactivity accumulates in the abscess. To test this hypothesis, healthy animals were 
injected with 111In-DPC11870. Sixteen hours later an abscess was induced. Remarkably, 
at 24 h after t e induction of the abscess, radioactivity concentrations in the abscess of 
these animals were similar as compared to the abscess uptake in animals that were 
injected with the radiolabeled LTB4 antagonist after induction of the abscess (0.24±0.08 
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%ID/g and 0.37±0.16 %ID/g respectively). In this experiment there was also a significant 
difference between clearance of radioactivity from the bone marrow of infected animals 
and animals that were not infected with E. coli bacteria. Images showed faster clearance 
of radioactivity from the bone marrow after induction of the abscess, which is in line with 
the hypothesis of migration of in radiolabel from the bone marrow to the abscess. 
Apparently, the induction of the abscess induced activation of the immune system with 
subsequent recruitment of bone marrow cells to the site of infection. The biodistribution 
data further substantiated the hypothesis. Radioactivity concentration in the circulation of 
infected animals decreased 4.5-5.0 %ID (similar to healthy animals), whereas almost 9 
%ID of the radioactivity accumulated in the abscess during the same time interval. Since 
the amount of radioactivity in the abscess was higher than the amount that had cleared 
from the circulation, and blood clearance was similar in healthy and infected animals, the 
radioactivity present in the abscess could not have originated from the circulation. 
Migration of (cell-associated) radioactivity from the bone marrow to the abscess could 
further explain the differences in radioactivity concentration in the bone marrow of infected 
animals and healthy animals at time of dissection. At the time of dissection (40 h after 
injection of the radiolabel) the amount of 111In-DPC11870 in the bone marrow of healthy 
animals was approximately 24% higher as compared to the amount in infected animals 
(33.8±4.5%ID vs. 9.45±2.5 %ID). As a result, this experiment demonstrated that our 
hypothesis was valid. The question, however, remained whether the radioactivity recruited 
from the bone marrow to the site of infection was cell-associated. Therefore, in a third 
experiment we determined if in vitro 111In-DPC11870 targeted WBCs and BMCs could 
accumulate in the abscess. The images acquired after injection of the vitro labeled cells 
and unbound 111In-DPC11870 were comparable and demonstrated that the in vitro labeled 
cells also visualized the intramuscular abscess. Besides accumulation of radioactivity in 
the abscess all three agents showed uptake in bone marrow and spleen and a transient 
uptake in the lungs. These findings were in agreement with the pharmacokinetics of 
radiolabeled leukocytes13,14. Studies that focused on the kinetics of radiolabeled 
leukocytes showed that radiolabeled leukocytes are temporary trapped in the lungs and 
expose margination of activity in bone marrow and spleen.  Additionally, accumulation of 
radioactivity in the kidneys of the rabbits was observed, which indicated clearance of 
released 111In-DPC11870. The biodistribution data confirmed that in vitro labeled WBCs 
and BMCs accumulated in the abscess, comparable with 111In-DPC11870. Furthermore, 
the biodistribution data revealed differences in radioactivity concentration in the spleen 
and kidneys. Uptake in the spleen indicated removal of cell-associated radioactivity and 
inversely correlated with radioactivity concentrations in the kidneys (released 111In-
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s showed some release of radioactivity, due 
ether, our study indicates that visualization of infectious lesions with 111In-
ONCLUSION 
 this study the pharmacodynamics of the radiolabeled LTB4 antagonist DPC11870 were 
DPC11870). Since the spleen is involved in removal of scenescent granulocytes, the 
uptake in this organ reflects splenic granulocyte destruction and explained the difference 
in uptake in healthy and infected animals15. While in healthy animals the turnover of 
granulocytes is much higher this leads to higher (cell associated) radioactivity 
concentrations in the spleen than in infected animals where activated, in vivo radiolabeled, 
granulocytes were recruited to the abscess. 
Although the in vitro labeled BMCs and WBC
to similar imaging characteristics, the comparable abscess uptake, the high affinity of the 
LTB4 antagonist for its receptor6 and the expression of LTB4 receptors on immune cells16, 
it is conceivable that accumulation of radioactivity in the abscess is mainly due to 
migration of cell-associated radioactivity. Moreover, in healthy animals the radiolabel also 
remained associated with the bone marrow cells that were present in this organ. Only at 
relatively early time points after the injection of the radiolabeled compound, when blood 
levels are high, there might be a contribution of non-cell-associated activity that enters the 
site of infection and binds to receptors expressed by white blood cells present in the 
abscess. 
Taken tog
DPC11870 is mainly due to accumulation of cell-associated radioactivity. The compound 
might therefore exhibit similar imaging characteristics as radiolabeled leukocytes. Since 
preparation of 111In-DPC11870 is easy, rapid and without potential risks, disadvantages 
accompanied with preparation of radiolabeled leukocytes are absent. We therefore 
consider the radiolabeled LTB4 antagonist 111In-DPC11870 as a potential agent to 
visualize infectious and inflammatory lesions in patients and it is warranted to investigate 
the applicability of this compound in clinical studies. 
 
C
 
In
investigated in detail. The results of this study showed that the accumulation of 
radioactivity at the site of the infection occurs mainly due to migration of 111In-DPC11870 
from the bone marrow and circulation to the abscess. It is convincible that the radioactivity 
migrates cell-associated to the site of infection. Visualization of infectious foci with 111In-
DPC11870 is due to in vivo targeting of receptor positive hematopoietic cells and imaging 
characteristics resemble that of radiolabeled leukocytes. 
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ABSTRACT 
 
In previous studies we demonstrated that 99mTc-labeled Leukotriene B4 (LTB4) antagonist 
RP517 accumulated in infectious foci in rabbits. This lipophilic tracer cleared via the 
hepatobiliary route hampering imaging of abdominal lesions.  
Objectives: In the present study we report the synthesis and radiolabeling of three 
hydrophilic analogues of RP517.   
Methods: DPC11870-11 (15) is a divalent LTB4 antagonist conjugated to DTPA for 
radiolabeling with In-111. Monovalent LTB4 antagonists BMS57868-88 (13), and divalent 
LTB4 antagonist BMS57868-81 (16), are conjugated to bifunctional chelator HYNIC for 
radiolabeling with 99mTc. All three of these new imaging agents use cysteic acid groups as 
a pharmacokinetic modifier (PKM), giving them greatly improved water solubility.  
Results: The three compounds labeled efficiently with 111In or 99mTc with high 
radiochemical purity, and high specific activities. The biodistribution properties were 
determined in rabbits having intramuscular E. coli infection. These initial studies showed 
that, in contrast to RP517, clearance of all three compounds was exclusively renal. 
Furthermore, it was shown that the in vivo behavior of the 99mTc-labeled LTB4 antagonists 
was affected by the chelator/radionuclide combination, by the coligands used with the 
HYNIC chelator, and by the monovalent or divalent nature of the receptor-binding moiety. 
The use of tricine and isonicotinic acid (ISO) as co-ligands with HYNIC gave the highest 
uptake of radioactivity in the abscess and lowest radioactivity concentration in the non-
target tissues.  
Conclusion: Scintigraphic images of the three new LTB4 antagonist demonstrated that all 
visualized infectious foci in a rabbit model of acute intramuscular abscesses. The initial 
results of this study warrant additional detailed pharmacokinetic studies to investigate 
which of the three LTB4 antagonists exhibits most optimal characteristics for imaging 
infection and inflammation. 
 
INTRODUCTION 
 
The Leukotriene B4 (LTB4) receptors are G-protein-coupled receptors (GPCR) that are 
involved in recruitment and activation of leukocytes during an inflammatory response1. At 
present, two LTB4 receptor types are identified; BLT1 and BLT2, which have different 
affinities for LTB42,3. The high affinity receptor BLT1 is mainly expressed on neutrophils, 
while BLT2 is expressed more ubiquitously. LTB4 plays an essential regulatory role during 
the inflammatory response. However, its overproduction is reported to play a role in 
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pathological conditions such as asthma, inflammatory bowel disease and arthritis4,5. 
Consequently, a large number of LTB4 antagonists have been developed for clinical 
application as anti-inflammatory therapeutics6. The rapid detection of infectious and 
inflammatory foci in patients is essential for timely and adequate therapeutic intervention. 
One of the current methods for detection of infection and inflammation is scintigraphic 
imaging. The generally used radiopharmaceuticals for this purpose, 99mTc-labeled 
leukocytes and 67Ga-citrate, have several disadvantages. The blood handling required for 
the preparation of radiolabeled leukocytes is accompanied by the risk of infection from 
blood-borne pathogens, and is a time-consuming preparation7,8. The nuclear and 
biodistribution properties of 67Ga-citrate are far from ideal, resulting in poor image quality 
and increased radiation burden to the patient. 
We previously reported the synthesis of 99mTc-labeled LTB4 antagonist RP517 (Figure 1)9. 
LTB4 antagonist RPR6969810 was modified with a short PEG spacer to give compound 1, 
and the Boc group of 1 was replaced with the bifunctional chelator hydrazinonicotinic acid 
(HYNIC) to give drug precursor SG380 (2). The hydrazine was protected as the 
hydrazone of sodium 2-formylbenzenesulfonate to avoid reaction with trace quantities of 
formaldehyde and other carbonyl compounds commonly found in the research and 
manufacturing environment11. The radiolabeling of SG380 utilized 99mTc[TcO4]- in the 
presence of coligands tricine and trisodium triphenylphosphine-3,3',3''-trisulfonate 
(TPPTS)12. This radiolabeling procedure gave a rapid and clean formation of ternary 
ligand complex RP517. This tracer showed rapid accumulation in the infected thigh 
muscle in the rabbit E. coli model13. However, RP517 clears almost exclusively via the 
hepatobiliary route, and physiologic uptake in the intestines limits clinical applicability of 
this agent. Based on these observations, more hydrophilic compounds were designed, 
using cysteic acid (Csa) as a PKM. Initially, compound 1 was modified with four cysteic 
acids, converted to a bivalent ligand using glutamic acid, and conjugated to DTPA giving 
DPC11870-11 (15).  [111In(DPC11870-11)]  (21) was found to rapidly visualize infectious 
foci in the rabbit E. coli infected thigh muscle model14. The agent cleared rapidly from non-
target tissues, and excretion is almost exclusively renal. 
Although the biodistribution and imaging properties of [111In(DPC11870-11)] are very 
promising, a 99mTc-labeled tracer is generally preferred for scintigraphic imaging over an 
111In-labeled tracer because of the more favorable nuclear properties of 99mTc (140 keV 
gamma emissions, 6 h half-life) and the general availability of portable 99mTc generators. 
Herein we describe the synthesis and initial biological evaluation of two analogues of 
DPC11870-11. One compound (16) is structurally almost identical to DPC11870-11, with 
HYNIC replacing DTPA, while the other compound (13) is a monovalent version of 16. 
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Figure 1.  
Structures of lead LTB4 antagonist RPR69698, PEG-modified LTB4 antagonists 1, protected Hynic 
derivative SG380 (2), and RP517, the 99mTc ternary ligand complex. 
 
Both of these LTB4 antagonists were radiolabeled with 99mTc and the in vivo imaging 
characteristics were compared with those of  [111In(DPC11870-11)]. Furthermore, using 
divalent HYNIC conjugate 16, we have compared the biodistribution properties of three 
coligand systems, and shown that the coligand system can have a profound effect on the 
biodistribution properties of these 99mTc complexes. We also describe the complete 
synthesis of DPC11870-11, and provide an improved synthesis of PEGylated LTB4 
antagonist 1. 
 
MATERIALS AND METHODS 
 
Previously published procedures were used for the synthesis of Boc-Csa(Na)-OH29, Boc-
Glu(OTfp)-Otfp30, 6-Hydrazinonicotinic acid31, RPR6969810, and N-(t-butoxycarbonyl)-
4,7,10-trioxa-1,13-tridecanediamine32. HPLC-grade ACN was obtained from J.T. Baker. 
Absolute ethanol was obtained from Quantum Chemical Corp. All other reagents and 
solvents were purchased from Aldrich Chemical Corporation, Lancaster Synthesis, Inc., or 
Fluka Chemical Corporation and used as received. Merck silica gel, grade 9385, 230-400 
mesh, 60 Å was used for flash chromatography. Na-99mTcO4 (Mo-generator) and 111InCl3 
were obtained from Tyco Mallinckrodt, Netherlands. All reactions were carried out at 
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ambient temperatures under a nitrogen atmosphere unless noted otherwise. Organic 
reaction mixtures were concentrated under reduced pressure at 40-65 °C on a rotary 
evaporator. Reaction monitoring and low resolution mass data were obtained with an 
Agilent Model 1100 LC/MSD API-electrospray system using either a Phenomenex 
Synergi™ Polar-RP C18 column (4 µm, 80 Å, 4.6 x 150 mm), or a Zorbax SB-CN column 
(5 µm, 4.6 x 150mm), operated at 50 °C with 0.1% formic acid-modified ACN/water mobile 
phases. Final HPLC purity determination was made with an Agilent Model 1100 HPLC 
system, using either a Waters Atlantis™ dC18 column (5 µm, 4.6 x 100 mm) or a Zorbax 
SB-CN column (5 µm, 4.6 x 150mm), and 0.1% TFA or 0.1 M NaOAc-modified ACN/water 
as mobile phases. UV detection was carried out at 220 and 254 nm. Preparative HPLC 
purifications were performed on a Varian PrepStar system using SD-1 pumps equipped 
with a uv/vis detector model 320, using a Waters Atlantis™ dC18 column (5 µm, 30 x 
100mm) except as noted otherwise, and using the gradients and mobile phases given in 
the text. UV detection was carried out at 220 nm. All chromatography was carried out with 
HPLC grade organic solvents. 
Exact mass determination was performed on a 7.0 tesla Fourier transform ion cyclotron 
resonance (FTICR) mass spectrometer (IonSpec Corporation, Lake Forest, CA) equipped 
with an electrospray ionization source. A mixture of sample and internal calibrant 
(polyethylene glycol or polypropylene glycol) was prepared at approximately 10 µM each 
in ACN:water:acetic acid (500:500:1) and infused at 1 µL/minute. A spectrum was 
obtained using the IonSpec OMEGA data system by averaging five transients of 512K 
data points per transient. Mass calibration was derived from internal calibrant ions 
bracketing the m/z of interest for the sample. FT-NMR spectra were obtained on a Bruker 
Avance 600 MHz spectrometer at 600 MHz for 1H and 150 MHz for 13C using the indicated 
solvent.  Residual solvent signals were used for internal calibration.  Chemical shifts are 
reported in parts per million (δ), and signals are expressed as s (singlet), d (doublet), t 
(triplet), q (quartet), p (pentet), m (multiplet), or br (broad). Elemental analyses were 
performed at Oneida Research Services, Inc, Whitesboro, NY; found values agree 
favorably with the calculated ones. 
 
Ethyl 5-(5-(5-(4,6-Diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,4-tetraazolyl)-
pentanoate (3a) 
A solution of RPR69698 (35.0 g, 84.6 mmol) and bis(tri-n-butyltin)oxide (21.5 mL, 42.3 
mmol)  in absolute EtOH (1035 mL) was heated at reflux under nitrogen for 30 min.  The 
solution was concentrated under vacuum and the resulting was dissolved in cyclohexane 
(3x200 mL) and again concentrated to remove traces of EtOH.  The oil was dissolved in 
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cyclohexane (35 mL), treated with ethyl 5-bromovalerate (40.0 mL, 254 mmol), and 
heated at 85 ˚C in an oil bath under nitrogen for 28 h.  The reaction was cooled to ambient 
temperatures, diluted with ether (350 mL), washed sequentially with 10% KF solution (125 
mL) and saturated NaCl (400 mL), dried (MgSO4), and concentrated to give yellow oil.  
This oil was purified by silica gel flash chromatography. The column was initially eluted 
with hexane/EtOAc (75/25) until the unwanted N2 isomer was off the column, and the 
mobile phase was switched to hexane/EtOAc (60/40) to collect the desired N1 isomer.  
Product fractions were concentrated and the resulting solid was recrystallized (EtOH) to 
give 16.58g (36%) of the title compound as a colorless solid, MP 99.5-101.5 ˚C. 1H NMR 
(CDCl3): δ 8.10-8.01 (m, 2H), 7.69-7.62 (m, 2H), 7.55-7.36 (m, 7H), 6.85 (s, 1H), 4.43 (t, J = 6.3 Hz, 
2H), 4.34 (t, J = 7.5 Hz, 2H), 4.09 (q, J = 7.1 Hz, 2H), 2.32 (t, J = 7.2 Hz, 2H), 2.07-1.92 (m, 2H), 
1.91-1.60 (m, 8H), 1.50 (s, 6H), 1.21 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3): δ 172.7, 164.1, 159.8, 
155.1, 152.1, 139.1, 138.7, 129.0, 128.9, 128.6, 127.0, 126.8, 111.8, 107.1, 65.30, 60.49, 48.57, 
41.32, 34.84, 33.40, 29.38, 29.30, 27.17, 21.90, 21.29, 14.18; High Resolution MS:  Calcd for 
C32H40N5O3 [M+H]+: 542.3131, Found:  542.3140; Anal. (C32H39N5O3) C,H,N. 
 
Ethyl 5-(4-(5-(4,6-Diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,5-tetraazolyl)-
pentanoate (3b) 
Fractions from the above flash chromatography containing the unwanted N2 isomer were 
concentrated to give 10.2 g (22%) of the title compound as a colorless solid. 1H NMR 
(CDCl3):  8.10-8.01 (m, 2H), 7.69-7.61 (m, 2H), 7.55-7.35 (m, 7H), 6.86 (s, 1H), 4.54 (t, J = 7.1 Hz, 
2H), 4.42 (t, J = 6.6 Hz, 2H), 4.09 (q, J = 7.1 Hz, 2H), 2.31 (t, J = 7.3 Hz, 2H), 2.09-1.95 (m, 2H), 
1.90-1.70 (m, 4H), 1.70-1.56 (m, 2H), 1.45-1.28 (m, 8H), 1.21 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3):  
173.50, 172.81, 164.32, 155.12, 151.97, 139.18, 138.82, 128.94, 128.84, 128.57, 127.03, 126.81, 
111.66, 107.10, 65.83, 60.40, 52.32, 42.40, 34.77, 33.32, 29.59, 28.63, 27.21, 21.74, 21.31, 14.18; 
MS: m/e 542.4 [M+H]; High Resolution MS: Calcd for C32H40N5O3 [M+H]+: 542.3131, Found: 
542.3143; Anal. (C32H39N5O3) C,H,N.  
 
5-(5-(5-(4,6-Diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)-1,2,3,4-tetraazolyl)pentanoic Acid 
(4) 
A solution of ester 3a (16.2 g, 29.9 mmol) in inhibitor free, peroxide free THF (450 mL) 
was treated with 3 M LiOH (120 mL) and the resulting mixture was stirred rapidly for 19 h. 
The mixture was concentrated until most of the THF was removed.  The resulting aqueous 
mixture was adjusted to pH 3 with 6 N HCl and extracted with EtOAc (1 x 450, 1 x 60 mL). 
The combined EtOAc extracts were washed with saturated NaCl (100 mL), dried (MgSO4), 
and concentrated to give 15.3g (100%) of the title compound as a viscous colorless oil. 1H 
NMR (CDCl3): 8.02 (d, J = 8.4 Hz, 2H), 7.65(d, J = 8.2 Hz, 2H), 7.55-7.35 (m, 7H), 6.84 (s, 1H), 4.43-
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4.31 (m, 4H), 2.36 (t, J = 7.0 Hz, 2H), 2.10-1.92 (m, 2H), 1.89-1.62 (m, 6H), 1.49 (s, 6H), 1.42-1.20 
(m, 2H); High Resolution MS: Calcd for C30H36N5O3 [M+H]+; 514.2818, Found: 514.2819. 
 
N-(3-(2-(2-(3-((tert-Butoxy)carbonylamino)propoxy)ethoxy)ethoxy)propyl)-5-(5-(5-(4,6-
diphenyl(2-pyridyloxy))-1,1-dimethylpentyl)(1,2,3,4-tetraazolyl))pentanamide (1) 
A solution of 4 (5.60 g, 10.9 mmol), DIEA (4.75 mL, 27.3 mmol), and HBTU (5.68 g, 15.0 
mmol) in anhydrous DMF (75 mL) was stirred for 5 min and treated with a solution of N-(t-
butoxycarbonyl)-4,7,10-trioxa-1,13-tridecanediamine (4.81 g, 15.0 mmol) in anhydrous 
DMF (35 mL). Stirring was continued for 6 h.  The DMF was removed, and the resulting 
viscous oil was partitioned between EtOAc (330 mL) and water (75 mL) at pH 3.  The 
organic phase was washed consecutively with dilute (pH 3) HCl (2 x 75 mL), water (75 
mL), saturated (sat.) NaHCO3 (75 mL), and sat. NaCl (75 mL).  The organic phase was 
dried (MgSO4) and concentrated to give 8.80 g (99%) of 1 as an amber viscous oil.  1H 
NMR (CDCl3): δ 8.03 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 1.2 Hz, 1H), 7.49-7.37 
(m, 6H), 6.83 (d, J = 1.2 Hz, 1H), 6.30 (bs, 1H), 4.95 (bs, 1H), 4.41 (t, J = 6.4 Hz, 2H), 4.34 (t, J = 7.5 
Hz, 2H), 3.65-3.48 (m, 12H), 3.36-3.25 (m, 2H), 3.21-3.11 (m, 2H), 2.16 (t, J = 7.2 Hz, 2H), 2.02-1.94 
(m, 2H), 1.88-1.66 (m, 10H), 1.48 (s, 6H), 1.40 (s, 9H), 1.37-1.28 (m, 2H); 13C NMR (CDCl3): δ 
172.06, 170.25, 164.10, 159.91, 157.14, 156.10, 154.98, 152.41, 138.84, 138.58, 129.01, 128.64, 
127.59, 127.07, 126.85, 111,90, 78.94, 70.45, 70.42, 70.14, 70.01, 69.93, 69.43, 65.59, 48.72, 
41.28, 38.41, 37.88, 35.53, 34.84, 29.70, 29.48, 29.30, 28.90, 28.44, 27.15, 22.59, 21.33; High 
Resolution MS: Calcd for C45H66N7O7 [M+H]: 816.5024, Found:  816.5044. 
 
General procedure for pre-activation of Boc-Csa(Na)-OBt (6) 
Boc-cysteic acid mono sodium salt in anhydrous DMF (6 mL DMF for 1 mmol Boc-
Csa(Na)-OH) was treated with 1 equiv of HBTU and 2 equiv of DIEA, and stirred for 25 
min. The resulting solution of active ester was transferred to a solution of the reactive 
amine using anhydrous DMF to complete the transfer. 
 
LTB4-(Csa)-H (8) 
A solution of 1 (1.68 g, 2.1 mmol) in 50/40/5/5 DCM/TFA/TIS/H2O (40 mL) was stirred for 
30 min and concentrated yielding 5 as a yellow viscous oil. This oil was dissolved in DMF 
(25 mL), and made basic with DIEA (2.90 mL, 16.6 mmol). A solution of active ester Boc-
Csa(Na)-OBt (6) was prepared in a separate flask from Boc-Csa(Na)-OH (1.20 g, 4.1 
mmol), HBTU (1.56 g, 4.1 mmol), and DIEA (1.5 mL, 8.6 mmol) in DMF (25 mL). This 
solution of 6 was added to the solution of 5, and after 2 hours of stirring, the reaction 
mixture was concentrated, yielding a yellow oil. This oil was redissolved in CHCl3 (180 
mL), washed with water (2 x 100 mL), and sat. NaHCO3 (1 x 80 mL).  The aqueous layer 
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was back-extracted with CHCl3 (1 x 100 mL). The combined organic layers were dried 
(Na2SO4) and concentrated to give 7 as a pale yellow oily foam. This foam was dissolved 
in 50/40/5/5 DCM/TFA/TIS/H2O (40 mL), stirred for 20 min, and concentrated to give 
mono-cysteic acid derivative 8 as a yellow oil.  This oil was used in the subsequent 
reaction without further purification. MS: m/z 867.5 [M+H]+. 
 
LTB4-(Csa)2-H (9) 
A solution of 8 in DMF (25 mL) and DIEA (2.70 mL, 15.5 mmol) was treated with a solution 
of Boc-Csa(Na)-OBt (6) prepared from  Boc-Csa(Na)-OH (1.04 g, 3.6 mmol), HBTU (1.36 
g, 3.6 mmol), and DIEA (1.25 mL, 7.2 mmol) in DMF (20 mL). The solution was stirred for 
1 h and concentrated to give viscous yellow oil. This oil was dissolved in 50/40/5/5 
DCM/TFA/TIS/H2O (50 mL), stirred for 20 min and concentrated. Crude product was 
purified by HPLC using a 3%/min gradient of 36-72% ACN containing 0.1% TFA at a flow 
rate of 40 mL/min. The product fraction eluting at 5.7 min was lyophilized to give dicysteic 
acid derivative 9 (1.03 g, 0.91 mmol, 44% from compound 1) as a colorless solid. 
1
H NMR 
(CD3OD): δ 7.97-7.94 (m, 2H), 7.94-7.91 (m, 2H), 7.88 (d, J = 1.2 Hz, 1H), 7.63-7.57 (m, 6H), 7.53 
(d, J = 1.2 Hz, 1H), 4.87-4.83 (m, 1H), 4.56 (t, J = 6.3 Hz, 2H), 4.50 (t, J = 7.2 Hz, 2H), 4.30 (t, J = 
6.0 Hz, 1H), 3.61-3.56 (m, 4H), 3.55-3.50 (m, 4H), 3.48-3.37 (m, 7H), 3.25-3.16 (m, 4H), 3.11-3.05 
(m, 1H), 2.24 (t, J = 7.2 Hz, 2H), 1.22-1.88 (m, 6H), 1.75-1.66 (m, 6H), 1.51 (s, 6H), 1.39-1.32 (m, 
2H); 13C NMR (CD3OD): δ 175.4, 171.8, 168.7, 163.4, 161.7, 160.8, 153.4, 137.5, 134.3, 132.7, 
132.6, 130.8, 130.6, 129.4, 129.2, 116.1, 106.9, 72.10, 71.63, 71.32, 71.30, 70.06, 69.88, 53.02, 
52.74, 51.98, 51.47, 50.21, 42.12, 38.15, 38.11, 36.41, 36.21, 30.63, 30.46, 30.36, 30.06, 27.67, 
24.08, 22.3; High Resolution MS: Calcd for C46H68N9O13S2 [M+H]: 1018.4372; Found: 1018.4386. 
 
LTB4-(Csa)3-H (10) 
A solution of 9 (911 mg, 0.81 mmol), and DIEA (625 µL, 3.6 mmol) in DMF (10 mL) was 
treated with solution of Boc-Csa(Na)-OBt (6) prepared from  Boc-Csa-(Na)-OH (521 mg, 
1.8 mmol), HBTU (679 mg, 1.8 mmol), and DIEA (625 µL, 3.6 mmol) in DMF (10 mL). The 
reaction was stirred for 2 h and concentrated. The residue was dissolved in 50/40/5/5 
DCM/TFA/TIS/H2O (20 mL), stirred for 25 min, and concentrated. Crude product was 
purified by HPLC using a 3%/min gradient of 31.5-54% ACN containing 0.1% TFA at a 
flow rate of 40 mL/min. The product fraction eluting at 4.8 min was lyophilized to give 
tricysteic acid derivative 10 (1.01 g, 0.78 mmol, 97%) as a colorless solid. 1H NMR 
(CD3OD): δ 8.03-7.99 (m, 2H), 7.93-7.88 (m, 3H), 7.69-7.59 (m, 7H), 4.72 (dd, J = 3.5, 9.7 Hz, 1H), 
4.65 (dd, J = 3.6, 9.6 Hz, 1H), 4.60 (t, J = 6.7 Hz, 2H), 4.54 (t, J = 7.2 Hz, 2H), 4.37 (dd, J = 3.6, 9.6 
Hz, 1H), 3.63-3.58 (m, 4H), 3.58-3.53 (m, 4H), 3.53-3.39 (m, 6H), 3.36-3.30 (m, 1H), 3.30-3.19 (m, 
7H), 2.36 (t, J = 7.5 Hz, 2H), 2.06-1.99 (m, 2H), 1.99-1.90 (m, 4H), 1.79-1.70 (m, 6H), 1.52 (s, 6H), 
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1.41-1.33 (m, 2H); 13C NMR (CD3OD): δ 176.1, 172.4, 171.7, 168.9, 162.9, 162.1, 161.7, 152.6, 
136.9, 133.2, 133.0, 132.9, 130.8, 130.7, 129.8, 129.5, 116.7, 106.8, 73.30, 71.53, 71.21, 71.14, 
69.91, 69.63, 53.61, 53.04, 52.30, 52.03, 51.73, 50.99, 50.16, 41.93, 38.57, 38.04, 36.18, 36.03, 
30.53, 30.19, 30.09, 29.92, 27.63, 24.15, 22.23; High Resolution MS: Calcd for C49H73N10O17S3 
[M+H]: 1169.4312; Found: 1169.4309. 
 
LTB4-(Csa)4-H (11) 
A solution of 10 (705 mg, 0.55 mmol) and DIEA (630 µL, 3.6 mmol in DMF (12 mL)) was 
treated with a solution of Boc-Csa(Na)-OBt (6) prepared from  Boc-Csa-(Na)-OH (351 mg, 
1.2 mmol), HBTU (457 mg, 1.2 mmol), and DIEA (420 µL, 2.4 mmol) in DMF (7 mL). The 
reaction was stirred for 40 min and concentrated. The residue was dissolved in 50/40/5/5 
DCM/TFA/TIS/H2O (20 mL), stirred for 25 min, and concentrated. Crude product was 
purified by HPLC using a 3%/min gradient of 27-54% ACN containing 0.1% TFA at a flow 
rate of 40 mL/min. The product fraction eluting at 5.3 min was lyophilized to give 
tetracysteic acid derivative 11 (674.8 mg, 0.47 mmol, 86%) as a colorless solid. 1H NMR 
(CD3OD & CD3CN): δ 7.88-7.83 (m, 4H), 7.77 (d, J = 1.2 Hz, 1H), 7.61-7.53 (m, 4H), 7.34 (d, J = 1.2 
Hz, 1H), 4.71 (dd, J = 3.9, 9.3 Hz, 1H), 4.57-4.51 (m, 2H), 4.46-4.39 (m, 4H), 4.37 (dd, J = 4.2, 9.0 
Hz, 1H), 3.56-3.34 (m, 14H), 3.31-3.14 (m, 8H), 3.11 (t, J = 6.9 Hz, 2H), 2.17 (t, J = 7.2 Hz, 2H), 1.90 
(p, J = 7.5 Hz, 2H), 1.86-1.78 (m, 4H), 1.69 (p, J = 6.6 Hz, 2H), 1.66-1.57 (m, 4H), 1.44 (s, 6H), 1.27-
1.20 (m, 2H); 13C NMR (CD3OD & CD3CN): δ 175.6, 172.4, 172.0, 171.9, 168.8, 163.3, 161.8, 159.9, 
153.2, 137.2, 134.1, 132.7, 132.6, 130.8, 130.6, 129.2, 129.1, 115.8, 106.9, 71.71, 71.11, 70.91, 
70.87, 69.80, 69.53, 53.06, 52.88, 52.51, 51.86, 51.67, 51.53, 51.23, 50.95, 50.13, 41.66, 37.87, 
37.76, 36.32, 35.98, 30.28, 30.02, 29.84, 29.68, 27.58, 23.83, 21.99; High Resolution MS: Calcd for 
C52H78N11O21S4 [M+2H]: 660.7162; Found: 660.7163. 
 
6-(2-Benzaldehydehydrazono)nicotinic acid (12) 
A suspension of 6-hydrazinonicotinic acid (274 mg, 1.8 mmol) in DMF (11 mL) was treated 
with benzaldehyde (1.1 mL, 11 mmol), and stirred for 2 days. Filtration of the reaction 
mixture gave 12 as a pale yellow powder. The filtrate was diluted with DCM (100 mL) to 
give an additional crop of 12. The combined solids were washed with DCM and gave the 
title compound (284 mg, 1.2 mmol, 66%) as a light yellow powder. 1H NMR (DMSO-d6 & 
CD3OD): δ 8.53 (s, 1H), 8.42 (s, 1H), 8.30 (d, J = 9.0 Hz, 1H), 7.96 (s, 2H), 7.47 (dd, J = 1.8 & 5.4 
Hz, 3H), 7.38 (d, J = 9.0 Hz,1H); 13C NMR (DMSO-d6 & CD3OD): δ 164.5, 141.9, 133.4, 130.7, 
128.8, 127.8, 117.5; High Resolution MS: Calcd for C13H12N3O2 [M+H]: 242.0924; found: 242.0923.  
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BMS57868-88 (13) 
A solution of 12 (10.2 mg, 42.3 µmol), PyBOP (19.3 mg, 37.1 µmol) and DIEA (20 µL, 115 
µmol) in DMF (0.75 mL) was added to 11 (14.0 mg, 10.6 µmol) in DMF (1.0 mL), and the 
reaction was stirred for 40 min. Concentration gave crude 13, which was purified by HPLC 
using isocratic conditions of 27% ACN containing 0.1 M NaOAc, pH 7 for 2 min at a flow 
rate of 25 mL/min, followed by a 1.0%/min gradient of 27-54% ACN containing 0.1 M 
NaOAc, pH 7 at a flow rate of 25 mL/min. The product fraction eluting at 18.1 min was 
diluted with 3 volumes of H2O and reloaded on the same preparative HPLC column 
equilibrated with 4.5% ACN containing 0.1% TFA. The product on the column was 
desalted by elution with 4.5% ACN containing 0.1% TFA for 15 min at a flow rate of 25 
mL/min, followed by a 5.7%/min gradient of 4.5-90% ACN containing 0.1% TFA at a flow 
rate 25 mL/min. Product fraction eluting a 10.4 min was lyophilized to give HYNIC 
conjugated monovalent tetracysteic acid derivative 13 (4.9 mg, 3.2 µmol, 30%) as a 
colorless powder. 1H NMR (CD3CN & D2O): δ 8.50 (d, J = 2.1 Hz, 1H), 8.32 (dd, J = 2.1 & 9.0 Hz, 
1H), 8.21 (s, 1H), 8.01-7.96 (m, 2H), 7.85-7.80 (m, 2H), 7.78-7.74 (m, 2H), 7.69 (d, J = 1.2 Hz, 1H), 
7.53-7.41 (m, 9H), 7.71 (d, J = 9 Hz, 1H), 7.00 (d, J = 1.2 Hz, 1H), 4.88 (dd, J = 4.2 & 9.3 Hz, 1H), 
4.65 (dd, J = 4.2 & 8.4 Hz, 1H), 4.58 (dd, J = 4.2 & 8.4 Hz, 1H), 4.52 (dd, J = 4.2 & 8.4 Hz, 1H), 4.37 
(t, J = 7.2 Hz, 2H), 4.35 (t, J = 7.8 Hz, 2H), 3.53-3.44 (m, 8H), 3.44-3.35 (m, 5H), 3.35-3.25 (m, 3H), 
3.25-3.15 (m, 4H), 3.13 (t, J = 6.6 Hz, 2H), 3.07 (t, J = 6.7 Hz, 2H), 2.11 (t, J = 7.6 Hz, 2H), 1.88-1.78 
(m, 4H), 1.74 (p, J = 7.2 Hz, 2H), 1.65 (p, J = 6.6 Hz, 2H), 1.60 (p, J = 6.7 Hz, 2H), 1.57 (p, J = 7.6 
Hz, 2H), 1.40 (s, 6H), 1.22-1.14 (m, 2H); 13C NMR (CD3CN & D2O): δ 175.9, 172.3, 166.2, 165.1, 
163.0, 162.1, 155.7, 152.4, 144.0, 139.1, 138.8, 138.4, 134.5, 132.9, 131.6, 131.5, 130.8, 130.6, 
130.5, 129.6, 128.8, 128.7, 122.5, 114.1, 113.7, 107.7, 71.21, 71.17, 71.02, 70.97, 69.98, 69.74, 
68.62, 53.14, 53.01, 52.75, 52.17, 52.05, 51.76, 51.70, 50.32, 41.86, 38.07, 37.87, 36.60, 36.20, 
30.44, 30.17, 30.12, 29.92, 27.83, 23.99, 22.29; High Resolution MS: Calcd for C65H88N14O22S4 
[M+2H]2+: 772.2535; found 772.2535. 
 
(LTB4-(Csa)4)2-Glu-H (14) 
A solution of 11 (264 mg, 0.18 mmol), Boc-Glu(OTfp)-OTfp (41.2 mg, 0.076 mmol), HOAt 
(22.7 mg, 0.17 mmol), and DIEA (130 µL, 0.75 mmol) in DMF (2 mL) was stirred for 6 
hours and concentrated to give a viscous yellow oil. This oil was dissolved in DCM (6.5 
mL) and treated with a solution of anisole/H2O/TFA (0.75 mL/ 0.75 mL/ 7 mL) and stirred 
for 30 min. The reaction solution was concentrated to give crude title compound as a 
viscous yellow oil. Crude product was purified by HPLC using isocratic conditions of 36% 
ACN containing 0.1 M NaOAc, pH 7 for 2 min at a flow rate of 25 mL/min, followed by a 
0.78%/min gradient of 36-54% ACN containing 0.1 M NaOAc, pH 7 at a flow rate of 25 
mL/min. The product fraction eluting at 15 min was diluted with 3 volumes of H2O, and 
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reloaded on the same preparative HPLC column equilibrated with 4.5% ACN containing 
0.1% TFA. The product on the column was desalted by elution with 4.5% ACN containing 
0.1% TFA for 15 min at a flow rate of 25 mL/min, followed by a 5.7%/min gradient of 4.5-
90% ACN containing 0.1% TFA at a flow rate 25 mL/min. Product fraction eluting a 10 min 
was lyophilized to give divalent tetracysteic acid derivative 14 (134 mg, 0.047 mmol, 62%) 
as a colorless solid. 1H NMR (CD3CN & D2O): δ 7.78-7.70 (m, 8H), 7.64 (d, J = 1.2 Hz, 2H), 7.59-
7.47 (m, 12H), 7.26 (d, J = 1.2 Hz, 2H), 4.72 (dd, J = 3.9 & 9.3 Hz, 1H), 4.65-4.55 (m, 5H), 4.55-
4.49(m, 2H), 4.38 (t, J = 7.5 Hz, 4H), 4.33 (t, J = 6.3 Hz, 4H), 3.99 (dd, J = 5.4 & 7.8 Hz, 1H), 3.53-
3.43 (m, 16H), 3.42-3.35 (m, 9H), 3.32-3.14 (m, 15H), 3.12 (t, J = 7.2 Hz, 4H), 3.07 (t, J = 7.2 Hz, 
4H), 2.51 (t, J = 6.9 Hz, 2H), 2.21-2.11 (m, 5H), 2.09-2.01 (m, 1H), 1.85 (p, J = 7.6 Hz, 4H), 1.81-
1.71 (m, 8H), 1.65 (p, J = 6.8 Hz, 4H), 1.60 (p, J = 6.6 Hz, 4H), 1.55 (p, J = 7.4 Hz, 4H), 1.40 (s, 
12H), 1.21-1.12 (m, 4H); 13C NMR (CD3CN & D2O): δ 175.8, 175.2, 172.3, 172.1, 171.7, 170.2, 
162.4, 161.7, 160.2, 152.1, 136.2, 132.9, 132.7, 132.6, 130.6, 130.5, 128.9, 128.8, 115.6, 106.2, 
72.02, 70.58, 70.40, 70.35, 69.41, 69.14, 53.94, 52.43, 52.26, 52.17, 52.00, 51.73, 51.56, 51.45, 
51.38, 51.23, 50.88, 49.86, 41.12, 37.53, 37.42, 35.99, 35.63, 32.18, 29.75, 29.39, 29.27, 29.10, 
27.24, 26.82, 23.42, 21.52; High Resolution MS: Calcd for C109H159N23O44S8Na2 [M+2Na]+2: 
1397.9231; Found: 1397.920.  
 
DPC11870-11 (15) 
A solution of 14 (50.1 mg, 0.0182 mmol) and DIEA (64 µL, 0.364 mmol) in anhydrous 
DMF (2.0 mL) was treated dropwise with a solution of DTPA dianhydride (65.0 mg, 0.182 
mmol) and DIEA (16 µL, 0.091 mmol) in anhydrous DMF (3.0 mL) over 10 min. The 
reaction was quenched after 1.5 h by the addition of water (0.1 mL), and concentrated 
under vacuum to give a colorless glassy solid. The crude product was purified by HPLC 
on a Phenomenex Jupiter™ C18 column (10µ, 21.2 x 250 mm) using a 0.9%/min gradient 
of 27-63% ACN containing 0.1% TFA at a flow rate of 20 mL/min.  Product fraction eluting 
at 25.1 min was lyophilized to give 15 as a colorless solid (55.0 mg, 0.0176 mmol, 96%).  
1H NMR (D2O:CD3CN 1:9): δ 7.58 (d, J = 7.62 Hz, 8H), 7.52-7.36 (m, 14H), 7.04 (s, 2H), 4.74-4.69 
(m, 1H), 4.67-4.62 (m, 4H), 4.62-4.56 (m, 4H), 4.54-4.50 (m, 2H), 4.41-4.33 (m, 5H), 4.22-4.08 (m, 
12H), 3.64 (s, 2H), 3.53-3.41 (m, 20H), 3.41-3.13 (m, 25H), 3.09 (t, J = 6.75 Hz, 4H), 3.02 (t, J = 6.75 
Hz, 4H), 2.42-2.27 (m, 2H), 2.16-2.08 (m, 5H), 1.94-1.86 (m, 1H), 1.84-1.73 (m, 8H), 1.72-1.47 (m, 
16H), 1.39 (s, 12H), 1.12-1.04 (m, 4H); High Resolution MS: Calcd for C123H182N26O53S8 [M+2H]
2+: 
1563.5056; Found: 1563.505. 
 
BMS57868-81 (16)  
A solution of 12 (17.5 mg, 73 µmol), PyBOP (37.8 mg, 72.7 µmol), and DIEA (20 µL, 115 
µmol) in DMF (1.0 mL) was stirred for 15 min and added to a solution of 14 (50.0 mg, 17.4 
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µmol) and DIEA (30 µL, 172 µmol) in DMF (1.0 mL). Stirring was continued for 20 h and 
the reaction mixture was concentrated. Crude product was purified by HPLC using 
isocratic conditions of 40.5% ACN containing 0.1 M NaOAc, pH 7 for 2 min at a flow rate 
of 25 mL/min, followed by a 0.39%/min gradient of 40.5-49.5% ACN containing 0.1 M 
NaOAc, pH 7 at a flow rate of 25 mL/min. The product fraction eluting at 11 min was 
diluted with 3 volumes of H2O and reloaded on the same preparative HPLC column 
equilibrated with 4.5% ACN containing 0.1% TFA. The product on the column was 
desalted by elution with 4.5% ACN containing 0.1% TFA for 15 min at a flow rate of 25 
mL/min, followed by a 5.7%/min gradient of 4.5-90% ACN containing 0.1% TFA at a flow 
rate 25 mL/min. Product fraction eluting a 10.6 min was lyophilized to give HYNIC-
conjugated divalent tetracysteic acid derivative 16 (40.2 mg, 13.5 µmol, 78%) as a 
colorless solid.  1H NMR (D2O:CD3CN 1:1): δ 8.58-8.55 (m, 1H), 8.12-8.07 (m, 1H), 8.05-8.00 (m, 
4H), 7.98 (s, 1H), 7.73-7.65 (m, 6H), 7.62 (d, J = 1.2 Hz, 2H), 7.50-7.38 (m, 12H), 7.35 (t, J = 7.2 Hz, 
2H), 7.32-7.24 (m, 2H), 6.83 (d, J = 1.2 Hz, 2H), 4.75-4.68 (m, 3H), 4.66 (dd, J = 4.6 & 8.3 Hz, 1H), 
4.61 (dd, J = 4.6 & 8.1 Hz, 2H), 4.55-4.50 (m, 2H), 4.45 (dd, J = 4.8 & 8.3 Hz, 1H), 4.33 (t, J = 6.9 
Hz, 8H), 3.53-3.42 (m, 16H), 3.42-3.10 (m, 28H), 3.07 (t, J = 6.9 Hz, 4H), 2.42 (t, J = 7.6 Hz, 2H), 
2.22-2.16 (m, 1H), 2.13-2.07 (m, 4H), 2.07-2.00 (m, 1H), 1.86-1.75 (m, 8H), 1.70 (t, J = 7.2 Hz, 4H), 
1.66 (t, J = 6.6 Hz, 4H), 1.60 (t, J = 6.6 Hz, 4H), 1.54 (t, J = 7.6 Hz, 4H), 1.38 (s, 12H), 1.21-1.12 (m, 
4H); 13C NMR (D2O:CD3CN 1:1): δ 181.22, 175.76, 175.33, 174.19, 172.47, 172.18, 172.00, 171.88, 
171.78, 168.97, 165.27, 161.58, 159.24, 156.23, 153.30, 143.78, 139.73, 138.96, 135.84, 130.40, 
130.30, 130.19, 129.80, 128.06, 127.78, 121.42, 118.75, 116.81, 112.70, 107.69, 107.46, 70.64, 
70.73, 70.47, 70.41, 69.45, 69.25, 66.61, 54.99, 52.40, 52.39, 52.22, 52.05, 52.00, 51.90, 51.68, 
51.62, 49.76, 41.39, 37.57, 37.34, 36.08, 35.66, 32.96, 29.93, 29.81, 29.62, 29.41, 27.30, 24.45, 
23.45, 21.84; High Resolution MS: Calcd for C122H170N26O45S8 [M+2H]+2: 1487.4784; Found: 
1487.482. 
 
Receptor Binding Assay 
In vitro binding studies were performed on purified human granulocytes, purified as 
described previously33. Briefly, increasing amounts of DPC11870-11, SG380, BMS57868-
81, or  BMS57868-88 (0-20 µM) were added to 1 x 108 cells in the presence of 10,000 
cpm [111In(DPC11870-11)] (0.5 nM) in 0.25 M Tris/HCl, pH 7.2.  The cell suspensions 
were incubated for 1 h at 37 °C, the cells were washed twice (5 min, 5000 x g), 
supernatant was discarded, and the radioactivity in the pellet (total bound activity) was 
measured in a shielded well-type gamma counter (Wizard, Pharmacia-LKB, Uppsala, 
Sweden). The specifically bound fraction versus the LTB4 antagonist concentration was 
plotted. The IC50 (50% inhibitory concentration) was determined as being the 
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concentration of the LTB4 antagonist that caused 50% inhibition of the maximum binding 
of [111In(DPC11870-11)]. 
 
General Procedure for 99mTc-Radiolabeling of BMS57868-81 (16) 
A solution of BMS57868-81 (16) (10 µg), SnSO4  (25 µL of a 1 mg/mL solution in 0.1 N 
HCl), coligand(s), and 110 MBq Na-99mTcO4 in 350 µL PBS, pH 7.0 was heated for 30 min 
at 100 °C. Radiochemical purity was checked by instant thin layer chromatography (ITLC) 
on silica gel strips (Gelman Sciences, Inc., Ann Arbor, MI) in 0.1 M Na-citrate buffer, pH 
6.0. Strips were analyzed in a well-type gamma counter (Wizard, Pharmacia-LKB, 
Uppsala, Sweden). In addition, RP-HPLC was performed on a C18 column (Zorbax Rx-
C18 4.6 mm x 25 cm) on an Agilent 1100 HPLC system equipped with an in-line radio 
detector (Canberra Packard, Brussels, Belgium), using 5%/min gradient of 0-100% ACN 
containing 10 mM Ammonium acetate pH 7.2 at a flow rate of 1.0 mL/min. The 
radiolabeling efficiency was >95% in all cases. 
 
[99mTc(BMS57868-81)(tricine)(TPPTS)] (17) 
From 16, tricine (65 µg), and TPPTS (5 mg). 
 
[99mTc(BMS57868-81)(tricine)2] (18) 
From 16, and tricine (15 mg). 
 
[99mTc(BMS57868-81)(tricine)(ISO)] (19) 
From 16, tricine (15 mg), and isonicotinic acid (2 mg). 
 
[99mTc(BMS57868-88)(tricine)(ISO)] (20) 
A solution of BMS57868-88 (25 µg), tricine (15 mg), isonicotinic acid (2 mg), SnSO4 (25 
µL of a 1 mg/mL solution in 0.1 N HCl) and 555 MBq Na-99mTcO4 in 350 µL PBS (pH 7.0) 
was heated for 30 minutes at 100 °C. 
 
[111In(DPC11870-11)] (21) 
DPC11870-11 (15) (10 µg) was labeled with 37 MBq 111In in metal-free 0.25 M ammonium 
acetate buffer, pH 5.5 as described previously.14 
 
Infection model 
All animal experiments were approved by the local animal welfare committee in 
accordance with Dutch legislation and carried out in accordance with their guidelines. Nine 
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female New Zealand White (NZW) rabbits weighing 2.3-2.8 kg were kept in cages (one 
rabbit per cage) and fed standard laboratory chow and water ad libitum. Rabbits were 
anaesthetized by subcutaneous injection of 0.7 mL of a mixture of 0.315 mg/mL fentanyl 
and 10 mg/mL fluanison (Hypnorm®, Janssen Pharmaceutica, Buckinghamshire, UK). 
Twenty minutes after administration of anesthesia an E. coli infection was induced in the 
left thigh muscle by intramuscular injection of 4 x 109 colony-forming units of E. coli 
bacteria. Twenty-four hours after induction of the abscess, when swelling of the infected 
muscle was apparent, three rabbits were intravenously injected with 37 MBq 
[99mTc(BMS57868-81)L1L2] (3.0 µg), where L1L2 equals one of the coligand systems 
tricine/TPPTS, tricine2, or tricine/isonicotinic acid.  
In a following experiment fifteen animals were divided in three groups of five rabbits. To 
compare the imaging characteristics of the divalent compounds and the monovalent 
compound five animals each were injected with 37 MBq [99mTc(BMS57868-
81)(tricine)(ISO)] (19), 37 MBq [99mTc(BMS57868-88)(tricine)(ISO)] (20), and 11 MBq 
[111In(DPC11870-11)] (21) in the lateral ear vein.  
 
Imaging studies 
For scintigraphic imaging, the rabbits were immobilized in a mold and placed prone on a 
gamma camera (Orbiter, Siemens, Hoffman Estates, IL) using a low-energy parallel hole 
collimator in case of the 99mTc-labeled compounds, whereas a medium-energy collimator 
was used during acquisition of rabbits injected with 111In-DPC11870-11. Images (300,000 
cts/image) were obtained at several time points after injection starting immediately after 
injection until 8 h postinjection (p.i.). Images were stored digitally in a 256 x 256 matrix. All 
images were windowed identically, allowing a fair comparison among the various 
experiments. At 8 h p.i. all rabbits were euthanized. A blood sample was taken by cardiac 
puncture. Tissues were dissected and weighed. The activity in tissues was measured in a 
shielded well-type gamma counter together with the injection standards and was 
expressed as the percentage of the injected dose per gram (%ID/g). 
 
Statistical Analysis  
All mean values are presented as mean ± standard deviation. Statistical analysis was 
performed using one-way ANOVA. Results were corrected for multiple comparisons with 
the Bonferroni Multiple Comparisons Test. The level of significance was set at 0.05. 
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RESULTS 
 
Synthesis 
PEG-modified LTB4 antagonist 1 was synthesized as outlined in Scheme 1. The tetrazole 
ring of RPR69698 was alkylated with ethyl 5-bromovalerate in ACN. Selectivity for 
alkylation at the N1 position was increased by blocking the N2 position with the tri-n-
butyltin group15. 
 
 
Scheme 1 
Synthesis of Tetra-Cysteic Acid-Modified LTB4 Antagonist 11a  
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aReagents: i) bis(tri-n-butyltin)oxide, EtOH; ii) ethyl 5-bromovalerate, cyclohexane, 
36%; iii) aq LiOH, THF, 100%; iv) N-(t-butoxycarbonyl)-4,7,10-trioxa-1,13-
tridecanediamine, HBTU, DIEA, 99%; v) TFA, DCM, TIS, water; vi) Boc-Csa(Na)-OH, 
HBTU, DIEA, DMF. 
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Flash chromatography gave a 36% yield of the desired N1-alkylation product 3a, along 
with 22% of the unwanted N2 isomer 3b. The ester group of 3a was hydrolyzed with LiOH 
in aqueous THF to give a quantitative yield of compound 4.  Conjugation of 4 with N-(t-
butoxycarbonyl)-4,7,10-trioxa-1,13-tridecanediamine using HBTU coupling reagent 
afforded a 99% yield of 1. 
The tetracysteic acid derivative of 1 was synthesized by the sequential coupling of four 
Boc-cysteic acid-mono sodium salt residues (Boc-Csa(Na)-OH) as shown in Scheme 1. 
The Boc-protecting group of 1 was removed using a mixture of trifluoroacetic acid (TFA), 
dichloromethane (DCM), water, and triisopropylsilane (TIS). The amine TFA salt (5) 
resulting after concentration of the reaction solution was used without purification.   
Boc-Csa(Na)-OH was pre-activated using HBTU, and DIEA in DMF solution, and the 
resulting N-hydroxybenzotriazole ester (6) was added to a solution of 5 in DMF.  The 
resulting Boc-protected cysteic acid derivative (7) was purified my means of extraction into 
CHCl3, and washing with H2O and sat. NaHCO3. The sat. NaHCO3 wash removed the 1-
hydroxybenzotriazole (HOBt) from the organic layer, and the crude product was used 
without further purification. The Boc group of compound 7 was removed as described 
above giving 8. The products of the second, third and fourth deprotection/cysteic acid 
coupling cycles (9, 10, and 11, respectively) were too hydrophilic for purification by 
partitioning between aqueous and organic phases, and therefore were purified by 
preparative reverse phase HPLC on a C18 column. Products were recovered from the 
aqueous eluants by lyophilization, and were obtained as flocculent colorless solids. 
Scheme 2. 
Synthesis of Monovalent Hynic Conjugate BMS57868-88 (13)a 
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104 
Synthesis of LTB4 antagonists 
6-Hydrazinonicotinic acid was converted to 6-(2-benzaldehydehydrazono)nicotinic acid 
(12) using an excess of benzaldehyde as shown in Scheme 211,16. Unreacted 
benzaldehyde was removed by trituration with DCM to give pure 12 in 66% yield. The 
conjugation reaction between 11 and 12 was mediated with benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and DIEA in DMF solution to 
give a 30% purified yield of BMS57868-88 (13). 
Preparation of the bivalent LTB4 antagonist was achieved by the conjugation of 
tetracysteic acid derivative 11 to both of the carboxylic groups of Boc-glutamic acid, using 
Boc-Glu(OTfp)-OTfp as the activated form (Scheme 3). The addition of HOAt significantly 
increased the reaction rate, and the reaction was complete in 6 h at ambient temperature.  
The Boc group was removed using a cocktail of TFA/DCM/water/anisole, and the resulting 
amine was purified by HPLC to give a 62% yield of divalent LTB4 antagonist 14 as a 
flocculent, colorless solid. Compound 14 was used for the preparation of divalent DTPA 
conjugate DPC11870-11 (15) and divalent HYNIC conjugate BMS57868 (16).  Reaction of 
14 with DTPA dianhydride in DMF gave a 96% yield of 15 after HPLC purification.  HYNIC 
conjugate 16 was isolated in 78% yield by a PyBOP-mediated coupling of 14 and 12 in 
DMF. 
Scheme 3.   
Synthesis of Hynic and DTPA Chelator 
Conjugates of Bivalent LTB4 
Antagonista 
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aReagents: i) Boc-Glu(OTfp)-OTfp, HOAt, DIEA, DMF; ii) TFA, DCM; iii) DTPA 
dianhydride, DIEA, DMF; iv) 6-(2-benzaldehydehydrazono)nicotinic acid (12), PyBOP 
DIEA, DMF. 
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Receptor Binding Assay.   
The IC50 values for all of the chelator conjugates described here were obtained in a 
competition assay with [111In(DPC11870-11)].  As shown in Table 1, the receptor affinities 
of monovalent conjugates SG380 and BMS57868-88, and divalent DTPA conjugate 
DPC11870-11 were nearly identical to that of parent LTB4 antagonist RPR69698.  
Divalent HYNIC conjugate BMS57868-81 showed a greater than 10-fold loss of receptor 
affinity. 
 
Table 1.  IC50 Values (nM) of Chelator Conjugates 
 
 
Radiolabeling.   
HPLC analyses, performed after 99mTc-labeling of divalent HYNIC-conjugated compound 
BMS57868-81 (16), indicated that with all three coligand systems                    
the compound labeled at a specific activity of 37 MBq/µg (110 MBq/nmol) with a labeling 
efficiency >95%. Monovalent HYNIC-conjugated LTB4 antagonist BMS57868-88 (13) 
labeled at a specific activity of 110 MBq/nmol with a labeling efficiency >95%. Divalent 
DTPA-conjugated LTB4 antagonist DPC11870-11 (15) was labeled with 111In at a specific 
activity of 12 MBq/nmol with a labeling efficiency >95%.  
 
Animal studies 
Divalent LTB4 antagonist BMS57868-81 was radiolabeled with 99mTc using three different 
coligand systems, tricine/TPPTS, tricine2, and tricine/ISO, to give complexes of the 
general formula [99mTc(BMS57868-81)L1L2]. The structures of these three ligand systems 
are shown in Figure 2.  
 Competing Agent 
Compound [3H]LTB4 [111In(DPC11870-11)] 
RPR69698 20a  
SG380 45 (n = 4)b 44 (n = 2) 
14 8 (n = 2)b  
DPC11870-11 54 (n = 2)b 30 (n = 2) 
BMS57868-88  16 (n = 2) 
BMS57868-81  230 (n = 2) 
a Reference 10.  b NovaScreen, Hanover, MD
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Figure 2.  
Comparison of the structures of 
[99mTc(HYNIC)(L1)(L2)] complexes 
and [111In(DCP11870-11)]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pharmacokinetics of these three tracers were studied in three groups of rabbits with E. coli 
infection, with images acquired 5 min, 4 h and 8 h post injection (p.i.). As shown in Figure 
3, immediately after injection the distribution of [99mTc(BMS57868-81)L1L2] was similar for 
all three coligand systems. Uptake of the tracer was observed in the heart, lungs, liver, 
and kidneys and in the bone marrow. At 4 h and especially at 8 h after injection of the 
compounds, the radioactivity had accumulated in the abscess resulting in clear delineation 
of the infectious lesions. The images acquired at 8 h p.i. clearly indicated that the coligand 
used during the labeling procedure affected the in vivo distribution of the LTB4 antagonist. 
Visualization of the abscess was better when TPPTS or ISO was used as coligand in 
combination with tricine, than when tricine was used alone.  
Ex vivo biodistribution determination of radioactivity concentration in the dissected tissues 
confirmed the observations in the imaging experiment (Figure 4). Radioactivity 
concentrations in the abscess were highest when [99mTc(BMS57868-81)] was labeled with 
the tricine/TPPTS and tricine/ISO coligand systems. Uptake in non-target organs was also 
affected by the coligand system. The radioactivity concentration in the spleen and kidneys 
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was significantly higher using tricine/TPPTS coligands, as compared to the uptake in 
these organs using tricine/ISO or tricine alone (p<0.01). Altogether, the abscess 
visualization was best after injection of [99mTc(BMS57868-81)(tricine)(ISO)] (19), because 
this preparation combined high uptake in the abscess with low radioactivity concentration 
in non-target tissues, particularly in the kidneys. 
 
In the next imaging experiment, rabbits with intramuscular infection were injected with 
either the divalent or monovalent 99mTc-labeled LTB4 antagonist [99mTc(BMS57868-
81)(tricine)(ISO)] (19) or [99mTc(BMS57868-88)(tricine)(ISO)] (20), respectively) or with the 
111In-labeled divalent LTB4 antagonist [111In(DPC11870-11)] (21). The images acquired at 
8 h p.i. showed that all three tracers visualized the intramuscular abscess (Figure 5). 
When the three agents were compared, it appeared that the distribution of both divalent 
analogs was very similar. All three analogs clearly delineated the intramuscular abscess. 
Non-target uptake of radioactivity for the three agents was similar in bone marrow, liver, 
and spleen. However, the kidney uptake of monovalent agent [99mTc(BMS57868-
88)(tricine)(ISO)] (20) appeared to be significantly lower.  
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Figure 4. Biodistribution data obtained 8 h p.i. using 
divalent imaging agent  [99mTc(BMS57868-81)] 
radiolabeled using tricine/TPPTS, tricine2, and tricine/ISO
coligand systems. Each bar represents the mean values ±
SD.
Figure 3. Anterior images of rabbits induced with an intramuscular infection. Images were 
acquired immediately, 4 and 8 h p.i of  37 MBq divalent imaging agent [99mTc(BMS57868-81)], 
radiolabeled using tricine/TPPTS (A), tricine2 (B) and tricine/ISO (C) coligand systems.
A
0.75
1.00 TPPTS
Tricine
Isonic. acid
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Figure 5.  
Comparison of divalent imaging agent 
[99mTc(BMS57868-81)(tricine)(ISO)] (A), monovalent 
imaging agent [99mTc(BMS57868-88)(tricine)(ISO)] 
(B) and divalent imaging agent [111In(DPC11870-11)] 
(C).  All are anterior images of rabbits induced with 
an intramuscular infection.  Images were acquired 8 
h p.i of  37 MBq for (A) and (B) and 11 MBq for (C). 
 
 
 
DISCUSSION 
 
Leukotriene B4 (LTB4) is a potent pro-inflammatory lipid mediator derived from 
arachidonic acid via the 5-lipoxygenase pathway.  It is produced by neutrophils, 
monocytes, macrophages, keratinocytes, lymphocytes, and mast cells.  The physiological 
responses to LTB4 include potent neutrophil chemotactic activity, adhesion of PMNs to 
the vascular endothelium, stimulation of the release of lysosomal enzymes and 
superoxide radicals by PMNs, and an increase in vascular permeability.  Increased levels 
of LTB4 have been detected in patients with asthma, acute respiratory distress syndrome, 
chronic obstructive pulmonary disease, contact dermatitis, cystic fibrosis, inflammatory 
bowel disease, gout, myocardial ischemia, psoriasis, and rheumatoid arthritis.  Thus, it is 
widely believed that LTB4 is an important mediator of acute and chronic inflammatory 
events. This has made the LTB4 receptor the target of intense research by major 
pharmaceutical companies for therapeutic applications, and in recent years, a number of 
highly potent and selective LTB4 antagonists have been reported.  These compounds 
have been shown to be safe and efficacious in both animal models and in humans6,17,18. 
This wealth of information on LTB4 antagonists made the LTB4 receptor the most 
attractive of the various approaches available for the development of a neutrophil-binding 
radiolabeled infection/inflammation imaging agent.  
In the present study the syntheses of three structurally related LTB4 antagonists are 
described. These antagonists were designed for scintigraphic visualization of infectious 
and inflammatory foci. In the field of nuclear medicine, there is an ongoing search for the 
ideal radiopharmaceutical to visualize infectious and inflammatory foci. For this purpose 
many radiolabeled peptides, cytokines and antagonists have been studied8. In our original 
work in this area we synthesized LTB4 antagonist SG380 (structure 2, Figure 1), for the 
visualization of infectious and inflammatory lesions. This compound was based on 
A B C
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RPR69698, a lipophilic BLT1 receptor-binding ligand10. SG380 is a conjugate of 
bifunctional chelator hydrazinonicotinic acid (HYNIC) to allow efficient radiolabeling with 
99mTc. The ternary ligand complex of 2, utilizing TPPTS and tricine as coligands (RP517 in 
Figure 1), accumulated rapidly in infected tissues containing infiltrated BLT1-positive 
neutrophils12,13. However, due to the lipophilicity of the receptor-binding moiety of RP517, 
the tracer cleared via the hepatobiliary route, and the rapid physiologic uptake of the 
tracer in the liver and the intestines interfered with visualization of inflammatory lesions in 
the abdomen13. 
Various strategies have been used to enhance the hydrophilicity of radiopharmaceutical 
drugs, in order to increase their water solubility and/or renal clearance.  These include the 
introduction of polar function groups (carboxyl, amine, etc.)19 and PEG chains20, and the 
use of different radionuclide chelators21. Our experience with SG380 indicated that we 
were unlikely to achieve a significant change in solubility or biodistribution properties by 
the introduction of simple PEG tethers. Here we present the synthesis and 
characterization of three hydrophilic tracers (DPC11870-11 (15), BMS57868-81 (16), and 
BMS57868-88 (13) in Schemes 2 and 3) based on the same receptor binding moiety used 
in the synthesis of SG380. The lipophilicity of SG380 was reduced by the introduction of 
multiple cysteic acids as a PKM. Cysteic acid was chosen for this role because of the high 
polarity of the sulfonic acid group, and because it is an unnatural amino acid and is 
therefore less likely to undergo metabolism. We have also examined the effect of two 
different radionuclide chelators (DTPA for coordination to 111In, and HYNIC for 
coordination to 99mTc) because it is known from other studies that the chelator can 
influence the biodistribution of the tracer21. Finally, we have examined the effect of 
different coligands with HYNIC because previous reports have shown that the nature of 
the coligand can have a marked effect on biodistribution22,23. 
In our original synthesis of SG380 the tetrazole ring of RPR69698 was alkylated with ethyl 
5-bromovalerate in refluxing ACN in the presence of DIEA as base24. Alkylation of 5-
substituted tetrazoles under these conditions always produces the N2 isomers in greater 
proportion than the N1 isomers.  In our original synthesis the N1/N2 ratio was a very 
unfavorable 0.14.  We subsequently learned that the product ratio could be shifted in favor 
of the N1 isomer by blocking the N2 position with the tri-n-butyltin group15. Preparation of 
the 2-(tri-n-butylstannyl)tetrazole was accomplished by treatment of RPR69698 with 
bis(tri-n-butyltin)oxide in refluxing EtOH (Scheme 1). The EtOH solvent was replaced with 
cyclohexane, ethyl 5-bromovalerate was added, and the solution was heated to reflux. 
The reaction solution was then diluted with ether and washed with aqueous KF to remove 
tin by-products.   Final purification by flash chromatography gave a 36% yield of the N1 
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isomer (3a), and a N1/N2 ratio of 1.64.  We discovered that formation of the N1 isomer is 
favored by the use of nonpolar solvents, and that even trace quantities of EtOH remaining 
from the formation of the 2-(tri-n-butylstannyl)tetrazole have a negative effect on the yield 
of the N1 isomer.  With this improvement over our original synthesis we were able to carry 
out the tetrazole alkylation on a relatively large scale, producing 16.58 g of purified 3a.  
The remaining steps in the synthesis of compound 1 followed our original procedures, as 
described in the experimental section. The four cysteic acid PKMs were added stepwise in 
a series of deprotection/coupling cycles, as shown in Scheme 1.  Boc-Csa(Na)-OH was 
preactivated using HBTU and the resulting N-hydroxybenzotriazole ester (6) was added to 
a DMF solution of the amine.  After the addition of one cysteic acid residue (i.e., 7, R = 
Boc), the product was still sufficiently lipophilic that polar by-products could be removed by 
water washes.  But subsequent cysteic acid coupling cycles gave products that were too 
hydrophilic for an aqueous workup procedure. These compounds were deprotected and 
the products (i.e., 9, 10, 11) of these reactions were purified by reverse phase HPLC and 
isolated from the eluants by lyophilization.  The overall yield for these four coupling cycles 
was 37%. 
The biomolecules employed as the basis for development of radiopharmaceuticals are 
frequently very potent, and elicit a biological response even at low doses.  Radiolabeling 
in the clinical setting must therefore be carried out using very small quantities of the 
biomolecule, and a substantial effort has been made to find radionuclide chelators that 
can be easily radiolabeled in aqueous solution at very low concentrations of the 
biomolecule, and with high specific activity.  One of the best chelators for 99mTc is 6-
hydrazinonicotinic acid (HYNIC), which is efficiently labeled in aqueous solutions having a 
ligand concentration as low as 10-5 molar12. Protection of the hydrazine group of HYNIC 
during conjugation to the targeting molecule is essential in order to prevent unwanted 
conjugation reactions. Protection is also desirable during manufacturing of the lyophilized 
kit used for preparation of the radiopharmaceutical, because the hydrazine moiety reacts 
readily with aldehydes and ketones found in the manufacturing environment.  Such 
materials are extracted from various rubber and plastic materials and are also used in 
common disinfectants.  Formaldehyde is particularly ubiquitous.  In our initial work in this 
area we discovered that hydrazones of aromatic aldehydes were particularly useful as 
hydrazine protecting groups on HYNIC11. These hydrazones are stable during synthesis 
and HPLC purification, and protect the hydrazine moiety from reaction with common 
carbonyl impurities.  The hydrazone is spontaneously cleaved during the radiolabeling 
process allowing formation of the diazenido-technetium bond.  We found that the 
hydrazone of 2-formylbenzaldehyde was especially useful because the sulfonic acid group 
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greatly improved water solubility of the HYNIC conjugate (see Figure 1).  With multiple 
cysteic acid PKMs present on the LTB4 antagonists described here, a further increase in 
water solubility was unnecessary, and we used the simpler hydrazone of benzaldehyde for 
protection of the hydrazine moiety (12 in Scheme 2). Conjugation of 12 to tetracysteic acid 
derivative 11 was accomplished using PyBOP to give a 30% purified yield of BMS57868-
88 (13). 
Many interactions in biological systems are polyvalent in nature (e.g., DNA helix, 
carbohydrate interactions, virus-cell wall interactions). However, it is only recently that 
polyvalency has begun to be explored in drug development25. In previous studies we have 
shown that divalency of a cyclic RGD peptide targeting the vitronectin receptor on tumors 
caused enhanced receptor affinity and enhanced retention in the target tissue in vivo26. 
We have explored the effect of divalency in these radiolabeled LTB4 antagonists by 
preparing the pseudo-dimer of 11. Tetracysteic acid derivative 11 was efficiently converted 
to a divalent ligand by reaction with Boc-Glu(OTfp)-OTfp and HOAt in DMF (Scheme 3). 
The HOAt greatly accelerated the reaction rate, reducing the reaction t½ from 12 h to 1 h.  
Removal of the Boc protecting group gave a 62% yield of 14 after HPLC purification.  
Conjugation of 14 to DTPA was accomplished by using a 10-fold excess of DTPA 
dianhydride, and gave a 96% purified yield of DPC11870-11 (15). Conjugation of 14 to 12 
gave a 78% purified yield of divalent HYNIC conjugate BMS57868-81 (16).  
The IC  values of the chelator conjugates reported in this study are shown in Table 1. 
Lipophilic HYNIC conjugate SG380 has a receptor affinity of 48 nM, which is only slightly 
weaker than the 20 nM value of parent LTB4 antagonist RPR69698.  Divalent water-
soluble amine 14 shows a slight increase in receptor affinity to 8 nM, while the 
corresponding DTPA conjugate (DPC11870-11) shows a slight loss of affinity to 54 nM.  
These data confirm our original hypothesis that the LTB4 receptor is very tolerant of 
substitutions on the tetrazole ring.  Monovalent water-soluble HYNIC conjugate 
BMS57868-88 has affinity of 16 nM, but surprisingly the divalent version (BMS57868-81) 
shows a large loss of receptor affinity with an IC
50
50 value of 230 nM.  Comparison with the 
affinities of the other divalent LTB4 antagonist (DPC11870-11) suggests this is not due 
solely to the divalent nature of the molecule, and comparison with the other two HYNIC 
conjugates (SG380 and BMS57868-88) suggests this is not due solely to the HYNIC 
chelator.  This value does not appear to be an outlier as the duplicate numbers are nearly 
identical.  At this time we have no explanation for the relatively low receptor affinity of 
BMS57868-81. 
Divalent DTPA conjugate DPC11870-11 (15) was radiolabeled with 111In as described in a 
previous publication to give [111In(DCP11870-11)] (21) as shown in Figure 214. The 99mTc 
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complexes of divalent HYNIC conjugate BMS57868-81 (16) were prepared from Na-
99mTcO4, SnSO4, and one of three coligand systems by heating at 100 °C for 30 min in 
phosphate buffered saline, pH 7.0.  The three coligand systems (tricine/TPPTS, tricine2, 
and tricine/ISO) gave complexes 17, 18, and 19 as shown in Figure 2.  Radiolabeling was 
rapid and efficient using each of the three coligand systems. The radiochemical purity of 
all complexes was verified by the analytical methods described in the experimental 
section.  While the binary complex formed from tricine alone (18) has been used 
extensively in pre-clinical research, it suffers from the drawback that it exists in solution in 
several isomeric forms, many of which are interconverting at room temperature27. It would 
be very difficult to develop such a system for clinical use.  In contrast, ternary complexes 
formed from TPPTS and tricine (e.g., 17) form only two non-interconverting diastereomeric 
radiolabeled products when the biomolecule is itself chiral12.  
Scintigraphic images after injection of divalent 99mTc complexes 17, 18, and 19 are shown 
in Figure 3.  Whole body distribution of the three agents was similar immediately after 
injection, with significant activity in the lungs and heart (blood pool), and in the kidneys.  
By four hours p.i. uptake in the abscesses was clearly visible with all three agents, and 
there was high activity in the kidneys. Images acquired eight hours p.i. clearly showed that 
uptake in the abscesses was greater with the tricine/TPPTS and tricine/ISO complexes 
(17 and 19).  It was also apparent that kidney uptake was higher with tricine/TPPTS 
complex 17.  Thus, the images obtained with ternary complex 19 were qualitatively 
superior to the images obtained with the other divalent 99mTc complexes.  The 
biodistribution data for complexes 17, 18, and 19 at eight hours p.i. (Figure 4) confirmed 
these visual impressions.  Uptake of 17 and 19 in the abscesses was twice that of 18, and 
the kidney uptake of 17 was nearly twice that of 18 and 19. In addition, the levels of 17 
were slightly higher in the spleen and marrow, and 18 showed slightly slower clearance 
from the blood.  Thus, for this divalent LTB4 antagonist platform, the tricine/ISO coligand 
system (19) combined the highest uptake in the abscess with the lowest uptake in non-
target tissues. 
In a final experiment we compared divalent tricine/ISO ternary complex 19 with 
monovalent tricine/ISO ternary complex 20, and with divalent 111In-DTPA complex 21.  
Scintigraphic images eight hours p.i. are shown in Figure 5.  The radioactivity 
concentration in the abscesses is similar for all three agents, but the kidney concentration 
appears significantly lower for monovalent complex 20.  This combination of high uptake 
in the target tissue and low uptake in non-target tissues makes monovalent 
[99mTc(BMS57868-88)(tricine)(ISO)] (20) the qualitatively superior imaging agent.  It is 
interesting that there is little difference in the images resulting from divalent 99mTc-HYNIC 
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complex 19 and divalent 111In-DTPA complex.  Structurally, the two chelator-radionuclide 
complexes are very different.  It is also interesting that the potential divalent interaction 
with LTB4 receptors on the cell membrane of the neutrophils did not enhance the 
accumulation of the either 19 or 21 in the abscess. However, divalent agent 
[99mTc(BMS57868-81)(tricine)(ISO)] (19) did showed enhanced retention in the kidneys as 
compared to monovalent compound [99mTc(BMS57868-88)(tricine)(ISO)] (20). In this 
instance, divalency did not result in enhanced uptake in the target, but apparently the 
divalent compound was more efficiently reabsorbed in the renal tubules as has been 
observed with other HYNIC-conjugated tracers28. As a result, abscess-to-background 
ratios of the monovalent compound were higher, resulting in scintigraphic images with 
improved contrast. 
 
CONCLUSION 
 
This study describes the syntheses of three new radiolabeled LTB4 antagonists for 
imaging infection and inflammation. All three of these tracers visualized intramuscular 
infection in rabbits within a few hours after injection, and the incorporation of multiple 
cysteic acid PKMs allowed these tracers to be cleared exclusively via the kidneys. The 
structural parameters investigated with these tracers included the use of either 99mTc-
HYNIC or 111In-DTPA complexes, monovalent vs. divalent LTB4 antagonists, and the 
coligands used in the 99mTc-HYNIC complexes. The coligand system had a marked effect 
on biodistribution in the rabbit model, with the ternary complex using tricine and ISO as 
coligands (i.e., 19) providing the best scintigraphic images and the best biodistribution 
data of the divalent HYNIC derivatives. Monovalent ternary 99mTc-HYNIC complex 20 gave 
better scintigraphic images than either divalent 99mTc-HYNIC complex 19, or divalent 111In-
DTPA complex 21. Tracer 20 appears to be the most promising of these new tracers, 
combining the highest uptake in abscesses with lowest uptake in non-target tissues. More 
detailed studies of the pharmacokinetic and imaging properties of this promising 
infection/inflammation imaging agent are ongoing and will be published elsewhere.  
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ABSTRACT 
 
Previous studies demonstrated that the bivalent 111In-labeled Leukotriene B4 (LTB4) 
antagonist, DPC11870 visualized infectious and inflammatory lesions in various rabbit 
models. The radioactive tracer accumulated quickly at the site of infection and cleared 
rapidly from the circulation, resulting in high-quality images. 
Objectives: In this study, two new HYNIC-conjugated compounds, which are structurally 
related to DPC11870, were studied, in order to further improve image quality.  
Methods: A bivalent HYNIC-conjugated LTB4 antagonist (MB81), and a monovalent one 
(MB88) were labeled with 99mTc. The radiolabeled compounds were intravenously (i.v.) 
injected in New Zealand White (NZW) rabbits with E. coli infection in the left thigh muscle. 
The imaging characteristics of both compounds were compared with those of the bivalent 
111In-labeled LTB4 antagonist.  
Results: Both 99mTc-labeled LTB4 antagonists visualized the abscess from two hours after 
injection onwards. Abscess uptake at 8 h p.i. of both compounds was similar (0.22±0.08 
%ID/g and 0.36±0.13 %ID/g for the bivalent and monovalent compound respectively). 
However, visualization of the abscess and the quality of the images after injection of MB88 
were superior as compared to both bivalent LTB4 antagonists. The excellent delineation of 
the abscess by MB88 was mainly due to the more rapid clearance of this compound from 
non-target organs.  
Conclusion: The 99mTc-labeled HYNIC conjugated LTB4 antagonists MB88 and MB81 
visualized infectious foci in rabbits within a few hours after injection. Imaging 
characteristics of monovalent 99mTc-MB88 were superior to those of the bivalent LTB4 
antagonists DPC11870 and MB81. Therefore, of the three LTB4 antagonists, the 
monovalent LTB4 antagonist MB88 is the most potent and promising agent to visualize 
infection and inflammation to evaluate in patients. 
 
INTRODUCTION 
 
Detection and localization of infectious and inflammatory lesions is important for appropriate 
treatment in patients. One of the methods for detection of infection and inflammation is 
scintigraphic imaging. For scintigraphic detection of inflammatory and infectious lesions in 
patients, 67Ga-citrate and radiolabeled leukocytes are the most commonly applied 
radiopharmaceuticals1. However, there is a continuous search for new radiopharmaceuticals 
that allow rapid and accurate visualization of the lesions and lack the disadvantages of 
currently used compounds (laborious preparation, time consuming, contamination risks etc.)2. 
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Chemotactic and chemokinetic peptides and their antagonists are attractive candidates for 
this application3. These compounds accumulate at the site of infection due to specific 
receptor interaction and clear rapidly from non-target tissues. Compounds like IL-2, IL-8 and 
PF4 accumulate at the site of infection due to specific interaction with receptors expressed on 
activated and infiltrated granulocytes4,5,6. The LTB4 receptor, expressed on 
polymorphonuclear granulocytes is involved in leukocyte function during the inflammatory 
response7,8. Several studies were performed with a radiolabeled LTB4 antagonist to visualize 
infection and inflammation by targeting of its specific receptors expressed on activated and 
infiltrated neutrophils9,10. The LTB4 antagonist, 111In-DPC11870, rapidly visualized infectious 
and inflammatory lesions in several rabbit models of acute inflammation11,12. The compound 
cleared rapidly from the non-target tissues and physiologic uptake was only seen in spleen, 
bone marrow and kidneys. In an in vivo receptor blocking experiment we demonstrated that 
accumulation at the site of infection was receptor mediated10. 
Although the promising characteristics of 111In-DPC11870 warranted clinical evaluation in 
patients, for this application a 99mTc-labeled tracer is preferred. The use of 99mTc could 
improve image resolution and would reduce the radiation dose to the patient. Therefore two 
analogs of DPC11870 were synthesized in which the DTPA chelator was replaced by the 
bifunctional chelator succinimidyl-hydrazinonicotinamide (S-HYNIC). One compound was 
structurally almost identical to DPC11870, only differing in metal ligand and consisted of 
two LTB4 receptor-binding sites, the other LTB4 antagonist was a monomeric derivative of 
DPC11870, consisting of one LTB4 binding site and again conjugated with HYNIC. Here 
both LTB4 antagonists were labeled with 99mTc and the imaging characteristics of both 
compounds were compared with those of 111In-DPC11870. 
 
MATERIALS AND METHODS 
 
Radiolabeling 
The chemical structure of the two HYNIC-conjugated LTB4 antagonists is presented in 
Fig.1. Synthesis of the HYNIC-conjugated LTB4 antagonist MB81 (bivalent, BMS57868-
81) and MB88 (monovalent, BMS57868-88) is described in detail elsewhere13. MB81 and 
MB88 (25 µg) were labeled with 555 MBq Na-99mTcO4 (Tyco Healthcare Mallinkrodt, The 
Netherlands) in the presence of 15 mg tricine, 2 mg isonicotinic acid in 350 µL phosphate 
buffered saline (PBS), pH 7.0 and 25 µL SnSO4 (1 mg/mL) in 0.1 N HCl. After incubation 
for 30 minutes at 100 °C quality control was performed using RP-HPLC (Agilent 1100, 
S.a./N.V) on a C18 column (Zorbax Rx-C18 4.6 mm x 250 mm, Agilent) at a flow rate of 1 
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mL/min with a gradient mobile phase starting from 100 % 10 mM ammonium acetate pH 
7.2 to 100% acetonitrile in 20 minutes.  
DPC11870 was labelled with 111InCl3 (TycoHealthcare Mallinkrodt, The Netherlands) as 
described previously 10,12. The 20 µg LTB4 antagonist DPC11870 was labeled with 111In 
with 74 MBq DPC11870. Quality control of the DPC11870 compound was performed 
using the same HPLC protocols as described above. 
 
Figure 1. 
Chemical structure of MB81 (A) and MB88 (B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infection Model 
Fifteen female New Zealand White (NZW) rabbits weighing 2.3-2.8 kg were kept in cages 
(one rabbit per cage) and fed standard laboratory chow and water ad libitum. Rabbits 
were anaesthetized by subcutaneous injection of 0.7 mL of a mixture of 0.315 mg/mL 
fentanyl and 10 mg/mL fluanison (Hypnorm®, Janssen Pharmaceutica, Buckinghamshire, 
UK). Twenty minutes after administration of anesthesia, an E. coli infection was induced in 
the left thigh muscle by intramuscular (i.m.) injection of 4 x 109 colony-forming units (CFU) 
of E. coli bacteria.  
All animal experiments were approved by the local animal welfare committee in 
accordance with the Dutch legislation and carried out in accordance with their guidelines. 
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Imaging and Biodistribution 
Twenty-four hours after induction of the abscess, when swelling of the infected muscle 
was apparent, five rabbits were intravenously injected with 37 MBq 99mTc-MB81 (3.0 µg), 
five animals were injected with 37 MBq 99mTc-MB88 (3.0 µg) and five rabbits received 11 
MBq 111In-DPC11870 (3.0 µg) via the lateral ear vein. For scintigraphic imaging, the rabbits 
were immobilized in a mold and placed prone on a gamma camera (Orbiter, Siemens, 
Hoffman Estates, IL) using a low-energy parallel hole collimator in case of the 99mTc-labeled 
compounds, whereas a medium-energy collimator was used during acquisition of rabbits 
injected with 111In-DPC11870. Images (300,000 cts/image) were obtained at several time 
points after injection starting immediately after injection until 8 h postinjection (p.i.). Images 
were stored digitally in a 256x256 matrix. All images were adjusted at the same background 
and intensity level, allowing a fair comparison among the various images. The scintigraphic 
results were analyzed by drawing regions of interest (ROI) over the heart, lungs, liver, spleen, 
kidneys, bone marrow, abscess and the contralateral muscle (background). Abscess-to-
organ ratios were calculated. Blood samples were drawn at 1 minute and at 3, 5, 10, 30, 60, 
120, 240 and 480 minutes p.i.. The activity in the samples was determined in a gamma 
counter (Wizard, Canberra Packard, Belgium) and expressed as a percentage of the injected 
dose assuming that the total blood weight accounted for 6% of total body weight14. The t½α 
and t½β were calculated assuming a two-phase linear model for the blood clearance. At 8 h 
p.i. all rabbits were euthanized. A blood sample was taken by cardiac puncture. Tissues were 
dissected and weighed. The activity in tissues was measured in a shielded well-type gamma 
counter together with the injection standards and was expressed as the percentage of the 
injected dose per gram (%ID/g). 
 
Statistical Analysis  
All mean values are presented as mean ± standard deviation. Statistical analysis was 
performed using one-way ANOVA. Results were corrected for multiple data sets with the 
Bonferroni Multiple Comparisons Test. The level of significance was set at 0.05. 
 
RESULTS 
 
Radiolabeling  
Results of the HPLC radioactivity analysis indicated that both the bivalent MB81 
compound and the monovalent MB88 could be labeled with 99mTc with a specific activity of 
37 MBq/µg (110 MBq/nmol MB81, 60 MBq/nmol MB88). The labeling efficiency exceeded 
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95%. RP-HPLC analysis showed that the labeling efficiency of DPC11870 was above 95% 
with a specific activity of 3.7 MBq/µg (12 MBq/nmol). 
 
Figure 2. 
Blood clearance of 111In-DPC11870, 
99mTc-MB81 and 99mTc-MB88 in NZW 
rabbits. The average amount of 
radioactivity of three rabbits is 
expressed as %ID/g present in the 
blood. The curves represent the best 
non-linear exponential decay curve 
calculated by the software program 
(Graphpad Prism). 
 
 
 
 
 
Imaging and Biodistribution 
Analysis of the blood samples indicated that 99mTc-MB88 cleared rapidly from the 
circulation (Fig 2). Calculation of t½α, revealed a distribution half-life (t½α) of 7 minutes 
for 99mTc-MB88 and 20 minutes for the bivalent 99mTc-labeled antagonist MB81. The 
clearance half-life (t½β) also differed between the 99mTc-labeled LTB4 antagonists. The 
clearance half-life of monovalent MB81 was 16.5 hour, while the t½β of 99mTc-MB88 was 
much longer (t½β = 85.6 hours). 
The scintigraphic images after the injection of bivalent 111In-DPC11870, bivalent 99mTc-
MB81 and monovalent 99mTc-MB88 are shown in Fig. 3. Immediately after injection the 
whole body distribution of all three radiolabeled LTB4 antagonists was similar. 
Accumulation of radioactivity was observed in lungs, liver, kidneys and bone marrow of all 
animals. At two hours after injection of the three LTB4 antagonists the abscesses were 
already visualized in all animals. However, the images of the monovalent LTB4 antagonist 
at this time point were qualitatively superior to the images acquired with both bivalent 
antagonists. The 2 hour images and images at later time points indicated that monovalent 
MB88 cleared more rapidly from the circulation and non-target tissues as compared to the 
bivalent LTB4 antagonists MB81 and DPC11870. Additionally, MB88 showed hardly any 
retention in the kidneys. Due to the low radioactivity concentration in the non-target 
tissues the visualization of the abscess in the animals injected with 99mTc-MB88 was better 
as compared to the images acquired after injection of both 111In-DPC11870 and 99mTc-
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MB81 at equal time points. Abscess-to-organ ratios calculated from the ROI analysis of 
the images acquired at 8 h p.i. are shown in Fig. 4. When the HYNIC-conjugated 
antagonists were compared, only a few differences between the monovalent and bivalent 
compounds were observed. The abscess-to-kidney ratio for monovalent 99mTc-MB88 was 
significantly higher as compared to that of the bivalent 99mTc-MB81 (p<0.0001). 
Furthermore, as all ratios of the monovalent LTB4 antagonist exceeded one, with MB88, 
the radioactivity concentration in the abscess was the highest of all organs and tissues. 
When ratios of MB88 were compared with 111In-DPC11870, it was noticed that only the 
abscess-to-kidney ratio differed significantly (p<0.01). The abscess-to-organ ratios of both 
bivalent radiolabeled compounds (respectively, 99mTc-MB81 and 111In-DPC11870) were 
similar. 
 
Figure 3. 
Anterior images of rabbits induced with 
an intramuscular infection. Images 
were acquired immediately, 2, 4, 6 and 
8 h p.i of 11 MBq 111In-DPC11870 (A), 
37 MBq 99mTc-MB81 (B) and 37 MBq 
99mTc-MB88 (C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The biodistribution data derived from ex vivo counting of dissected tissues as summarized 
in Fig. 5, were in agreement with the scintigraphic images. Blood levels of both 99mTc-
labeled compounds were low (0.10±0.01% ID/g and 0.09±0.01% ID/g for the bivalent and 
the monovalent 99mTc-labeled compounds at 8 h p.i., respectively). Furthermore, the 
abscess uptake did not differ significantly between the two HYNIC-conjugated 
A
B
C
0           2 4           6          8 h p.i.
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antagonists. However, there were significant differences in radioactivity concentration 
between the compounds in liver and in the kidneys. The kidney uptake of 99mTc-MB88 was 
significantly lower as compared to the bivalent 99mTc-MB81 (0.58±0.06 %ID/g) (p<0.001). 
Also the radioactivity concentration in the liver was higher after injection of 99mTc-MB81. 
When the results of the HYNIC-conjugated antagonists were compared to those of the 
initially synthesized reference compound (111In-DPC11870), more differences were found.  
 
Figure 4. 
Abscess-to-organ ratios 
calculated from the ROI data, 
presented for several organs 
and tissues after injection of 
respectively 111In-DPC11870, 
99mTc-MB81 and 99mTc-MB88. 
ROI data obtained from the 
images at 8 h postinjection 
were used for the calculation. * 
= P <0.05, ** = P <0.01. 
 
 
 
 
 
 
 
 
 
Figure 5. 
Biodistribution data obtained 8 
h postinjection of 111In-
DPC11870, 99mTc-MB81 and 
99mTc-MB88. Each bar 
represents the mean values ± 
SD. Values were analyzed 
using ANOVA; * and #= P 
<0.05, ** and ##= P <0.01, *** 
and ###=P<0.001. P-values 
refer to differences in 
radioactivity concentration 
between rabbits injected with 
111In-DPC11870 and 99mTc-
MB81 or 99mTc-MB88  (*) or 
between rabbits injected with 
99mTc-MB81 and 99mTc-MB88 
(#). 
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Firstly, 111In-DPC11870 showed very high radioactivity concentration in the bone marrow 
(0.57±0.19 %ID/g) as compared to both 99mTc-labeled compounds (0.26±0.1% ID/g and 
0.25±0.06 for respectively MB81 and MB88). Secondly, the kidney uptake of 111In-
DPC11870 was low and significantly different from the radioactivity concentration of 
bivalent 99mTc-MB81 (p<0.001). However, the kidney uptake of 111In-DPC11870 was 
comparable with that of monovalent 99mTc-MB88. Thirdly, significant differences were 
found between the radioactivity concentration of the three compounds in liver and spleen. 
In both organs the concentration of 99mTc-MB88 was lowest (0.07±0.01 %ID/g and 
0.25±0.01 %ID/g for respectively liver and spleen). The spleen and the bone marrow were 
the two organs that contained the highest radioactivity concentration of 111In-DPC11870. 
For the bivalent 99mTc-MB81 the highest concentration of was found in the kidneys, while 
after injection of monovalent 99mTc-MB88 the highest radioactivity concentration was 
present in the abscess. As a result, the 99mTc-MB88 revealed the best visualization and 
the highest concentration of radioactivity in the abscess. 
 
DISCUSSION 
 
In previous studies we demonstrated that the bivalent 111In-labeled LTB4 antagonist 
DPC11870 adequately visualized infectious and inflammatory foci in distinct rabbit 
models10,11,12. Although previous results warranted clinical studies, we synthesized two 
HYNIC-conjugated analogs of this compound to allow radiolabeling with 99mTc. In this 
study the imaging characteristics of 111In-DPC11870 were compared with those of the 
99mTc-labeled bivalent analog MB81 and the monovalent 99mTc-labeled derivative MB88. 
The results of the imaging and biodistribution experiments indicated that besides the 111In-
DPC11870 also both 99mTc-labeled antagonists visualized infectious foci within a few hours 
after injection. Furthermore, both MB81 and MB88 compounds showed physiologic uptake in 
bone marrow, spleen and in the kidneys. The radioactivity concentration of the infected tissue 
measured at 8 h p.i. was similar for both 99mTc-labeled compounds. Radioactivity 
concentration in the kidney of monovalent 99mTc-MB88 was much lower as compared to the 
concentration in the kidneys of bivalent 99mTc-MB81. Comparison of the 99mTc-labeled bivalent 
and monovalent LTB4 antagonist revealed that images acquired after injection of the 
monovalent 99mTc-MB88 were superior in abscess visualization due to very fast clearance of 
99mTc-MB88 from non-target tissues and good accumulation of radioactivity in the abscess. 
Additionally, the delineation of the abscess by 99mTc-MB88 occurred earlier after injection as 
compared to the bivalent analog. When the characteristics of the best performing 99mTc-
labeled antagonist, MB88, were compared with those of 111In-DPC11870, again the images 
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acquired after injection of the 99mTc-compound were superior. In this case, despite similar 
abscess and kidney uptake, better images were obtained due to lower radioactivity 
concentrations in the bone marrow of animals injected with monovalent 99mTc-MB88. 
In a previous study we cautiously analyzed the pharmacodynamics of the 111In-labeled LTB4 
antagonist DPC1187015. From the results found in this study we concluded that accumulation 
at the site of infection was based on initial targeting of receptor-positive cells in the bone 
marrow, followed by migration of radioactivity from the bone marrow to the site of infection. In 
addition, we determined that 111In-DPC11870 showed physiologic uptake in spleen, liver 
and bone marrow, similar to radiolabeled leukocytes16,17. The radioactivity concentration in 
the bone marrow after injection of both newly synthesized HYNIC-conjugated LTB4 
antagonists was lower as compared to that of 111In-DPC11870. The lower bone marrow 
concentration was an important factor determining the quality of abscess visualization 
after injection of the 99mTc-labeled compounds. The rapid blood clearance of the 
monomeric LTB4 antagonist may explain the low bone marrow uptake. However, since 
blood clearance of both bivalent compounds (99mTc- and 111In-labeled) was similar this 
could not explain the lower bone marrow uptake of the bivalent 99mTc-MB81. Another 
explanation for the lower bone marrow uptake of both HYNIC compounds might be the 
introduction of the HYNIC chelator, which could affect the kinetics of the compound. The 
low radioactivity concentration in the spleen for both HYNIC compounds supports this 
explanation. 
Present results indicated that the chelator (HYNIC or diethylenetriaminepentaacetic acid 
(DTPA)) obviously affected the in vivo behaviour and biodistribution of the radiolabeled 
LTB4 antagonist. Several studies have focused on the in vivo effect of a chelator18,19. 
These studies demonstrated that a chelator may affect the in vivo characteristics of a 
compound. In a comparative study where the biodistribution of 99mTc-labeled and 111In-
labeled octreotide was evaluated, they also found that kidney retention of the 99mTc-
labeled compound was less as compared to the 111In-DTPA-octreotide20. MB81 showed 
less favourable characteristics as compared to MB88 due to higher kidney retention and 
the slower t½α of the compound. Since the distribution half-life of 111In-DPC11870 
(t½α=30 minutes) is comparable with that of MB81, the longer t½α of MB81 probably is 
caused by its bivalency. The higher radioactivity concentration of 99mTc-MB81 in the 
kidney is difficult to explain. The kidney retention of both 111In-DPC11870 (bivalent, DTPA) 
and 99mTc-MB88 (monovalent, HYNIC) were lower as that of 99mTc-MB81 and therefore it 
is not clear whether the kidney retention is caused by the bivalency and/or the HYNIC-
conjugation of the LTB4 antagonist. The high quality images obtained with 99mTc-MB88 
were the result of the use of the high-resolution radiolabel 99mTc, the rapid clearance of 
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MB88 from non-target tissues and the preserved accumulation of this LTB4 antagonist to 
the site of infection. 
The ideal imaging agent for detection of infectious and inflammatory foci should satisfy 
several requirements. First of all, the agent has to accumulate in the foci specifically and 
rapidly and should clear from the non-target tissues quickly in order to visualize the lesion 
in a limited time after injection. Secondly, the labeling procedure ought to be relatively 
easy and simple and labeling with 99mTc is preferred over other radionuclides. Finally, the 
ideal imaging agent should not provoke side effects when administered to patients21. The 
results found in present study indicated that 99mTc-MB88 suffices the requirements for a 
potential infection-imaging agent. When these results are compared with other currently 
studied compounds, 99mTc-MB88 remains a very promising candidate. Other agents 
currently under investigation are other radiolabeled cytokines and chemotactic peptides 
(IL-2, IL-8 and PF4)4,22,23. These compounds, however, exhibit biologic activity, and have 
the disadvantage that they may provoke side effects after administration in patients. 
Furthermore, the production of these recombinant peptides is complicated and expensive. 
Another group of compounds are the antimicrobal agents (Infecton® and human neutrophil 
peptides)24,25. These compounds have the advantage over 99mTc-MB88 that they may 
target specifically to bacteria. Therefore, these agents can potentially differentiate 
between infectious lesions and inflammatory foci. Infecton® has been evaluated in several 
clinical studies and yields a high overall sensitivity and specificity (respectively 85.4% and 
81.7%)24. Another advantage of Infecton® over MB88 is the lack of bone marrow uptake 
which makes Infecton® possibly suited for detection of infection after orthopedic 
intervention (e.g. osteomyelitis).  
In summary, clinical evaluation with 99mTc-MB88 is warranted to assess the value of 99mTc-
MB88 as an infection-imaging agent in patients. Clinical studies are warranted to allow a 
fair comparison with the other currently studied agents. 
 
CONCLUSION 
In the present study we compared the imaging characteristics of three radiolabeled LTB4 
antagonists to visualize infection and inflammation. The LTB4 antagonist 99mTc-MB88 
revealed images that visualized the infectious foci with superior quality as compared to the 
other two compounds. Therefore, we consider the 99mTc labeled monovalent LTB4 
antagonist MB88 as a potent and promising agent to visualize infection and inflammation 
in patients. 
 
 
Chapter 7 
 
128 
REFERENCES 
 
1. Knight LC. Non-oncologic applications of radiolabeled peptides in nuclear medicine. Q J Nucl Med. 
2003;47:279-291. 
2. Weiner RE, Thakur ML. Radiolabeled peptides in diagnosis and therapy. Semin Nucl Med. 
2001;31:296-311. 
3. Signore A, Chianelli M, Bei R, Oyen WJ, Modesti A. Targeting cytokine/chemokine receptors: a 
challenge for molecular nuclear medicine. Eur J Nucl Med Mol Imaging. 2003;30:149-56. 
4. Bleeker-Rovers CP, Boerman OC, Rennen HJ, Corstens FH, Oyen WJ. Radiolabeled compounds in 
diagnosis of infectious and inflammatory disease. Curr Pharm Des. 2004;10:2935-2950. 
5. van Eerd JE, Boerman OC, Corstens FH, Oyen WJ. Radiolabeled chemotactic cytokines: new agents 
for scintigraphic imaging of infection and inflammation. Q J Nucl Med. 2003;47:246-255. 
6. Signore A, Annovazzi A, Barone R, et al. 99mTc-interleukin-2 scintigraphy as a potential tool for 
evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. J Nucl Med. 
2004;45:1647-52.  
7. Pettersson A, Richter J, Owman C. Flow cytometric mapping of the leukotriene B4 receptor, BLT1, in 
human bone marrow and peripheral blood using specific monoclonal antibodies. Int 
Immunopharmacol. 2003;3:1467-1475. 
8. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 
that mediates chemotaxis. Nature. 1997;387:620-624. 
9. Brouwers AH, Laverman P, Boerman OC, et al. A 99mTc-labeled leukotriene B4 receptor antagonist 
for scintigraphic detection of infection in rabbits. Nucl Med Commun. 2000;21:1043-1050. 
10. van Eerd JE, Oyen WJ, Harris TD, et al. A bivalent leukotriene B(4) antagonist for scintigraphic 
imaging of infectious foci. J Nucl Med. 2003;44:1087-1091. 
11. van Eerd JE, Laverman P, Oyen WJ, et al. Imaging of experimental colitis with a radiolabeled 
leukotriene B4 antagonist. J Nucl Med. 2004;45:89-93. 
12. van Eerd JE, Rennen HJ, Oyen WJ, et al. Scintigraphic detection of pulmonary aspergillosis in rabbits 
with a radiolabeled leukotriene B4 antagonist. J Nucl Med. 2004;45:1747-1753. 
13. Broekema M, van Eerd JE, Oyen WJ, et al. Synthesis of Leukotriene B4 antagonists labeled with In-
111 or Tc-99m to image infectious and inflammatory foci. Submitted to the Journal of medicinal 
chemistry. 
14. Blood volume and water balance. In: Jain NC, ed. Shalm’s Veterinary Hematology. Vol 91. 
Philadelphia, PA: Lea and Febiger; 1986:87–102.  
15. van Eerd JE, Oyen WJ, Harris TD, et al.. Scintigraphic imaging of infectious foci with an 111In-LTB4 
antagonist is based on in-vivo labeling of granulocytes. J Nucl Med. 2004. In Press. 
16. Hughes DK. Nuclear medicine and infection detection: the relative effectiveness of imaging with 111In-
oxine-, 99mTc-HMPAO-, and 99mTc-stannous fluoride colloid-labeled leukocytes and with 67Ga-citrate. J 
Nucl Med Technol. 2003;31:196-201. 
17. Love C, Palestro CJ. Radionuclide imaging of infection. J Nucl Med Technol. 2004;32:47-57. 
18. Ono M, Arano Y, Mukai T, Uehara T, Fujioka Y, Ogawa K, Namba S, Nakayama M, Saga T, Konishi 
J, Horiuchi K, Yokoyama A, Saji H. Plasma protein binding of (99m)Tc-labeled hydrazino nicotinamide 
derivatized polypeptides and peptides. Nucl Med Biol. 2001;28:155-164. 
19. Qu T, Wang Y, Zhu Z, Rusckowski M, Hnatowich DJ. Different chelators and different peptides 
together influence the in vitro and mouse in vivo properties of 99mTc. Nucl Med Commun. 2001;22:203-
215. 
Imaging of infection with improved 99mTc-labeled LTB4 antagonist 
129 
20. Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-[Tyr3]-octreotide for 
imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-
octreotide. J Nucl Med. 2000;41:1114-1119. 
21. Corstens FH, van der Meer JW. Chemotactic peptides: new locomotion for imaging of infection? J 
Nucl Med. 1991;32:491-494.  
22. Rennen HJ, Boerman OC, Oyen WJ, Corstens FH. Kinetics of 99mTc-labeled interleukin-8 in 
experimental inflammation and infection. J Nucl Med. 2003;44:1502-1509. 
23. Signore A, Procaccini E, Annovazzi A, Chianelli M, van der Laken C, Mire-Sluis A.The developing role 
of cytokines for imaging inflammation and infection.Cytokine. 2000;12:1445-54. 
24. Britton KE, Wareham DW, Das SS, Solanki KK, Amaral H, Bhatnagar A, Katamihardja AH, Malamitsi 
J, Moustafa HM, Soroa VE, Sundram FX, Padhy AK. Imaging bacterial infection with 99mTc-
ciprofloxacin (Infecton). J Clin Pathol. 2002;55:817-23. 
25. Welling MM, Nibbering PH, Paulusma-Annema A, Hiemstra PS, Pauwels EK, Calame W. Imaging of 
bacterial infections with 99mTc-labeled human neutrophil peptide-1.J Nucl Med. 1999;40:2073-80. 
 
 
Chapter 7 
 
130 
  
 
 
Chapter 8 
 
 
 
General discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8 
 
132 
Imaging of infection and inflammation 
 
Diagnosis of infection and inflammation is eminent for management of patients suspected 
for infectious and inflammatory disorders. Visualization of the localization and the extent of 
an inflammatory process will allow guided verification procedures and initiation of 
appropriate treatment in most cases. For the detection of infectious and non-infectious 
processes, radiological techniques (e.g. CT and MRI) and scintigraphic techniques  are 
available. In most institutions, scintigraphic imaging to detect inflammatory and infectious 
foci is performed with radiolabeled leukocytes or gallium-67 citrate. However, due to 
several insuperable disadvantages of these agents, there is a great interest in the 
development of a new radiopharmaceutical for this application.  
In this thesis, the potential of three radiolabeled LTB4 receptor antagonists to image 
infectious and inflammatory foci were described. LTB4 is a chemotactic mediator that 
targets specific receptors expressed on leukocyte sub-populations. Radiolabeled LTB4 
analogs can potentially be used, like other chemotactic compounds, to visualize infection 
and inflammation since they comprise several characteristics essential for an infection-
imaging agent.  
The requirements for the ideal radiotracer are:  
• Efficient and specific accumulation in inflammatory foci 
• Visualization of inflammatory lesion rapidly after injection 
• Good retention in the inflammatory lesion 
• Rapid clearance from the background 
• No toxicity 
• Good availability, low costs 
• Easy and non-hazardous preparation 
• Low radiation exposure 
• Possibility to differentiate between infection and sterile inflammation 
 
Efficient and specific accumulation in inflammatory foci 
Distinct imaging experiments described in this thesis demonstrated that all three LTB4 
antagonists, accumulated rapidly and efficiently at the site of infection. Furthermore, the 
receptor saturation experiment, demonstrated that the interaction of the LTB4 antagonist 
in the infectious foci was receptor mediated. Therefore, the LTB4 antagonists investigated 
in this thesis meet the requirements of efficient and specific accumulation. 
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Visualization rapidly after injection 
New agents suitable to visualize infectious and inflammatory disorders should allow rapid 
and timely diagnosis. Early detection is preferred but not always necessary as in the case 
of osteomyelitis and infected bone/joint prothesis. In case of severe and acute illness a 
one-day imaging protocol is intended. The radiolabeled LTB4 antagonists were able to 
delineate infectious and inflammatory foci already a few hours after the injection. 
Depending on the organ of interest, visualization of the inflammation was achieved 
between 1 and 6 hours after the injection. Due to relatively slow clearance of 111In-
DPC11870 from the normal lung tissue, visualization of the pulmonary lesions tooke place 
at later time points as compared to delineation of acute colitis and intramuscular E. coli 
abscess. With 111In-DPC11870 images can be obtained easily up to at least 48 hours after 
injection. With the 99mTc-labeled compounds imaging is limited within 24 hours. 
With monovalent 99mTc-MB88, detection of the intramuscular abscess occurred more 
rapidly after injection as compared to the bivalent agents 99mTc-MB81 and 111In-
DPC11870, due to efficient clearance from non-target tissues, low physiologic uptake in 
bone marrow and spleen and lack of retention of radioactivity in the kidneys. Although the 
monovalent compound has not been evaluated in a model of pulmonary infection, it is 
expected that -due to the overall faster clearance- visualization of pulmonary infection with 
99mTc-MB88 occurs at earlier time points as compared to 111In-DPC11870. 
With each of the three LTB4 antagonists rapid and timely diagnosis in patients is 
expected. 
 
Retention of the radiolabel in the inflammatory foci 
Chemotactic compounds are retained at the site of inflammation due to specific interaction 
with their receptors expressed on leukocytes, infiltrated at the site of the lesion. The LTB4 
antagonists accumulated and were retained in the inflammatory foci due to their 
interaction with the receptor expressed by neutrophilic granulocytes. Imaging and 
biodistribution studies, performed up to 24 h after injection, demonstrated that radioactivity 
present in the inflammatory lesion was retained almost completely. Within 24 hours, a 
decrease in the radioactivity concentration in the inflammatory site could not be observed. 
 
Rapid clearance from non-target tissues 
Radiolabeled small molecular weight compounds exhibit a rapid blood clearance and a 
short biological half-life. The molecular weight of the LTB4 antagonists was 3127, 2975 
and 1631 for the bivalent DPC11870, MB81 and monovalent MB88, respectively. The 
images and analysis of blood samples demonstrated that all compounds exhibited a short 
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distribution half-life and were cleared rapidly from the background. Due to a more efficient 
clearance of 99mTc-MB88 and the lack of retention of this compound in non-target organs, 
the visualization of infectious lesions with this compound was superior to the images 
obtained after injection of 111In-DPC11870 and 99mTc-MB88.  
Physiologic uptake of the three LTB4 antagonists was seen in bone marrow, spleen and 
kidneys, although the radioactivity concentration in these organs differed for each 
compound. The highest uptake in the bone marrow was found after injection with 111In-
DPC11870, while low, uptake was found after injection of both 99mTc-HYNIC-conjugated 
LTB4 antagonists. The presence of radiolabeled LTB4 antagonists in the kidney is a result 
of normal renal clearance of small agents. Since 99mTc-MB88 showed less retention in the 
kidneys as compared to both bivalent analogs, 99mTc-MB88 has the most favorable 
biodistribution of the three LTB4 antagonists for application as imaging agent. 
 
Absence of biological effects 
In general, radiolabeled chemotactic peptides are an interesting class of compounds to 
visualize infectious and inflammatory foci because they meet several requirements that 
are essential for an ideal imaging agent. One of the disadvantages of many of these 
compounds however, is their potency, which causes a biologic response after interaction 
with the receptor. Side-effects, that may occur after administration of these compounds, 
are leukopenia, leukocytosis, fever and hypotention and due to the biologic activities, 
clinical applicability of these compounds is limited. Often, receptor antagonists, that lack 
biological activity, exhibit low receptor affinity and consequently reduced imaging potential. 
The LTB4 antagonists investigated in this thesis, showed efficient and good accumulation 
at the infectious foci reflecting their high receptor affinity. White blood cell counts were not 
affected bij 111In-DPC11870, not even after administration of 2 mg DPC11870.  
 
Good availability, low costs, easy and non-hazard preparation 
The use of radiolabeled autologous leukocytes is considered the “gold standard” nuclear 
medicine technique to detect infection and inflammation. The radiolabeled leukocytes 
accumulate specifically in inflammatory foci and demonstrate a high diagnostic accuracy 
to visualize inflammatory disorders. Unfortunately, the preparation of radiolabeled 
leukocytes is time consuming, requires specialized equipment and is associated with 
hazardous risks. The radiolabeling of the 111In-DPC11870 and the 99mTc-labeled LTB4 
antagonists, is easy, fast and without the handling of potentially contaminated material. 
The 111In-DPC11870 labeling is performed at room temperature, while 99mTc-labeling is 
performed at 100°C. All antagonists can be prepared and stored in kit formulation, where 
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a one step labeling procedure is sufficient. Due to chemical synthesis, these compounds 
can be prepared in large quantities and are readily available. As compared to other 
chemotactic analogs (e.g. recombinant cytokines), synthesis is relatively inexpensive.  
 
Low radiation exposure 
The LTB4 antagonists investigated in this study were labeled with 111In or 99mTc. For 
scintigraphic imaging the use of 99mTc is preferred over 111In because of the more 
favorable γ-energy, physical half-life, availability of 99mTc and dosimetry. On the other 
hand, these radionuclides require a chelator for radiolabeling which might affect the 
pharmacokinetics of the compound. Especially, low molecular weight compounds, like the 
LTB4 antagonists used in this study, might therefore demonstrate different in vivo 
behavior after conjugation with different chelators. The monovalent HYNIC-conjugated 
analog 99mTc-MB88 demonstrated the most favorable characteristics, with similar 
accumulation of radioactivity in the infectious lesion and low physiologic uptake and 
retention in non-target tissues. For imaging of infection with radiolabeled LTB4 antagonists 
the use of HYNIC-conjugated 99mTc-MB88 is preferred over DTPA-conjugated 111In-
DPC11870, due to the most optimal characteristics and the most favorable radionuclide. 
 
Differentiation between infection and sterile inflammation 
Detection of infection and inflammation with radiolabeled leukocytes or radiolabeled 
compounds that target to leukocytes, is based on the induced immune response of the 
host that recruits leukocytes towards the site of infection. With these agents there is no 
targeting of the agent that causes the infectious process. Therefore, with these 
radiopharmacuticals it is not possible to differentiate between infection and sterile 
inflammation. The radiolabeled LTB4 antagonists investigated in this thesis accumulates 
at the site of inflammation due to specific interaction with receptors expressed by 
leukocyte populations. The presence of radioactivity is an indication for leukocyte 
infiltration but not for infection. When discrimination between infection and inflammation is 
essential, the LTB4 antagonists cannot be used. In this case radiolabeled compounds that 
specifically target micro-organisms are required. Compounds that specifically interact with 
micro-organisms have been studied for the scintigraphic detection of infection 
(radiolabeled ciprofloxacin derivatives, radiolabeled antifungal drugs) but are not yet 
available for use in clinical practice.   
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99mTc-MB88 versus other leukocyte receptor targeting agents used for scintigraphic 
imaging  
 
The studies described in this thesis demonstrate that the LTB4 antagonist 99mTc-MB88 
has ideal characteristics for imaging of infection and inflammation. Additionally, the 
considerations mentioned above, indicate that 99mTc-MB88 meets several requirements of 
the ideal radiopharmaceutical. However, the radiolabeled LTB4 antagonist is only one 
potential imaging agent that is currently under investigation. Also other cytokines and 
chemotactic molecules are intensively studied for this application. The use of radiolabeled 
cytokines to visualize infection and inflammation is often limited due to biological activity of 
these molecules (C5a, fMLF and IL-1). Studies with the 111In-labeled LTB4 antagonist did 
not show any changes in white blood cell counts in rabbits after injection of doses up to 2 
mg. Other cytokine receptor antagonists, that lack biological activity like IL-1ra, often 
display reduced affinity for their receptor and therefore demonstrate insufficient 
accumulation in the inflammatory lesion. There are also radiolabeled cytokines that do not 
induce biologic effects but display too low receptor affinity for high accumulation at the site 
of infection (C5adR, NAP-2). Only a few high affinity peptides can be labeled with 99mTc in 
high specific activities to prevent biologic activity. The cytokines IL-2 and IL-8 are two 
peptides that have been successfully studied for the detection of infection and 
inflammation. Radiolabeled IL-2 targets IL-2 receptors mainly expressed on T-
lymphocytes, whereas IL-8 targets CXCR1 and CXCR2 receptors expressed on 
neutrophils. Biologic activity induced by IL-8 can be circumvented because this compound 
can be labeled with very high specific activity. Both IL-2 and IL-8 have proven their 
imaging abilities in preclinical animal models. IL-2 has also demonstrated its applicability 
in clinical trials to visualize T-cell infiltrates in patients with chronic inflammatory and 
autoimmune disorders.  
Taken together, when 99mTc-MB88 is compared to other leukocyte receptor targeting 
agents, currently under investigation for this purpose, 99mTc-MB88 is a very promising 
candidate. Therefore the results found with 99mTc-MB88 warrant further evaluation in 
patients. 
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SUMMARY 
 
The aim of the studies described in this thesis, was to investigate the potential of 
radiolabeled Leukotriene B4 antagonists for the scintigraphic detection of infectious and 
inflammatory lesions.  
 
Scintigraphic imaging of infectious and inflammatory lesions using radiolabeled 
leukocytes, generally allows adequate and rapid delineation of infectious and inflammatory 
foci. Visualization of the localization and extent of an inflammatory process enable guided 
verification procedures, therapeutic decisions and initiation of appropriate treatment in 
most cases. In most institutions, scintigraphic imaging of inflammatory and infectious foci 
is performed with radiolabeled leukocytes as standard imaging agent. However, due to 
several inevitable disadvantages of this agent, there is a great interest in the development 
of a new radiopharmaceutical for this application. A new radiopharmaceutical should 
accumulate efficiently and rapidly in the infected/inflamed tissue. Furthermore, it should 
clear rapidly from the blood and other non-target tissues.  
A promising class of compounds are chemotactic and chemokinetic mediators and their 
analogs. The use of radiolabeled chemotactic compounds (fMLF, cytokines, chemokines) 
is based on the high affinity interaction of these compounds, for their receptors expressed 
on specific leukocyte sub-populations. In addition, due to their low molecular weight, they 
can penetrate rapidly into the inflamed tissue and clear rapidly from the non-target tissue 
and from the circulation. In addition, the antagonists of these chemotactic mediators may 
provide good alternative agents, especially when biological effects of the agonistic 
peptides limit clinical application. Since the knowledge of the human inflammatory 
response has expanded and the number of identified chemokines and chemokine 
receptors has increased, it is now possible to investigate in detail those chemokines that 
potentially can be applied as radiopharmaceutical for visualization of inflammatory and 
infectious processes. 
 
Chapter 1 describes the specific characteristics of the chemotactic and chemokinetic 
compounds that are currently under investigation as potential radiopharmaceuticals to 
visualize infectious and inflammatory foci. The characteristics of a series of cytokines (IL-
1, IL-2), chemokines (IL-8, PF-4, MCP-1, NAP-2), complement factors (C5a, C5adR), 
chemotactic peptides (fMLF) and other chemotactic factors (LTB4) are described. The 
potentials of these compounds to serve as an imaging agent are discussed. 
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In Chapter 2 a fundamental study is described to determine the potential of the bivalent 
111In-labeled leukotriene B4 (LTB4) antagonist, DPC11870, to visualize infectious foci 
scintigraphically. The LTB4 antagonist DPC11870 was labeled with 111In and i.v. injected 
in NZW rabbits with intramuscular E. coli infection in the left thigh muscle.  
The in vivo characteristics were determined by serial scintigraphic imaging and by ex vivo 
counting of dissected tissues. The receptor-mediated in vivo localization of the compound 
was investigated in rabbits that received an excess of non-radioactive agent, prior to the 
administration of the 111In-labeled LTB4 antagonist. The results of the in vivo receptor 
blocking experiment indicated specific receptor-ligand interaction of the radiolabeled 
compound. 
The scintigraphic images showed that 111In-DPC11870 clearly visualized infectious foci 
within a few hours after injection. Furthermore, the data from the biodistribution analysis 
indicated that the compound accumulated in the infectious tissue and was cleared rapidly 
from the circulation, resulting in high abscess-to-background ratios. 
 
Once it was observed that 111In-DPC11870 accumulated in infected muscle tissue and 
could visualize infectious lesions, in Chapter 3 and Chapter 4 the applicability of this 
compound was determined in a rabbit model of acute colitis and a model of pulmonary 
infection, respectively. The imaging characteristics of 111In-DPC11870 were compared 
with those of 18FDG, 99mTc-labeled leukocytes and 67Ga-citrate, the radiopharmaceuticals 
generally used for detection of respectively abdominal and pulmonary infection. In rabbits 
with chemically-induced colitis, the inflammatory lesions were clearly delineated from one 
hour after injection. Compared with 99mTc-granulocytes and 18F-FDG, the radiolabeled 
LTB4 antagonist revealed the highest uptake in the infectious lesions as well as the 
highest target-to-non-target tissue ratio. 
Additionally, 111In-DPC11870 also distinctly visualized pulmonary aspergillosis infection in 
the rabbits. Due to relatively slow clearance from the non-target tissues as compared to 
67Ga-citrate, the visualization of the pulmonary abscess by 111In-DPC11870 occurred at 
later time points. Good visualization of pulmonary lesions with 111In-DPC11870 was 
observed from 6 hours after injection onwards. Due to ongoing clearance of radioactivity 
from the circulation and ongoing accumulation at the pulmonary infection, infected-to-
normal lung ratios found with 111In-DPC11870 increased with time and resulted in higher 
ratios for 111In-DPC11870 as compared to 67Ga-citrate at 24 h postinjection. 
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In Chapter 5 studies on the pharmacodynamics of 111In-DPC11870 are described. In 
addition, several experiments to determine the mechanism of accumulation of the 
radiolabeled LTB4 antagonist in the abscess are described. In previous animal studies it 
was found that accumulation of 111In-DPC11870 in the abscess continued while 
radioactivity had cleared from the circulation almost completely. The pharmacodynamics 
of 111In-DPC11870 were studied by serial imaging and by ex vivo counting of dissected 
tissues. The mechanism of accumulation of the 111In-labeled LTB4 antagonist in the 
abscess was investigated in rabbits with intramuscular infection that was induced 16 h 
after i.v. administration of 111In-DPC11870. In addition, heterologous leukocytes and bone 
marrow cells of a donor rabbit were labeled with 111In-DPC11870 in vitro and in vivo 
distribution of these in vitro radiolabeled cells was compared with the biodistribution of 
111In-DPC11870. 
Quantitative analysis of the images confirmed accumulation of 111In-DPC11870 in the 
abscess at time points when the compound had cleared almost completely from the 
circulation. From the pharmacokinetic analysis a hypothesis was derived: 111In-DPC11870 
associates with receptor positive (bone marrow) cells and due to subsequent migration of 
cell-associated activity, radioactivity accumulates in the abscess. Results of the study 
showed that at the time of induction of the abscess, 16 hours after injection of 111In-
DPC11870, the tracer had cleared from the circulation completely. Surprisingly however, 
despite the low radioactivity concentrations in the blood, 111In-DPC11870 accumulated in 
the rising abscess. Additional studies with peripheral blood leukocytes and bone marrow 
cells labeled ex-vivo with 111In-DPC11870 confirmed the ability of these cells to migrate to 
the abscess. Overall, the results of these studies demonstrated that 111In-DPC11870 
accumulated in infectious foci due to initial targeting of receptor-positive bone marrow 
cells and subsequent migration of radioactivity from the bone marrow to the infected 
muscle tissue. 
  
Since 99mTc is a radionuclide with better imaging characteristics as compared to 111In 
(physical half-life, gamma-energy, availability), we developed two LTB4 antagonists that 
were structurally related to DPC11870. In Chapter 6 the chemical synthesis of the 
bivalent DTPA conjugated LTB4 antagonist DPC11870, the bivalent HYNIC-conjugated 
analog MB81 and the monovalent HYNIC-conjugated LTB4 antagonist MB88 is described. 
In addition, we investigated the labeling efficiency and in vivo characteristics of 99mTc-
MB81 in a rabbit model of intramuscular E. coli infection after radiolabeling with three 
different coligand systems (tricine, TPPTS or isonicotinic acid).  
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HPLC analysis showed that MB81 could be labeled with 99mTc rapidly and efficiently with 
each of the three coligand systems. Scintigraphic images demonstrated that all three 
analogs delineated intramuscular abscesses in rabbits. Furthermore, the results of the 
imaging and biodistribution experiments showed that the in vivo behavior of the 99mTc-
labeled LTB4 antagonist MB81 was affected by the coligand used for labeling. The best 
imaging characteristics are obtained when the HYNIC-conjugated LTB4 antagonist was 
labeled with 99mTc using isonicotinic acid as coligand.  
 
In Chapter 7 the imaging characteristics and pharmacokinetics of both HYNIC-conjugated 
LTB4 antagonists, MB81 and MB88 were evaluated in rabbits with intramuscular E. coli 
infection. In addition, the results found with both HYNIC-compounds were compared with 
the characteristics of 111In-DPC11870 which was used as a reference compound in this 
study. Images demonstrated that both 99mTc-labeled LTB4 antagonists visualized the 
abscess from two hours after injection onwards.  
Furthermore, abscess uptake at 8 h p.i. of both compounds was similar. However, the 
monovalent antagonist, 99mTc-MB88 showed superior imaging characteristics as 
compared to both bivalent LTB4 antagonists (99mTc-MB81 and 111In-DPC11870) mainly 
due to lower retention of radioactivity in the kidneys and the bone marrow. After injection 
of monovalent 99mTc-MB88, the abscess was the tissue with the highest radioactivity 
concentration at 8 h p.i.. From the results of this study, we concluded that the 99mTc 
labeled monovalent LTB4 antagonist MB88 is a potent and promising agent to visualize 
infection and inflammation in patients. 
 
Conclusion 
The three radiolabeled LTB4 antagonists investigated in this thesis appeared to have 
excellent imaging characteristics for detection of infectious and inflammatory lesions. In a 
comparative study however, the monovalent LTB4 antagonist MB81 revealed superior 
imaging characteristics as compared to both bivalent compounds. Since preparation of the 
compound is convenient and safe, the use of this agent may be preferred over 
radiolabeled white blood cells, the current gold standard technique. The results obtained 
in various studies warrant evaluation of 99mTc-MB81 in patients, to determine the value of 
this agent in clinical situations. 
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SAMENVATTING 
 
In dit proefschrift worden studies beschreven waarin onderzocht wordt of radioactief 
gelabelde Leukotriene B4 (LTB4) antagonisten de potentie hebben om ontstekingen en 
infectiehaarden op een scintigrafische manier te detecteren. 
 
Detectie en lokalisatie van acute en chronische ontstekings- en infectiehaarden is 
belangrijk voor het tijdig en adequaat instellen van de juiste behandeling. Voor het 
lokaliseren van een infectie- of ontstekingshaard zijn verschillende onderzoekstechnieken 
beschikbaar. Behalve radiologische technieken zoals röntgenfoto’s, echografie, CT-
tomografie en MRI-scan, kan met behulp van scintigrafische technieken, waarbij gebruik 
gemaakt wordt van van radioactieve stoffen, diagnostisch onderzoek uitgevoerd worden. 
Bij scintigrafische detectie van infectie- en ontstekingshaarden wordt in de meeste 
instituten gebruik gemaakt van radioactief gelabelde leukocyten, de gouden referentie 
standaard. Echter, de bereiding van radioactief gelabelde leukocyten brengt een aantal 
belangrijke nadelen met zich mee. Daarom is binnen de nucleaire geneeskunde veel 
belangstelling voor de ontwikkeling van een nieuw radiofarmacon voor deze toepassing. 
Het nieuw te ontwikkelen radiofarmacon dient aan een aantal eisen te voldoen. Het ideale 
radiofarmacon wordt snel en efficiënt in het ontstoken weefsel opgenomen. Daarnaast 
moet het radiofarmacon snel uit de normale weefsels klaren. Vanzelfsprekend moet de 
bereiding van het radiofarmacon eenvoudig en snel kunnen gebeuren en gaat de voorkeur 
uit naar een preparaat dat met 99mTc gelabeld kan worden vanwege de gunstige 
radioactieve eigenschappen hiervan (γ-energie, stralenbelasting, halfwaardetijd).  
Chemotactische peptiden en cytokinen zouden mogelijk voor deze toepassing gebruikt 
kunnen worden. De toepassing van radioactief gelabelde chemokines (fMLF, cytokinen) 
voor visualisatie van ontstekingen, is gebaseerd op de hoge affiniteit van deze moleculen 
voor hun specifieke receptor aanwezig op het celoppervlak van bepaalde leukocyten-
populaties. Daarnaast, kunnen deze peptiden, ten gevolge van hun lage moleculaire 
gewicht, efficiënt penetreren in het ontstoken weefsel en worden deze stoffen snel 
geklaard uit normale weefsels en organen. Bovendien, biedt het gebruik van radioactief 
gelabelde antagonisten een alternatief indien toepassing van het chemotactisch peptide 
zelf een belemmering is vanwege zijn biologische activiteit.  
Doordat de kennis betreffende het immunologisch systeem de laatste jaren enorm is 
uitgebreid en een aantal goed gekarakteriseerde chemotactische peptiden beschikbaar is 
gekomen, is het mogelijk specifiek die chemokines te onderzoeken, waarvan de 
verwachting bestaat dat deze geschikt zijn voor het visualiseren van ontstekingshaarden. 
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In hoofdstuk 1 worden de specifieke kenmerken beschreven van een aantal biologische 
eiwitten en de chemisch structureel afgeleiden hiervan. Deze worden momenteel 
bestudeerd worden als potentieel radiofarmacon voor de detectie van ontstekings- en 
infectiehaarden.  
De kenmerken van een aantal cytokinen (IL-1, IL-2), chemokines (IL-8, PF-4, MCP-1, 
NAP-2), complement factoren (C5a, C5adR), chemotactische peptiden (fMLF) en andere 
chemotactische factoren (LTB4) worden beschreven. Daarnaast worden de belangrijkste 
bevindingen uit recente studies met deze radioactief gelabelde moleculen samengevat. 
De potentie van de verschillende stoffen voor de toepassing als radiofarmacon voor het 
detecteren van ontstekingshaarden wordt bediscussieerd. 
 
Hoofdstuk 2 beschrijft een fundamentele studie waarin wordt onderzocht of de bivalente 
met 111In-gelabelde LTB4 antagonist, DPC11870, in staat is om infectiehaarden te 
visualiseren. Hiertoe werd de LTB4 antagonist DPC11870 na labeling met 111In, 
intraveneus ingespoten in konijnen met een intramusculair E. coli abces in de linker 
dijbeenspier. Na injectie werden op verschillende tijdstippen opnamen gemaakt met de 
gamma-camera. Daarnaast werd bij een aantal konijnen de LTB4 receptor geblokkeerd 
met behulp van een injectie van 2 mg niet radioactief DPC11870. Hierdoor kon 
onderzocht worden of de lokalisatie van 111In-DPC11870 in het abces het gevolg was van 
specifieke interactie met de receptor.  
De intramusculaire infectiehaarden werden gevisualiseerd vanaf een paar uur na de 
injectie van 111In-DPC11870. Uit de biodistributie analyse bleek dat het 111In-DPC11870 
efficiënt accumuleerde in het geinfecteerde weefsel en tegelijkertijd snel klaarde uit de 
circulatie en andere receptor-negatieve weefsels, waardoor hoge abces/spier 
verhoudingen gevonden werden. Het receptor-saturatie experiment toonde aan dat 
opname van de LTB4 antagonist op de plaats van de ontsteking receptor gemedieerd is. 
 
Nu vastgesteld was dat 111In-DPC11870 accumuleerde in geïnfecteerd spierweefsel, 
werd, zoals beschreven in hoofdstuk 3 en hoofdstuk 4, de toepassing van 111In-
DPC11870 onderzocht in een konijnen model van acute colitis en een model van 
pulmonaire aspergillosis, eveneens in konijnen. Het in-vivo gedrag van 111In-DPC11870 in 
deze modellen, werd vergeleken met 18FDG, 99mTc-gelabelde leukocyten en 67Ga-citraat, 
de radiofarmaca welke standaard gebruikt worden voor het aantonen van dit soort 
ontstekingen in patiënten.  
In de konijnen met chemisch geïnduceerde colitis was opname van 111In-DPC11870 in het 
ontstoken colon reeds zichtbaar vanaf 1 uur na de injectie.  
Chapter 9 
 
144 
Ten opzichte van 18FDG en 99mTc-gelabelde leukocyten werd met de radioactief gelabelde 
LTB4 antagonist behalve de hoogste opname in ontstoken weefsel ook de hoogste target-
to-non-target ratio gevonden. 
111In-DPC11870 was ook in staat de pulmonaire longinfecties in de konijnen zichtbaar te 
maken. Echter, in vergelijking met 67Ga-citraat was de pulmonaire infectie met behulp van 
111In-DPC11870 pas zichtbaar op latere tijdstippen. Dit werd veroorzaakt door een 
langzamere klaring van 111In-DPC11870 uit de longen. Duidelijke afbeelding van de 
pulmonaire infectie, met behulp van 111In-DPC11870, ontstond vanaf 6 uur na de injectie. 
Ten gevolg van voortdurende klaring van de tracer uit het bloed en het niet-ontstoken 
longweefsel waren de target-to-non-target ratio’s op het tijdstip van biodistributie (24 uur 
p.i.) hoger met 111In-DPC11870 dan met 67Ga-citraat. 
 
In hoofdstuk 5 is een uitgebreide studie naar de farmacodynamiek van 111In-DPC11870 
beschreven. Daarnaast zijn een aantal experimenten beschreven waarin het mechanisme 
van 111In-DPC11870 accumulatie in het abces nader werd onderzocht. 
In eerdere studies met 111In-DPC11870 werd gezien dat - op tijdstippen waarop de tracer 
bijna volledig uit de circulatie was geklaard - er nog steeds accumulatie van radioactiviteit 
in het abces plaatsvond. De farmacodynamiek van 111In-DPC11870 werd bestudeerd aan 
de hand van seriële opnames en het meten van radioactiviteit in gedissecteerde weefsels 
en organen. Het mechanisme van accumulatie van 111In-DPC11870 in het abces werd 
bestudeerd door het induceren van een intramusculair E. coli abces, 16 uur na injectie van 
111In-DPC11870. Daarnaast werden heterologe witte bloedcellen en beenmergcellen 
afkomstig van een donor konijn, gelabeld met 111In-DPC11870. De biodistributie van deze 
in-vitro gelabelde cellen werden geëvalueerd naast de biodistributie van ongebonden 
111In-DPC11870 in konijnen met een intramusculaire E. coli infectie.  
Kwantitatieve analyse van de gamma-camera opnamen, bevestigde de eerdere 
bevindingen van accumulatie van radioactiviteit op tijdstippen waarop 111In-DPC11870 
concentraties in het bloed laag waren. Vanuit de resultaten van de farmacokinetiek 
experimenten werd een hypothese opgesteld: 111In-DPC11870 detecteert infectie- en 
ontstekingshaarden ten gevolge van associatie met receptor-positieve cellen in het 
beenmerg en daarop volgende migratie van radioactiviteit vanuit het beenmerg naar de 
ontsteking. In konijnen waarbij de ontsteking werd geïnduceerd 16 uur na de injectie van 
111In-DPC11870, was op het moment van de inductie van de ontsteking een zeer lage 
concentratie van het radiolabel aanwezig in de circulatie. Ondanks deze lage concentratie 
werd normale accumulatie van radioactiviteit in het ontwikkelende abces waargenomen.  
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Dit duidde erop dat accumulatie van radioactiviteit in het abces, niet direct afkomstig kon 
zijn uit de circulatie. Het verschil in klaring van radioactiviteit uit het beenmerg van 
gezonde en geïnfecteerde konijnen impliceerde dat 111In-DPC11870 mogelijk vanuit het 
beenmerg naar het abces zou kunnen migreren. De in-vitro met 111In-DPC11870 
gelabelde cellen toonde bovendien aan dat deze cellen in staat waren naar het abces te 
migreren.  
Samenvattend, toonden de resultaten uit deze studie aan dat 111In-DPC11870 in 
ontstekingshaarden lokaliseert ten gevolge van initiële binding aan receptor-positieve 
beenmergcellen en daaropvolgende migratie van radioactiviteit vanuit het beenmerg naar 
het abces.  
 
Voor scintigrafische detectie wordt bij voorkeur gebruik gemaakt van een met 99mTc-
gelabelde tracer. Dit omdat 99mTc een radionuclide is met een gunstigere half-waarde tijd 
en foton-energie. Bovendien is 99mTc een generator product en daardoor eenvoudig 
beschikbaar. Daarom zijn naast de DTPA-geconjugeerde LTB4 antagonist DPC11870, 
twee structureel verwante met HYNIC geconjugeerde LTB4 antagonisten, MB81 en 
MB88, gesynthetiseerd. In hoofdstuk 6 is de chemische synthese beschreven van de 
bivalente met DTPA geconjugeerde LTB4 antagonist DPC11870 en de met HYNIC 
geconjugeerde bivalente antagonist MB81 en monovalente analoog MB88. In dit 
hoofdstuk zijn de resultaten beschreven van de initiële labelings-experimenten van MB81 
met 99mTc, gebruik makend van de verschillende coligand systemen (tricine, TPPTS en 
isonicotinezuur).  
Met behulp van HPLC analyse werd aangetoond dat MB81 efficiënt gelabeld kon worden 
met 99mTc ongeacht de gebruikte coligand. Uit de gamma-camera opnames en 
biodistributie analyse bleek dat het coligand, gebruikt tijdens de 99mTc labeling, van invloed 
was op de farmacokinetiek van MB81. De meest optimale farmacokinetische 
eigenschappen werden gevonden wanneer MB81 gelabeld was met 99mTc en 
isonicotinezuur werd gebruikt als coligand. De scintigrafische opnamen toonden verder 
aan dat de drie LTB4 antagonisten geschikt zijn voor de scintigrafische detectie van 
ontstekingshaarden.  
 
Nadat was aangetoond dat de HYNIC-geconjugeerde LTB4 antagonisten, MB81 en 
MB88, gelabeld konden worden met 99mTc, bij voorkeur met behulp van isonicotinezuur, 
werden in hoofdstuk 7 de farmacokinetische en imaging eigenschappen van beide 
stoffen beschreven. 99mTc-MB81 en 99mTc-MB88 werden geëvalueerd in konijnen met een 
acute infectie in de dijbeenspier. 111In-DPC11870 werd meegenomen als referentie. 
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De scintigrafische opnamen toonden aan dat het abces werd gevisualiseerd door beide 
99mTc-gelabelde preparaten vanaf twee uur na de injectie. Na dissectie en meting van de 
radioactiviteit in de weefsels bleek dat de concentratie radioactiviteit van beide preparaten 
in het geïnfecteerde spierweefsel gelijk was. Echter, met 99mTc-MB88 werd een 
duidelijkere afbeelding van het abces waargenomen dan met 99mTc-MB81. Dit werd 
veroorzaakt door het feit dat de concentratie 99mTc-MB88 in de nieren veel lager was dan 
concentratie 99mTc-MB81.  
De concentraties 99mTc-MB81 en 99mTc-MB88 aanwezig in het abces, waren vergelijkbaar 
met die van 111In-DPC11870. Opnieuw was echter de afbeelding van het abces na injectie 
van 99mTc-MB81 beter dan na injectie van 111In-DPC11870. Nu kon superieure abces 
visualisatie door 99mTc-MB88 verklaard worden uit het feit dat de concentratie 99mTc-MB88 
in het beenmerg veel lager was dan die van 111In-DPC11870. Uit biodistributie data bleek 
dat na injectie van 99mTc-MB88 de hoogste concentratie radioactiviteit aanwezig was in het 
abces.  
Op basis van de resultaten van deze studie werd geconcludeerd dat de monovalente 
99mTc-gelabelde LTB4 antagonist MB88 de meest potente en veelbelovende tracer is voor 
het detecteren en visualiseren van infecties en ontstekingen. 
 
CONCLUSIE 
In dit proefschrift zijn meerdere studies beschreven waarbij drie verschillende radioactief 
gelabelde LTB4 antagonisten zijn onderzocht voor de geschiktheid om infecties en 
ontstekingen te detecteren. De resultaten toonden aan dat elke van deze LTB4 
antagonisten geschikt is voor de scintigrafische detectie van ontstekingen en 
infectiehaarden. Uit een vergelijkende evaluatie is echter gebleken dat de monovalente 
HYNIC-geconjugeerde LTB4 antagonist, MB88, superieure farmacokinetische 
eigenschappen bezit, ten opzichte van MB81 en DPC11870. Aangezien de bereiding van 
deze stof eenvoudig, snel en veilig is, zou het gebruik van 99mTc-MB88 mogelijk 
geprefereerd worden boven het gebruik van radioactief gelabelde leukocyten, momenteel 
de gouden standaard voor deze toepassing in de kliniek. Met de in dit proefschrift 
beschreven resultaten zijn voldoende argumenten naar voren gekomen die een klinische 
evaluatie van 99mTc-MB88 in patiënten rechtvaardigen. 
 
 
 147 
LIST OF PUBLICATIONS 
 
1. Troost EG, Bussink J, Kaanders JH, van Eerd J, Peters JP, Rijken PF, Boerman OC, 
van der Kogel AJ. Comparison of different methods of CAIX quantification in relation 
to hypoxia in three human head and neck tumor lines. Radiother Oncol. 2005 Jul. 
2. Kok PJ, Eerd JE, Boerman OC, Corstens FH, Oyen WJ. Biodistribution and Imaging 
of FDG in Rats with LS174T Carcinoma Xenografts and Focal Escherichia coli 
Infection. Cancer Biother Radiopharm. 2005;20:310-315.  
3. van Eerd JE, Broekema M, Laverman P, Harris TD, Edwards DS, Oyen WG, 
Corstens FH, Boerman OC. Imaging of Infection and inflammation with an improved 
99mTc-labeled LTB4 antagonist. J Nucl Med. 2005; In Press 
4. Broekema M, van Eerd JEM, Oyen WJG, Corstens FHM, Liskamp RMJ, Boerman 
OC, Harris TD. Synthesis of Leukotriene B4 antagonists labeled with In-111 or Tc-
99m to image infectious and inflammatory foci. J Med Chem. 2005; In Press 
5. van Eerd JE, Oyen WJ, Harris TD, Rennen HJ, Edwards DS, Corstens FH, Boerman 
OC. Scintigraphic Imaging of Infectious Foci with an 111In-LTB4 Antagonist is Based 
on In-vivo Labeling of Granulocytes. J Nucl Med. 2005;46:786-793. 
6. van Schaijk FG, Broekema M, Oosterwijk E, van Eerd JE, McBride WJ, Goldenberg 
DM, Cortsens FH, Boerman OC. Residualizing iodine markedly improved tumor 
targeting using bispecific antibody-based pretargeting. J Nucl Med. 2005;46:1016-
1022. 
7. Rennen HJ, Bleeker-Rovers CP, van Eerd JE, Frielink C, Oyen WJ, Corstens FH, 
Boerman OC. 99mTc-labeled interleukin-8 for scintigraphic detection of 
pulmonary infections. Chest. 2004;126:1954-1961. 
8. van Eerd JE, Rennen HJ, Oyen WJ, Harris TD, Edwards DS, Corstens FH, Boerman 
OC. Scintigraphic detection of pulmonary aspergillosis in rabbits with a radiolabeled 
leukotriene B4 antagonist. J Nucl Med. 2004;45:1747-53. 
9. Brouwers A, Verel I, Van Eerd J, Visser G, Steffens M, Oosterwijk E, Corstens F, 
Oyen W, Van Dongen G, Boerman O. PET radioimmunoscintigraphy of renal cell 
cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother 
Radiopharm. 2004;19:155-63.  
  
 
148 
10. van Eerd JE, Boerman OC, Corstens FH, Oyen WJ. Radiolabeled chemotactic 
cytokines: new agents for scintigraphic imaging of infection and inflammation. Q J 
Nucl Med. 2003;47:246-55. Review.  
11. Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, 
Boerman OC. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of 
monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med. 2004;45:327-
337.  
12. van Eerd JE, Laverman P, Oyen WJ, Harris TD, Edwards DS, Ellars CE, Corstens 
FH, Boerman OC. Imaging of experimental colitis with a radiolabeled leukotriene B4 
antagonist. J Nucl Med. 2004;45:89-93.  
13. de Geus-Oei LF, van Eerd-Vismale J, Molthoff C, Corstens F, Oyen W, Boerman O. 
Tracers to monitor the response to chemotherapy: in vitro screening of four 
radiopharmaceuticals. Cancer Biother Radiopharm. 2004;19:457-465. 
14. Verel I, Visser GW, Boellaard R, Boerman OC, van Eerd J, Snow GB, Lammertsma 
AA, van Dongen GA. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled 
monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003;44:1663-
1670.  
15. Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, Vosjan MJ, 
Stigter-van Walsum M, Snow GB, van Dongen GA. Long-lived positron emitters 
zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with 
PET. Cancer Biother Radiopharm. 2003;18:655-661.  
16. van Eerd JE, Oyen WJ, Harris TD, Rennen HJ, Edwards DS, Liu S, Ellars CE, 
Corstens FH, Boerman OC. A bivalent leukotriene B(4) antagonist for scintigraphic 
imaging of infectious foci. J Nucl Med. 2003;44:1087-1091. 
17. Rennen HJ, van Eerd JE, Oyen WJ, Corstens FH, Edwards DS, Boerman OC. 
Effects of coligand variation on the in vivo characteristics of Tc-99m-labeled 
interleukin-8 in detection of infection. Bioconjug Chem. 2002;13:370-377.  
18. Boerman OC, van Eerd J, Oyen WJ, Corstens FH. A 3-step pretargeting strategy to 
image infection. J Nucl Med. 2001;42:1405-11. 
 
 
 
 149 
DANKWOORD 
 
Graag zou ik de mensen die aan de totstandkoming van dit proefschrift hebben 
bijgedragen bedanken: 
Allereerst natuurlijk de personen die mij de mogelijkheid voor dit promotieonderzoek 
hebben geboden, de promotores Prof. Dr. F.H.M. Corstens en Prof. Dr. W.J.G.Oyen en 
co-promotor Dr. O.C.Boerman. Frans, Wim en Otto, zonder jullie steun en vertrouwen was 
deze promotie nooit tot stand gekomen. Beste Frans, vanaf de eerste dag dat ik op de 
afdeling nucleaire geneeskunde kwam werken heb je me aangespoord om verder te 
komen in het onderzoek en me alle vrijheid gegeven om me verder te ontwikkelen.  Met 
name jij hebt me de mogelijkheid gegeven om mijn studie te volgen en het 
promotieonderzoek uit te voeren. Wim, jou heldere visie,  analytische denkwijze en de 
combinatie van wetenschappelijke en medische kennis zijn essentieel geweest voor de 
totstandkoming van dit proefschrift. Meerdere malen, vooral op het gebied van de infectie 
modellen, heb ik je adviezen ter harte genomen. Otto, dankzij jouw positieve houding en 
enthousiaste karakter is het bespreken van resultaten en het bedenken van nieuwe 
experimenten altijd een uitdaging. Mede door je stimulerende geestdrift kon dit proefschrift 
vlot en efficiënt voltooid worden. 
Natuurlijk wil ik ook mijn collega’s bedanken die mij geholpen hebben tijdens de 
werkzaamheden op het laboratorium en in het dierenlaboratorium. Cathelijne, 
Annemieke en Ingrid, dank je wel voor jullie hulp en leuke samenwerking. Peter, 
Huub, Frank en Manuel, dank je wel voor jullie goede adviezen en hulp bij het 
opzetten van experimenten en de leuke gesprekken die we hadden. Ook Emile 
hartelijk dank voor je steun en suggesties tijdens menig labeling experiment. 
Natuurlijk wil ik jullie ook bedanken voor de goede werksfeer en de gezelligheid in het 
aquarium. Ook Adrienne, inmiddels vanuit het aquarium naar Groningen vertrokken, 
ik wil je bedanken voor de leuke tijd samen. Daarnaast zou dit proefschrift niet gereed 
gekomen zijn zonder de hulp van alle andere collega’s van de afdeling nucleaire 
geneeskunde. Vele van de afdeling hebben geholpen tijdens de camera 
experimenten, en met zijn allen kon het werk altijd op een plezierige manier gedaan 
worden. Dank je wel iedereen voor de collegialiteit en de prettige werksfeer. 
Essentieel voor dit promotieonderzoek was de bekwaamheid van de mensen van het 
Centraal Dierenlaboratorium. Ik wil bij deze dan ook met name Gerrie Grutters, Hennie 
  
 
150 
Eijkholt en Bianca Lemmers bedanken voor hun hulp en inzet bij de uitvoering van het dier 
experimenteel werk. Door jullie expertise konden de experimenten op de meest 
diervriendelijke wijze verlopen. 
Whithout the help of Matthias and the cooperativeness of Bristol-Myers Squibb (BMS) 
Medical Imaging, the LTB4 antagonists would not be available. Therefore I would like to 
thank Matthias and BMS, especially Thomas Harris, for their contribution to this project. 
Behalve de mensen uit de werkkring wil ik ook mijn familie en vrienden bedanken. Mam 
en pap, Jo, Toon, Jolanda en Geert-Jan, overige familie, vrienden, vriendinnen en 
iedereen die interesse heeft getoond tijdens mijn studie en tijdens de werkzaamheden 
voor mijn promotieonderzoek, bedankt voor jullie belangstelling en steun. Dorée, 
Rombout, Harrie en Francis, bedankt voor de gezellige tijd en onze goede vriendschap, 
jullie zorgden voor de nodige ontspanning tussen het studeren en werken door. 
Mijn allerliefste Jan, zonder jouw onvoorwaardelijke steun was het nooit gelukt om 
tegelijkertijd mijn werk, mijn studie en mijn promotie onderzoek te volbrengen. Doordat je 
er altijd voor me bent en je mij je volledige vertrouwen en steun geeft, ben ik zo ver 
gekomen. Dank je wel hiervoor, en dank je wel voor al het andere. 
 151 
CURRICULUM VITAE 
 
Julliëtte Vismale, geboren op 1 mei 1968 te Sint-Oedenrode, begon in 1985 met de 
Hogere Laboratorium Opleiding aan de Hogeschool van Eindhoven. Deze studie, waarbij 
als afstudeerrichting Algemene Microbiologie was gekozen, werd in 1989 afgerond met 
een diploma. In de periode van 1990 tot en met 1999 was Julliëtte werkzaam bij de 
Gezondheidsdienst voor Dieren, eerst als research analist op de afdeling Onderzoek en 
Ontwikkeling, vervolgens als 1e analist en gedurende de laatste vijf jaar als hoofdanalist 
van de afdeling Immunologie en Virologie waar zij leiding gaf aan de mensen werkzaam 
binnen deze afdeling. In 1999 werd zij aangesteld als research analist bij de afdeling 
Nucleaire Geneeskunde van het Universitair Medisch Centrum St.Radboud te Nijmegen 
(Prof. Dr. F.H.M. Corstens). In september 2002 werd begonnen met de Master opleiding 
Biomolecular Sciences aan de universiteit van Utrecht. Deze opleiding werd in juni 2004 
Cum Laude afgerond, na onder andere een onderzoeksstage bij de afdeling Moleculaire 
Biologie van het Nijmegen Center for Molecular Sciences (Prof.Dr. H.G. Stunnenberg). De 
eveneens in het kader van deze opleiding uitgevoerde onderzoeksstage bij de afdeling 
Nucleaire Geneeskunde was mede aanleiding voor de werkzaamheden die geleid hebben 
tot dit proefschrift. 
  
 
 
 
